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ABSTRACT 
Rapid advances in bioinformatics and nanotechnology have sparked pre-clinical 
development of innovative therapies with potential to transform approaches to non-specific 
clinical practices such as chemotherapy and radiation.  One of few nanoparticle-based treatments 
in clinical trials is photothermal therapy (PTT), which is localized by near infrared light 
activation of heat-producing gold nanoshells.  Here we demonstrate nanoparticle-mediated PTT 
as a multifunctional platform to address key challenges of cancer medicine, to improve patient 
tolerance and long-term survival.  We present our work in two sections: enhancing efficacy in 
metastatic settings, and increasing specificity to reduce associated toxicity. 
In the first section, we focus on the efficacy of PTT against breast cancer stem cells 
(BCSCs) and tumor-mediated immunosuppressive signaling – vital drivers of cancer growth and 
metastasis.  First we study PTT via highly crystallized iron oxide nanoparticles (HCIONPs) in 
human breast cancer cells in immune-compromised mice.  PTT inhibits both epithelial-like 
(ALDH+) and mesenchymal-like (CD44+/CD24-) BCSCs and BCSC-driven secondary tumor 
formation.  PTT prior to surgery prevents lymph node metastasis.  Next we evaluate HCIONP-
mediated PTT and cancer immunotherapy (PD-L1 antibody) in immune-competent mice.  PTT 
significantly reduces mouse ALDH+ BCSCs when given alone and in combination with PD-L1 
antibody.  Combination treatment reveals promising reductions in tumor growth and formation 
of lung macrometastases.  Furthermore, increases of key inflammatory cytokines and immune 
     xvii 
 
cell-attracting chemokines suggest the potential to enhance T-cell tumor infiltration to trigger a 
systemic, cancer (stem) cell-specific immune response. 
In the second section, we focus on development of optimized targeted nanoparticle 
formulations, applicable for PTT, to improve specificity and efficiency of cancer therapy.  First 
we report a new technique – ‘living’ PEGylation – to control the density and composition of 
heterobifunctional poly(ethylene glycol) (HS-PEG-R) on gold nanoparticles.  Applications we 
demonstrate include control of targeting ligand (HS-PEG-RGD) density to maximize 
nanoparticle targeting efficiency, and development of double-charged, stealthy nanoparticles 
(optimal HS-PEG-NH2 to HS-PEG-COOH ratio) to minimize immune cell uptake.  Lastly, we 
describe targeted, theranostic nanocomposites with a core-satellite structure for PTT and 
magnetic resonance imaging.  A facilely produced “clickable” targeting peptide enables precise 
control over attachment to the nanoparticles to prevent steric hindrance and optimize binding to 
the target receptor. 
 
 1 
 
CHAPTER 1. INTRODUCTION 
1.1 The challenges posed by the complexity of cancer, and strategies to overcome them with 
novel approaches and optimal formulations of nanoparticles for photothermal therapy  
 While cancer is primarily described as uncontrolled cell growth, it is an extremely 
heterogeneous disease with many types and subtypes [1].  It can occur in the blood (e.g., 
lymphoma, leukemia) or as a solid tumor, defined as a carcinoma when originating from 
epithelial tissues and as a sarcoma when originating from connective tissues [2].  Solid cancers 
can occur in non-vital organs, such as the breast or skin, or vital organs such as brain, lung, and 
liver.  According to the “two hit” theory, whether arising from heritable genetic mutations, 
environmental exposures, or a virus, cancer progresses when both copies of a gene become 
mutated [3].  Such genes are known as oncogenes (often dubbed “gas pedals”) when driving 
proliferative and survival pathways, or as tumor suppressor genes (dubbed “brakes”) when 
driving inhibitory pathways such as cell cycle arrest and apoptosis [4]. 
 On the path to achieving a unified definition of cancer, Weinberg and Hanahan famously 
published the “Hallmarks of Cancer;” it was followed by an additional publication in 2011 to 
include emerging hallmarks and enabling characteristics [1, 5].  Their six original hallmarks of 
acquired capabilities included 1) sustaining proliferative signaling, 2) evading growth 
suppressors, 3) resisting cell death (evading apoptosis), 4) enabling replicative immortality, 5) 
inducing angiogenesis, and 6) activating invasion and metastasis.  To this they added 
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deregulating cellular energetics and avoiding immune destruction as emerging hallmarks.  
Finally, the authors attributed two enabling characteristics that allow cancer cells to acquire such 
capabilities: genome instability and mutation, and tumor-promoting inflammation driven by 
immune cells that normally function to fight infections and heal wounds.  With these in mind we 
discuss here some of the features of cancer that pose key challenges for developing effective 
therapies, and propose strategies that form the basis of this dissertation. 
 First, along the lines of Weinberg’s and Hanahan’s first hallmark of sustaining 
proliferative signaling, cancer cells are highly adaptable for survival.  Functional redundancy, 
crosstalk, and feedback loops in pathways driving cancer cell growth and survival often allow 
them to rely on alternate signaling in response to cancer therapy, leading to acquired resistance 
[6-8].  Second, cells comprising solid tumors can be heterogeneous in type(e.g., cancer-
associated fibroblasts) or differ more subtly in terms of genetic of epigenetic changes that alter 
phenotype and can lead to varying functional roles to sustain tumors [9, 10].  Consequently, 
these cellular differences may necessitate more than one therapeutic target for effective 
elimination [11].  For instance, cancer-associated fibroblasts (CAFs) in the tumor stroma are 
similar to normal fibroblasts that offer structural support in most epithelial tissues, but have 
become activated by cancer cells to release soluble factors that facilitate cancer growth and 
angiogenesis [5, 12].  Of (arguably) more significance are cancer stem cells (CSCs), a small 
population of cancer cells with defining stem cell features including the ability to self-renew and 
differentiate.  These long-lived cells have an increased likelihood of acquiring mutations, and 
growing evidence suggests they are responsible for tumor initiation and are key drivers of tumor 
growth and metastasis [13, 14]. 
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 Efficacy of treatment is severely impaired when cancer cells are no longer localized but 
have disseminated from the primary tumor site and established metastatic growths [15].  Many 
localized cancers caught early enough are not fatal.  However, more advanced cancers can 
metastasize to vital organs and interfere with their function and the body’s ability to make white 
blood cells and fight infections [16, 17].  In order for tumors to grow and metastasize, however, 
they must be able to escape recognition by immune cells [18, 19].  The ability of cancer to upset 
the immune system’s delicate balance of self-tolerance and maintaining tissue homeostasis by 
monitoring for signs of distress is a crucial factor for tumor-initiating cells to develop into 
macroscopic growths and establish growths at metastatic sites [20]. 
 Here we propose a nanomedicine platform to develop a cancer therapy that encompasses 
multiple strategies to overcome these challenges that stem from the inherent properties of cancer 
cells.  In the first section of this dissertation we focus on the efficacy of employing nanoparticle-
mediated hyperthermia, photothermal therapy (PTT) specifically, in the fight against cancer stem 
cells and tumor-mediated immunosuppressive signaling – vital drivers of cancer growth and 
metastasis.  Combination therapy incorporating nanoparticle-mediated PTT, as we present here, 
or modification of the nanoparticles themselves for multimodal therapy (e.g., PTT and drug 
delivery) may be utilized to enhance treatment efficacy and mitigate acquired resistance.  In 
addition to serving as a multifunctional platform to address key challenges cancer cells pose, 
another major advantage of nanoparticle-mediated PTT is its potential to improve the specificity 
and efficiency of cancer cell destruction by being localized and targeted.  Given the lack of 
specificity and off-target toxicity of mainstream cancer therapy (e.g., chemotherapy), we thus 
dedicated the second section of this dissertation to the development of optimized formulations of 
targeted nanoparticles for photothermal cancer therapy. 
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1.2 Targeting signaling pathways of CSCs driving tumor growth and metastasis 
Cancer cells with stem cell characteristics were first discovered in acute myeloid 
leukemia by John Dick’s group [21], and soon evidence for the cancer stem cell (CSC) model 
began to arise in many solid cancers [22-26].  According to the model, tumors are initiated by 
stem (or progenitor) cells normally responsible for tissue maintenance and repair but, by their 
long-lived nature, have a greater susceptibility to acquiring mutations [13].  Dysregulation of 
stem cell self-renewal results in transformed CSCs with the ability to drive tumor formation 
enabled by their pluripotent differentiation capacity [13, 14].  In line with their enhanced 
propensity to initiate tumors in immune-compromised mice [22, 27], CSC literature suggests that 
only disseminated CSCs have the capabilities to become activated and drive growth of 
macrometastases at distal sites [13, 28, 29].  Weinberg’s group reported an association between 
CSCs and epithelial-to-mesenchymal transition (EMT) [30], which results in phenotypic changes 
that could facilitate dissemination and metastasis such as loss of cell-to-cell contact and loss of 
polarity [31].  While CSCs have been credited as the drivers of metastasis in multiple cancers 
[31-36], CSCs of the breast remain among the most extensively studied largely in part to the 
work of Wicha and colleagues to elucidate the roles of breast CSCs (BCSCs) in tumor growth, 
dissemination, and metastasis formation. 
CSCs were first reported in solid tumors in 2003 when Al-Hajj et al. identified them in 
breast cancer by the surface receptor phenotype CD44+/CD24- [22], and in 2007 Ginestier et al. 
also identified breast cancer cells with high levels of aldehyde dehydrogenase (ALDH+) [27] as 
meeting the functional CSC requirements according to mammosphere and secondary 
implantation assays [37].  Recently the Wicha group conducted genetic profiling revealing that 
the two BCSC populations are distinct and yet plastically transition from one form to the other as 
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signaled by the tumor microenvironment [31].  The authors report that the ALDH+ BCSCs exist 
in a mesenchymal-to-epithelial (MET) state and are primarily proliferative and concentrated at 
the tumor’s interior.  In contrast, the CD44+/CD24- BCSCs exist in an epithelial-to-
mesenchymal (EMT) state and are primarily quiescent and concentrated at the tumor’s invasive 
edge.  Their findings suggest that ALDH+ epithelial-like BCSCs may play a more dominant role 
in tumor growth, while metastasis may be more driven by CD44+/CD24- mesenchymal-like 
BCSCs that are less dependent on cell-to-cell contact for survival. 
Given the crucial role of cancer stem cells in tumor and metastasis development and the 
increasing evidence of their resistance to traditional therapies that can lead to recurrence [38-43], 
innovative therapies that are effective against CSCs will be crucial to enhance long-term patient 
survival.  Several pathways have been reported to regulate CSCs in multiple cancer types and 
have been the subjects of targeted therapies, some advancing to human clinical trials.  The first 
three heavily studied pathways were Wnt, Hedgehog, and Notch, which regulate self-renewal in 
normal stem cells [13, 14, 44, 45].  Reya et al. were among the first to demonstrate the critical 
role of the Wnt pathway in haematopoietic stem cell (HSC) regulation [46]; it has since been 
implicated in regulating CSCs in a variety of cancers including colon [47].  Key players in the 
Wnt signaling pathway include the Frizzled and lipoprotein receptor-related protein (LRP) 
receptor families on the cell surface and the downstream target β-catenin, which translocates to 
the nucleus to activate gene transcription [48, 49].  Β-catenin is also influenced by crosstalk 
signaling from Akt (protein kinase B) and phosphoinositide 3-kinase (PI3-K) pathways to 
regulate CSCs [50].  Two clinically approved nonsteroidal anti-inflammatory drugs (NSAIDs) 
have begun clinical trials for Wnt targeting: Celecoxib for inhibition of β-catenin and Sulindac to 
block Dishevelled (DSH, DVL), which normally functions to prevent β-catenin from being 
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degraded following ubiquitination.  Among other agents being investigated in clinical trials are 
ones targeting β-catenin, and monoclonal antibodies targeting either Wnt ligands or the Frizzled 
and LRP receptors [45].  Sonic hedgehog (SHH) is the best studied of the three mammalian 
Hedgehog pathways [51-53].Hedgehog ligand binding to the Patched (PTCH) receptor allows 
Smoothened (SMO) to associate with the cell membrane, leading to GLI-mediated activation of 
transcription of genes such as GLI1 and PATCH1 [48, 49].  Vismodegib (Genentech), an 
inhibitor of SMO, was approved in 2012 by the Food and Drug Administration (FDA) for basal-
cell carcinoma (BCC) [45].  Like Vismodegib, most other agents in clinical trials are 
cyclopamine-competitive antagonists of SMO, including Sonidegib and Saridegib. 
Following the discovery of breast CSCs as the first solid tumor CSCs, Dontu et al. 
demonstrated the involvement of Notch signaling in mammary stem/progenitor cell self-renewal 
and differentiation and proposed that dysregulation of the pathway could give rise to breast CSCs 
[54].  Additional studies since have demonstrated a crucial role for Notch signaling in other types 
of CSCs [55-57].  The Notch receptor family is composed of four mammalian homologs (Notch 
1-4).  Signaling can be activated by binding of Delta-like (DLL-1, DLL-3, DLL-4) or Jagged 
(Jagged-1, Jagged-2) ligands on a neighboring cell.  This induces a series of receptor cleavage 
events involving A Disintegrin and Metalloproteinase (ADAM) and γ-secretase enzymes, 
resulting in release of the Notch Intracellular Domain (NICD) which traffics to the nucleus and 
relieves repression of transcription factors for genes such as those in the HES family [54, 58, 59].  
Clinical trials of Notch-targeting agents include several γ-secretase inhibitors (GSIs) produced 
by various companies as well as monoclonal antibodies to block ligand binding, including anti-
Notch 1, 2, and 3 antibodies and multiple anti-DLL-4 antibodies [45]. 
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Aside from the three classic CSC-regulating pathways, Wnt, Hedgehog, and Notch, 
therapeutics for additional targets have been explored and discussed in detail in the literature.  
These include but are not limited to Perifosine to inhibit AKT, inhibitors of IL-6 and IL-8 
cytokine signaling such as Repertaxin for CXCR1, and blocking of Her2 signaling (that occurs 
through PTEN and PI3-K) for which Trustuzumab is the pioneer Her2 inhibitor [49, 50].  
Monoclonal antibodies have also been developed against various stem cell surface markers 
expressed on CSCs, such as CD44 and CD133 [60-62].  While few nanoparticle-based therapies, 
and none targeting CSCs, have advanced to clinical trials, recent advances in nanoparticle 
development offer great potential to combine strategies to enhance cancer treatment efficacy 
against CSCs.   
 
1.3 Cancer evasion of immune surveillance and approaches for cancer immunotherapy 
In 1909 Paul Ehrlich first proposed a connection between immune system function and 
cancer development, suggesting the importance of immune suppression of cancer growth [63-
66].  Decades later experimental models began to confirm the ability of the immune system to 
suppress tumors, and in 1957 Burnet published the theory of immune surveillance of tumor-
associated antigens [64-68].  Later development of immunodeficient mouse models eventually 
led to definitive data supporting the theory.  In 2001 Shankaran et al. showed that mice lacking 
T-cells, B-cells, and natural killer T (NKT) cells experienced a greater incidence of 3-
methylcholanthrene (MCA)-induced sarcomas and spontaneous epithelial carcinomas compared 
to control mice [64, 66, 69].  A year later Dunn et al. published a review in which they outlined 
cancer immunosurveillance as part of a larger process termed immunoediting, broken down into 
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three components: elimination, equilibrium, and escape [18, 70].  As they describe it, 
“elimination represents the classical concept of cancer immunosurveillance, equilibrium is the 
period of immune-mediated latency after incomplete tumor destruction in the elimination phase, 
and escape refers to the final outgrowth of tumors that have outstripped immunological restraints 
of the equilibrium phase” [64]. 
The main idea behind cancer immunotherapy is to restore the balance of power in favor 
of the immune system and induce cancer cell destruction in a process like the elimination phase 
of immunoediting.  In the elimination (immunosurveillance) phase, the innate immune system, 
which includes natural killer (NK) cells and antigen-presenting cells (APCs) such as dendritic 
cells (DCs) and macrophages, detects the growing tumor; through antigen presentation it alerts 
cells of the adaptive immune system such as CD8+ and CD4+ T-cells.  These cells then home to 
the tumor site to attack the tumor cells expressing the recognized antigens.  However, the exact 
process by which the innate and adaptive immune system becomes alerted remains the subject of 
further study [18, 19].  The first mechanisms proposed came from Dunn et al., who suggested 
that chemokines released by tumor cells combined with proinflammatory molecules, present 
from structural remodeling in the stroma to support tumor growth, act as a danger signal that 
alerts cells of the innate immune system.  Upon detection of the tumor cells, an interferon-γ 
(IFN-γ)-dependent and NK cell-dependent mechanism triggers initial killing of tumor cells by 
the innate immune system.  As a result, APCs are exposed to tumor antigens and migrate to the 
tumor draining lymph nodes [18].  There, cross-presentation of antigenic tumor peptides 
displayed on MHC class I molecules on APCs activates CD8+ cytotoxic T-cells of the adaptive 
immune system [18, 71].  At the tumor the activated CD8+ T-cells bind MHC molecules on 
cancer cells via their T-cell receptors (TCRs).  The T-cells mediate cancer cell death by 
     9 
 
exocytosis of perforin, which forms pores in the cell membrane and allows granzymes, also 
released by the T-cells, to induce apoptosis by caspase-dependent and caspase-independent 
mechanisms [72, 73].  CD4+ T-helper cells release IL-2 to promote CD8+ T-cell function and 
viability.  Furthermore, the dying tumor cells release IFN-γ which triggers additional 
mechanisms of cell death, such as apoptosis [18].  If total cancer cell destruction occurs in the 
elimination phase, then the immunoediting process is complete.  However, tumor cell variants 
arising from genetic or epigenetic changes that are missed during the elimination phase and 
develop immune resistance in the equilibrium phase enter the escape phase and may expand to 
become clinically detectable tumors [18]. 
In 2013, Science Magazine named cancer immunotherapy as the Breakthrough of the 
Year; however, clinical investigations of this therapeutic approach had begun decades earlier.  In 
1992 IL-2, which promotes activation and proliferation of T-cells and NK cells, became one of 
the first FDA-approved immunotherapies, indicated for metastatic melanoma and renal cell 
carcinoma [74].  Some immunotherapy efforts have focused on therapeutic vaccines, in contrast 
to prophylactic vaccines such as the human papillomavirus (HPV) vaccine approved in 2006, to 
trigger T-cell responses.  However, this approach using peptides or proteins to generate effector 
T-cells did not prove to be very fruitful, and scientists considered other approaches such as cell-
based vaccines.  In 2010 the FDA approved the cell-based vaccine Provenge for advanced 
prostate cancer [75].  In this individualized therapy, APCs from the patient’s blood are co-
cultured with the prostate cancer antigen prostatic acid phosphatase (PAP) before being returned 
to the patient. 
More recent T-cell-focused cancer immunotherapies include adoptive cell transfer 
(ACT), genetic engineering of T-cells, and immune checkpoint inhibition.  In adoptive cell 
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transfer, a patient’s T-cells are first removed to culture and expand ex vivo and then reintroduced 
into the patient to expand the pool of viable tumor-infiltrating lymphocytes (TILs).  IL-2 may be 
included in either the culture or reintroduction steps following lymphodepletion in the patient by 
chemotherapy to facilitate engraftment [75-77].  Complete durable responses were observed 
when ACT was tested in melanoma patients for whom other therapies did not work [75, 78].  
Building off his pioneering successes with ACT, Rosenberg began to work with Eshhar to 
engineer the T-cells harvested from patients.  Known as CAR T-cells, they are genetically 
engineered to produce chimeric antigen receptors (CARs) on their surface to recognize tumor 
cells through the CAR’s affinity domain (usually a single chain variable fragment (scFv) 
antibody).  CAR technologies have been commercialized and shown marked results in Phase I 
clinical trials of patients with refractive acute lymphoblastic leukemia (ALL); second generation 
molecules are already in development [75, 79-81]. 
Development of therapeutic antibodies for immune checkpoint inhibition focuses on the 
breakdown of the Cancer-Immunity Cycle at different steps.  This cycle was defined in 2013 by 
Chen and Mellman, dividing it into seven steps essentially mirroring Dunn’s 2002 description of 
the elimination phase of immunoediting [82, 83].  As a mechanism to maintain balance of 
immune function, T-cells have coregulatory inhibitory signals that occur during the TCR-MHC-
mediated priming by APCs (step 3 of the cycle) and TCR-MHC-mediated recognition of tumor 
cells (step 6).  Inhibitory signaling through the cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) receptor on CD8+ T-cells during priming by APCs may function to dampen T-cell 
activation.  Anti-CTLA-4 antibodies block this first T-cell checkpoint.  Inhibitory signaling 
through the programmed death 1 (PD-1) receptor on activated CD8+ T-cells during binding to 
target cells in response to inflammation or infection may act to regulate T-cell activity in 
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peripheral tissues.  PD-1 expression has been found to be higher on tumor-infiltrating T-cells 
than those that infiltrate normal tissues.  Furthermore, studies have shown that various types of 
cancer cells, including melanoma, have elevated expression of the programmed death ligand 1 
(PD-L1) receptor that activates this second inhibitory T-cell checkpoint through PD-1; this has 
been correlated with poor clinical outcome [84, 85]. 
Antibodies targeting both PD-L1 and PD-1 have advanced to clinical trials in patients 
with melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC), and are 
sometimes used in combination with an anti-CTLA-4 antibody [82, 83, 85].  In a phase Ib 
clinical trial, Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4) were given to advanced 
melanoma patients either concurrently or sequentially.  Patient survival rates were an astonishing 
94% and 88% after one and two years, respectively, considering that the median survival of 
patients with metastatic melanoma is less than one year [86-88].  Various clinical trials have 
been conducted for anti-CTLA-4 antibodies as well.  After conclusive data of improved median 
survival in metastatic melanoma patients receiving Ipilimumab in phase III clinical trials, the 
treatment received FDA approval as either initial therapy or treatment after relapse in patients 
with metastatic melanoma [75, 87, 88].  However, given the decrease in specificity of T-cell 
inhibition by inhibiting the checkpoint during the priming phase rather than the effector phase at 
the tumor site, immune-related adverse reactions were observed in patients treated with 
Ipilimumab anti-CTLA-4 therapy [75, 87, 88].  Other immune checkpoint inhibitors have 
recently gained FDA approval as well, including Nivolumab for melanoma in 2014 and NSCLC 
in 2015 [89].  While not yet at the point of clinical investigation, the potential to improve long-
term survival in cancer patients receiving immunotherapy may be enhanced by combination with 
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treatments that kill cancer stem cells and result in a T-cell response that specifically recognizes 
cancer cells and also CSCs [90-94]. 
 
1.4 Cancer nanomedicine design strategies, and advantages and approaches to 
nanoparticle-mediated photothermal cancer therapy 
While still in its infancy, research in the field of nanomedicine is booming with potential 
to develop innovative solutions to solve current limitations of cancer therapies.  The diversity of 
nanoparticle design significantly enhances the ability to develop specialized therapies not 
possible with conventional chemotherapy alone.  Biodegradable or biocompatible nanoparticles, 
including those composed of polymers, carbon, iron oxide, and gold [95-98], can function 
themselves as therapeutics or imaging agents, serve as vessels for therapeutic drugs, and be 
modified to facilitate control over interactions in biological systems.  Iron oxide nanoparticles 
are capable of magnetic resonance imaging and gold-based nanoparticles of photoacoustic, 
Raman, and other imaging techniques; furthermore, both types of nanoparticles can be exploited 
to induce localized hyperthermia [96, 99-101].  Polymer-based nanoparticles such as liposomes 
and micelles can be encapsulated with therapeutics to improve their formulation; such designs 
may overcome poor solubility or protect and sustain delivery of biologic therapeutics, such as 
proteins and siRNA [102-105].  Similarly, drugs can be appended to and released from the 
surface of nanoparticles.  Through size-based passive targeting such as the enhanced 
permeability and retention (EPR) effect, drug delivery via nanoparticles can enhance control 
over drug distribution (tumor uptake), improve pharmacokinetic (PK) properties such as half-
life, and reduce off-target toxicity. 
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Nanoparticles may also be modified to impart features such as stealth or active targeting 
capabilities.  Stealth to minimize recognition by immune cells may be granted by coating the 
surface of nanoparticles with the hydrophilic polymer poly(ethylene glycol) (PEG) or 
zwitterionic molecules to create a neutral surface charge [106-108].  PEG is also frequently used 
to improve nanoparticle stability and solubility.  Ligands may be added to enhance uptake by 
cancer cells with certain phenotypes (e.g., Her2+ breast cancer) or specific populations of cancer 
cells (CD44+ breast cancer stem cells), or to target drugs to subcellular locations (e.g., cell 
nuclei) [62, 109, 110].  Finally, nanoparticles have been used in different capacities to stimulate 
an immune response, for instance by directly delivering antigen as with traditional vaccine 
development or more indirectly by triggering a T-cell attack in response to nanoparticle-
mediated death of tumor cells as previously discussed [111-115].  A summary of the various pre-
clinical strategies for which nanoparticles may be used to address limitations of conventional 
cancer therapy and representative literature is included in Table 1.1 below. 
 
Table 1.1. Nanoparticle-based pre-clinical strategies to improve conventional cancer therapy 
Cancer Nanomedicine Pre-Clinical Research Strategies References 
Improving formulation of therapeutics [102-105] 
Externally triggering drug release [116, 117] 
Increasing drug uptake at the tumor site [118, 119] 
Controlling intracellular drug localization [110, 120] 
Reducing off-target toxicity [121, 122] 
Offering multimodal treatment [123, 124] 
Non-invasive imaging to track particle or drug localization [125, 126] 
Stimulating immune response [111-115] 
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Few nanoparticle formulations have been approved for market use in cancer patients.  
Two more commonly known are Abraxane, albumin-bound Paclitaxel, and Doxil, Doxorubicin 
encapsulated into polymer-coated liposomes.  These passively targeted nanoparticle formulations 
have an improved therapeutic index, enhancing the efficacy-to-toxicity profile, compared to their 
drug-only counterparts [127].  A few iron oxide-based nanoparticles have been approved for 
diagnostic cancer imaging, such as Feridex [127].  Other nanoparticle-based therapies have 
advanced to clinical trials, but these have currently been limited to relatively simple 
formulations.  Examples include Aurimune, precisely sized, PEG-coated gold nanoparticles 
(AuNPs) for passive targeting of tumor necrosis factor (TNF) [128], and AuroLase, PEG-coated 
gold nanoshells that kill cancer cells through light-activated thermal ablation (i.e., photothermal 
therapy).  Biodegradable or biocompatible nanoparticle formulations with simple designs can be 
most easily translated from pre-clinical research to clinical trials in humans because they are 
easier to characterize, and the production process is more reproducible and scalable for mass 
manufacturing.  A more complex formulation may be denied FDA approval if the safety and 
efficacy of each component (e.g., polymer coating, targeting ligand) cannot be verified from 
clinical trials. 
For our studies, our goal was to develop nanoparticles to improve current cancer therapy 
approaches by enhancing efficacy in metastatic settings and increasing specificity to reduce 
associated toxicity.  Our work described here focuses on nanoparticle-mediated photothermal 
therapy (PTT), as it presents a multifunctional platform for localized, targeted therapies with 
potential to inhibit metastasis through multiple approaches.  PTT is also one of few examples of 
nanoparticle-mediated treatments to enter clinical trials in human cancer patients [127, 129].  
PTT produces hyperthermic cell destruction dependent upon application of near infrared (NIR) 
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laser light to tumor tissue containing nanoparticles which convert the light into heat.  While PTT 
offers multiple advantages of nanomedicine-based cancer treatments, possibly most significant is 
external control of localized hyperthermia to reduce off-target toxicity compared to other 
intravenously injected therapies such as conventional chemotherapy.  Other localized cancer 
therapies studied in pre-clinical research can be more difficult to precisely control, being 
dependent upon a tumor-specific trigger.  Examples include drug-loaded nanoparticles for which 
release is pH-dependent and activated by the slightly acidic tumor environment, or mediated by 
specific enzymes such as extracellular matrix (ECM)-degrading matrix metalloproteinases (e.g., 
MMP-2) with high extracellular expression in tumor tissue [126, 130-134].   
PTT-mediating nanoparticles can be formulated for active targeting in addition to passive 
targeting to improve the therapeutic window (efficacy-to-toxicity profile).  Passive targeting 
relies on physical properties of the nanoparticles, such as size or surface charge, that enhance 
physiological characteristics such as half-life in the bloodstream (i.e., rate of elimination), 
plasma protein binding, recognition by immune cells, and the ability to exploit the enhanced 
permeability and retention (EPR) effect resulting from the relatively leaky vasculature and poor 
drainage of the tumor environment.  Actively targeted therapeutics incorporate receptor-homing 
ligands designed to increase cellular uptake once nanoparticles have accumulated at the tumor 
site through passive targeting.  Various approaches have been taken to develop actively targeted 
cancer therapeutics and become clinically available, including monoclonal antibodies (e.g., 
Herceptin for Her2+ breast cancer) and antibody-drug conjugates (e.g., Herceptin-containing 
Kadcyla).  Actively targeted nanoparticles are formulated using monoclonal antibodies and 
peptides.  The gold nanoshells used for clinical trials of AuroLase PTT solely rely on passive 
targeting; development of actively targeted nanoparticles may reduce the intravenous dose 
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required to achieve a similar intratumoral nanoparticle concentration, potentially benefiting the 
patient and lowering the cost of treatment. 
Another advantage of nanoparticle-mediated PTT is that cancer cell death by 
hyperthermia may be less likely to result in development of treatment resistance, compared to 
nanoparticles delivering biologics and small molecule drugs that rely on inhibition of a particular 
molecular pathway; the latter can be faced with development of resistant cancer cells that have 
learned to rely on alternative survival pathways [43, 135].  As PTT isn’t pathway specific it is 
applicable to a wider variety of patients, including difficult-to-treat subtypes such as triple 
negative breast cancer which lacks estrogen, progesterone, and Her2 receptors exploited for 
targeted therapy.  Perhaps most exciting is the potential employ nanoparticle-mediated PTT in 
combination therapy that can be applied to metastatic cancer settings.  Initial research has shown 
nanoparticle-mediated PTT has applications in enhancing therapies to target cancer stem cells 
[40, 136] suggested to be responsible for driving tumor growth and metastasis.  Development of 
imagable, targeted nanoparticles may allow for localized PTT at sites of macrometastases.  
Inhibition of both micro- and macrometastases may also be possible in light of recent findings 
that nanoparticle-mediated hyperthermia induces a systemic cancer-specific immune response in 
which cytotoxic T-cells are trained to recognize and inhibit distal cancer cells [113], a response 
that may be strengthened by coupling with immunotherapy [137, 138]. 
 Gold-based nanoparticles are the gold standard for nanoparticle mediators of 
photothermal cancer therapy [99, 100, 129, 139-144], following the pioneering research of 
Mostafa El-Sayed’s group with gold nanorods (AuNRs) and Jennifer West’s group that 
developed the silica-core gold nanoshells (AuNSs) commercialized into AuroLase therapy [99, 
100, 110, 140, 144].  These particular gold structures have a peak absorbance of near infrared 
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(NIR) light, which allows for maximal tissue penetration and selective heating of nanoparticles 
due to the low light absorbance by tissue chromophores at this wavelength [145].  Gold 
efficiently converts light irradiation into heat by causing oscillations of electrons at the 
nanoparticle surface, a phenomenon known as surface plasmon resonance [146].  In addition to 
being biocompatible, an advantage of gold nanoparticles (AuNPs) is gold’s affinity to form 
covalent Au-S bonds for facile surface modification (with polymer coatings, targeting ligands, 
therapeutic agents, etc) using thiol functional groups [106].  Various types of imaging are 
possible with AuNPs, including photoacoustic, Raman, and computed tomography (CT), 
although clinical nanoparticle-based cancer imaging has been predominantly magnetic resonance 
imaging (MRI) via magnetic nanoparticles [147-149]. 
Following gold nanoparticles, carbon nanotubes have become more commonly selected 
for pre-clinical PTT research [61, 136, 138, 150-155].  Among their chief attributes for PTT is 
the ability of NIR light to induce single-walled and multi-walled carbon nanotubes composed of 
graphene to enter an excited state, resulting in release of vibrational energy that produces heat 
[156].  Like gold-based nanoparticles they can be produced in ideal size ranges for circulation in 
the blood stream and for passive tumor targeting via the EPR effect, and can be modified for 
loading of therapeutics or active targeting agents.  Formulation strategies to maximize carbon 
nanotube (CNT) biocompatibility and minimize off-target toxicity remain the subject of further 
investigation.  Other types of nanomaterials have been investigated to a lesser extent for 
photothermal therapy, including copper sulfide nanoparticles and nanographene sheets [111, 
157]. 
Iron-oxide containing nanoparticles have traditionally been used for cancer hyperthermia 
controlled by an alternating magnetic field (AMF) [101, 113, 129, 158].  However, all 
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intravenously injected nanoparticles will undergo significant uptake in off-target organs, 
particularly the liver, due to the reticuloendothelial system (RES) or mononuclear phagocyte 
system (MPS) [159-161].  Many iron oxide nanoparticle (IONP) formulations for cancer 
hyperthermia are intratumorally injected [101, 113] to avoid off-target heating in other organs; 
consequently, this form of hyperthermia is less translatable for human clinical trials than PTT.  
Our group recently reported that production of highly crystallized iron oxide nanoparticles 
(HCIONPs) in organic solvent via thermal decomposition results in significant and selective 
heating capabilities not attainable with all IONP formulations [96].  Synchotron x-ray diffraction 
(XRD) revealed significantly stronger peaks in the 400 and 440 planes for our HCIONPs 
compared to commercial IONPs produced in aqueous solution, indicating a preferred lattice 
orientation despite both IONP formulations having the Fe3O4 chemical composition.  Iron levels 
of HCIONPs in different tissues of mice returned to background levels within three months of 
intravenous injection, suggesting their ability to biodegrade.  Their ability to image tumors via 
MRI, a method currently used clinically, gives the HCIONPs another distinct advantage.  
Furthermore, the relatively small size (< 20 nm) of our stealthy, polymer-coated HCIONPs 
facilitates efficient tumor accumulation after intravenous injection.  Consequently, we employ 
these HCIONPs for our work in subsequent chapters to investigate novel applications of 
nanoparticle-mediated PTT in metastatic breast cancer: inhibiting cancer stem cells and eliciting 
a T-cell-mediated immune response.  These HCIONPs also function as a component of the 
nanoparticle formulation we develop for targeted photothermal therapy. 
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1.5 Specific Aims 
The overall goal of this work was to develop a nanoparticle approach to address two key 
challenges of cancer medicine: enhancing efficacy in metastatic settings and increasing 
specificity to reduce associated toxicity.  As such, we developed two objectives utilizing 
nanoparticle-mediated photothermal therapy as a multifunctional platform: 1) to inhibit cancer 
stem cells and tumor-mediated immunosuppressive signaling as vital drivers of tumor growth 
and metastasis, and 2) to enhance targeting specificity of therapy.  The work described here is 
divided into two parts and an appendix. 
 Part I: Novel approaches to nanoparticle-mediated photothermal therapy in metastatic 
breast cancer 
o Aim 1: To inhibit epithelial-like and mesenchymal-like breast cancer stem cells 
via nanoparticle-mediated photothermal therapy to prevent metastasis of human 
breast cancer in immune-compromised mice 
o Aim 2: To inhibit breast cancer stem cells and metastasis in immune-competent 
mice via nanoparticle-mediated photothermal therapy, and investigate 
photothermal therapy conditions that will trigger a tumor-specific T-cell attack to 
enhance immune checkpoint blockade efficacy against metastatic breast cancer  
 Part II: Engineering nanoparticles for targeted photothermal cancer therapy 
o Aim 3: To optimize cancer cell uptake of gold nanoparticles by ‘Living’ 
PEGylation to control targeting ligand and charge densities 
o Aim 4: To develop an optimal, stable formulation for peptide-targeted theranostic 
nanoparticles for localized PTT  
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 Appendix A: Evaluation of Jagged1 peptides to target breast cancer stem cells 
through Notch receptor expression 
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CHAPTER 2. INHIBITION OF EPITHELIAL-LIKE AND MESENCHYMAL-LIKE 
BREAST CANCER STEM CELLS TO PREVENT METASTASIS THROUGH IRON 
OXIDE NANOPARTICLE-MEDIATED PHOTOTHERMAL THERAPY 
 
2.1 Abstract 
Increasing evidence suggesting breast cancer stem cells (BCSCs) drive metastasis and 
evade traditional therapies underscores a critical need to exploit the untapped potential of 
nanotechnology to develop innovative therapies that will significantly improve patient survival.  
Photothermal therapy (PTT) to induce localized hyperthermia is one of few nanoparticle-based 
treatments to enter clinical trials in human cancer patients, and has recently gained attention for 
its ability to induce a systemic response targeting distal cancer cells in mouse models.  Here, 
translational models of triple negative breast cancer are used to demonstrate PTT, mediated by 
highly crystallized iron oxide nanoparticles, targets two populations of BCSCs and can be 
combined with surgery to prevent metastasis formation.  First, PTT preferentially targets 
epithelial-like ALDH+ BCSCs compared to mesenchymal-like CD44+/CD24- BCSCs and bulk 
cells in vitro.  Second, PTT inhibits breast cancer stem cell self-renewal through reduction of 
mammosphere formation in primary and secondary generations.  Third, secondary implantation 
reveals the ability of PTT to impede BCSC-driven tumor formation.  Finally, PTT before surgery 
can significantly reduce metastasis to lymph nodes and other distal sites.  These results suggest 
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the feasibility of incorporating PTT into standard clinical treatments such as surgery to enhance 
BCSC destruction and prevent metastasis, and provide impetus to investigate the potential for 
PTT to induce systemic BCSC immunity and improve long-term survival in patients with 
metastatic breast cancer. 
 
2.2 Introduction 
Cancer stem cells (CSCs) pose what is arguably the greatest challenge in developing 
therapies that will truly cure cancer patients.  First discovered in 1997 in acute myeloid leukemia 
by Dick and colleagues [1], soon evidence for a small population of stem-like cells with the 
ability to drive tumor formation began to arise in solid cancers [2-6].For more than a decade 
Wicha and others have conducted extensive studies to characterize breast cancer stem cell 
(BCSC) populations identified by either the Aldefluor enzymatic assay (ALDH+) or the surface 
receptor phenotype CD44+/CD24- [2, 7-11].  In an effort to better understand the role of BCSCs 
in tumor growth, dissemination, and metastasis formation, recent genetic profiling by the Wicha 
group revealed the two BCSC populations are distinct and yet plastically transition from one 
form to the other as signaled by the tumor microenvironment [12].  The authors report that the 
ALDH+ BCSCs exist in a mesenchymal-to-epithelial (MET) state and are primarily proliferative 
and concentrated at the tumor interior.  In contrast, the CD44+/CD24- BCSCs exist in an 
epithelial-to-mesenchymal (EMT) state and are primarily quiescent and concentrated at the 
tumor invasive edge.  Their findings suggest that ALDH+ MET BCSCs and EMT CD44+/CD24- 
BCSCs may have distinct roles in driving tumor growth and metastasis.  
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In light of this recent discovery it remains pertinent that future breast cancer therapies not 
only account for the BCSCs in addition to the differentiated cancer cells [13], but also 
distinguish the two distinct BCSC populations.  However, for most patients it is unlikely the 
BCSCs will be localized to the primary tumor at the time of treatment.  Up to 30% of Stage I 
breast cancer patients already have micrometastases detectable from bone marrow biopsies [14].  
With metastasis being the primary cause of death in breast cancer patients [15, 16], to be most 
effective future therapies must perform essential two roles: act locally against all populations of 
cancer cells to prevent future metastasis, and act systemically against all populations of cancer 
cells in existing metastases.  However the resistance of CSCs to traditional therapy such as 
chemotherapy or radiation, which when used alone can enrich the CSC population [17-19], 
remains a significant challenge.  Therapeutic regimens exploiting advances in nanoparticle 
development offer a tremendous potential to enhance treatment efficacy against CSCs. 
Photothermal therapy (PTT) is one of the few examples of nanoparticle-mediated 
treatments to enter clinical trials in human cancer patients [20, 21].Gold-based nanoparticles and 
carbon nanotubes have been the predominant subjects of laboratory investigation to produce heat 
targeted to kill cancer cells in response to near infrared (NIR) light [21-34].  Similarly, in the 
presence of an alternating magnetic field, iron oxide nanoparticles have been explored for cancer 
hyperthermia [21, 35-37].  Such therapy offers several advantages to cancer patients.  External 
control of localized hyperthermia translates to reduced off-target toxicity compared to other 
intravenously injected therapies (e.g., chemotherapy).  Biologics and many small molecule drugs 
rely on inhibition of a particular molecular pathway, which limits the patient population who will 
respond to such therapy and can even lead to development of resistant cancer cells that have 
learned to rely on alternative survival pathways [9, 38].  In contrast, nanoparticle-mediated PTT 
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offers broader applicability, including difficult-to-treat subtypes such as triple negative breast 
cancer which lacks estrogen, progesterone, and Her2 receptors exploited for targeted therapy.  
Development of imagable, targeted nanoparticles may even allow for localized PTT at sites of 
macrometastases.  Perhaps most promising are the initial findings that nanoparticle-mediated 
hyperthermia induces a systemic cancer-specific immune response in which cytotoxic T-cells are 
trained to recognize and inhibit distal cancer cells [36], a response that may be strengthened by 
coupling with immunotherapy [32, 39], suggesting the potential to inhibit already formed micro- 
and macrometastases in human patients. 
Extensive research into the effects of photothermal therapy on CSCs will become critical 
as basic research and clinical studies suggest its feasibility in human patients with local and 
metastatic cancers.  PTT was first realized into a commercial therapy applicable to cancer 
patients through AuroLase Therapy, which uses silica-cored gold nanoshells [40].  Clinical trials 
began in patients with head and neck cancer and more recently expanded to patients with 
primary and/or metastatic lung tumors [41, 42].  In Science Translational Medicine Atkinson et 
al conducted an elaborate study using patient-derived xenografts, revealing that mild 
hyperthermia (42 °C) via Aurolase therapy can sensitize MET ALDH+ BCSCs to ionizing 
radiation (IR).  They found PTT impairs their ability to repair double-stranded breaks in DNA 
caused by IR, which was suggested to be the result of changes in heat shock protein expression 
caused by PTT [18].  However, it remains unclear whether differences exist in the sensitivities of 
MET and EMT BCSCs to PTT alone.  
Previous studies examining the effects of nanoparticle-mediated hyperthermia alone on 
CSCs have been conducted using models that are more difficult to interpret whether the results 
would translate to human cancers: using a Ecadherin knockdown model to examine CSCs 
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separately rather than grown in the presence of differentiated cancer cells [43], exposing cells to 
nanoparticles in vitro before injecting them to mice for in vivo hyperthermia [26], or evaluating 
tumor growth on cells that received nanoparticle-mediated hyperthermia in vitro before 
implantation into mice [44].  There is a need for rigorous analysis using functional assays to 
evaluate treatment effect on stem cell properties such as self-renewal and tumor initiating 
frequency of treated tumors.  Further investigation, particularly using translational in vivo 
models, is required to better characterize the effect of photothermal therapy on BCSCs and, 
consequently, to inhibit cancer metastasis to ultimately improve survival. 
Photothermal therapy may be a prime candidate for inclusion in cancer therapy that is 
effective in the two essential roles to eliminate both MET and EMT BCSCs as well as 
differentiated cancer cells, both locally and systemically.  Here we sought to establish the 
efficacy of PTT in this first role, laying the foundation for future investigations into its systemic 
potential.  We conduct a rigorous analysis of the local effects of PTT, providing rationale for 
incorporating it into standard breast cancer therapy – to inhibit BCSCs at the primary tumor site 
to prevent future metastasis.  As such, we sought to discern the sensitivities of both MET and 
EMT BCSCs to various clinically relevant PTT conditions.  Our lab has previously demonstrated 
the ability to treat mice bearing orthotopic tumors derived from human breast cancer cells via 
photothermal therapy mediated by biodegradable highly crystallized iron oxide nanoparticles 
(HCIONPs).  In contrast to most PTT mediators, the HCIONPs produced by our lab are capable 
of magnetic resonance imaging (MRI) and efficient intratumoral accumulation following tail 
vein injection [45].  Here we conduct translational studies to evaluate the effect of PTT via 
HCIONPs on BCSCs in order to prevent the spread of metastasis from the primary tumor site.  
Our work focuses on triple negative breast cancer (TNBC), which is generally more aggressive 
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and metastatic than other subtypes.  We reveal in vitro that PTT eliminates MET BCSCs with the 
greatest sensitivity and identify conditions in which EMT BCSCs are also eliminated 
preferentially to differentiated cancer cells.  For the first time, we show that PTT inhibits breast 
cancer stem cell self-renewal in vitro. Through secondary implantation we demonstrate the 
ability of in vivo PTT to inhibit BCSCs in triple negative breast tumors.  Finally, we show in vivo 
that addition of PTT to standard surgical treatment can reduce metastasis formation in TNBC.  
Combining these results with further studies to employ PTT to induce a systemic immune 
response capable of inhibiting BCSCs at metastatic sites could address an unmet need in breast 
cancer to develop novel therapies that effectively eradicate existing micro- and macrometastases 
and prevent future metastasis. 
 
2.3 Results 
HCIONPs enable selective hyperthermia of cell culture medium under near-infrared 
laser light: Our lab previously demonstrated the ability to use biodegradable, highly crystallized 
iron oxide nanoparticles (HCIONPs) coated with antifouling polymer for photothermal therapy 
in vivo [45].  The intravenously injected HCIONPs effectively accumulate in breast cancer 
tumors via the enhanced permeation and retention (EPR) effect [45-47], and their highly 
crystallized structure enables effective tumor heating upon stimulation by near infrared (NIR) 
light.   
Here we compared heating curves on 96-well plates containing cell culture medium 
spiked with HCIONPs or PBS (Laser Only control).  We hypothesized that conducting PTT at 
increasing laser powers for our in vitro studies would allow us to determine whether a difference 
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exists in the sensitivities of BCSCs and differentiated cancer cells.  As shown in Figure 2.1A, 
laser powers less than 0.5 W, designated P1, P2, and P3, are sufficient to trigger hyperthermia up 
to 42, 45, and 48 °C after 10 minutes of laser irradiation in medium containing HCIONPs.  In 
contrast, the same laser powers result in minimal temperature increases in control media without 
HCIONPs. 
PTT by HCIONPs inhibits cell viability of triple negative breast cancer cells: The 
majority of our studies were conducted using the human SUM159 breast cancer cell line, which 
is triple negative and has quantifiable populations of both ALDH+ and CD44+/CD24-/EpCAM+ 
BCSCs [48].  For our first in vitro study we investigated the effect of HCIONP-mediated 
photothermal therapy (10 min) at P1, P2, and P3 laser powers on SUM159 cell viability after 72 
h, as shown in Figure 2.1B.  Control treatments tested include Laser Only (P1, P2, P3), 
HCIONPs Only, and Non-Treated.  While cell viabilities after Laser Only and HCIONPs Only 
control treatments are not statistically different from the Non-Treated group, a dose-dependent 
decrease is observed for PTT-treated cells irradiated at increasing laser powers in the presence of 
HCIONPs.  Significant decreases in viability are observed after irradiation at power levels P1 
and P2, but some cells are able to survive and proliferate within 72 h.  This capacity is abrogated 
by PTT at P3, for which the relative number of viable cells is 4.7% of the Non-Treated control. 
MET BCSCs are preferentially sensitive to PTT: Next we performed flow cytometry on 
PTT-treated SUM159 cells to examine the relative sensitivities of the ALDH+ epithelial-like 
(MET) BCSCs and CD44+/CD24-/EpCAM+ mesenchymal-like (EMT) BCSCs to each other 
and the bulk cancer cells.  Cells were counted and bulk viability determined 24 hours following 
PTT, prior to quantification of each BCSC population by flow cytometry.  As shown in Figure 
2.2A, a dose-dependent decrease the ALDH+ MET BCSC percentage occurs for 10 min PTT at 
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increasing laser powers.  PTT significantly decreases the percentage of ALDH+ BCSCs using 
the P2 laser power while the P3 power is required to significantly decrease cell viability (Figure 
2.2C), suggesting an increased sensitivity compared to bulk cancer cells.  The significant 
decrease in CD44+/CD24-/EpCAM+ EMT BCSC absolute number, but not percentage, at the P3 
laser power (Figure 2.2B) suggests that the sensitivity of EMT CSCs is similar to the bulk cancer 
cells after 10 min PTT.  Control treatments with P3 Laser Only and HCIONPs Only do not affect 
either BCSC population (Figure 2.S1). 
An enhancement of BCSC sensitivity to PTT relative to bulk cancer cells is more 
apparent after 20 min irradiation using the same laser powers.  Hyperthermia at the P1 laser 
power reveals that a significant decrease in the percentage of ALDH+ MET CSCs (Figure 2.2D) 
occurs without a significant decrease in the overall cell viability (Figure 2.2F).  Increasing the 
irradiation time to 20 minutes also enhances the sensitivity of EMT CSCs, for which a significant 
difference in percentage and absolute number is observed after P2 PTT compared to the Non-
Treated group (Figure 2.2E). 
Mammosphere formation reveals PTT inhibits BCSC self-renewal: We next employed the 
mammosphere assay, the classic in vitro functional BCSC assay, to evaluate the effect of 
HCIONP-mediated PTT on BCSC self-renewal. Treatment is performed in non-adherent 
conditions in medium lacking serum, and stem cells that survive form three-dimensional 
mammospheres.  These primary spheres are then passaged and re-plated, without further 
treatment, to form secondary mammospheres.  A reduction in secondary mammosphere 
formation suggests inhibition of CSC self-renewal. 
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Here, for the first time, the effect of PTT on BCSC self-renewal is studied based on the 
formation of secondary mammospheres.  Our lab has found that the SUM159 cell line is one of 
few not ideally suited for the mammosphere assay, as nearly all cells able to survive and form 
spheres (data not shown).  Instead, MCF7 breast cancer cells were selected to assess the effect of 
PTT on mammosphere formation by BCSCs [49, 50].  Primary mammospheres were quantified 
and imaged seven days after treatment of single cells (10 min).  As shown in Figure 2.3A, only 
PTT treatment with both HCIONPs and laser irradiation results in a significant decrease in 
primary mammosphere formation, which occurs in a dose-dependent manner with increasing 
laser power.  Furthermore, increases in laser power reduce mammosphere size in addition to 
mammosphere number, as shown in Figure 2.3B.  Control treatments with P3 Laser Only and 
HCIONPs Only do not affect mammosphere formation or size (Figure 2.S2). 
Following counting and imaging, the primary mammospheres were collected, dissociated 
into single cells, and re-plated to quantify CSC self-renewal to form secondary mammospheres 
over seven days.  As shown in Figures 2.3C and 2.3D, secondary spheres are significantly 
reduced in number and size in the P1 PTT treatment group.  Most secondary spheres from the P2 
PTT treatment group just met the size threshold for counting (45 µM).  In the P3 PTT treatment 
group, of the few primary spheres large enough to be collected and re-plated as single cells their 
ability to form secondary spheres was completely abrogated.   
PTT delays BCSC-driven tumor formation after secondary implantation: The functional 
assay for inhibition of CSCs in vivo is secondary implantation, which assesses the degree to 
which treatment affects the CSCs’ ability to self-renew and differentiate to drive tumor 
formation in immunodeficient mice.  Treated tumors are removed from primary mice and 
isolated as single cells for implantation at limiting dilutions into non-treated secondary mice, to 
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calculate a tumor initiating cell frequency [2, 7, 9].  Here we performed PTT in mice bearing 
orthotopic SUM159 tumors as previously described by our lab [45] using immunodeficient 
NOD/SCID mice.  Tumors of primary mice were subjected to 1.0 W and 0.5 W PTT (10 min), 
resulting in final tumor temperatures of 60 ± 5 °C and 42 ± 2 °C, respectively.  Mice were 
sacrificed 72 h after PTT to remove tumors for secondary implantation at dilutions of 50, 500, 
and 5,000 cells per injection per treatment group. 
Secondary tumor volumes up to 50 days post-implantation of 500 and 5,000 cells are 
shown in Figures 2.4A-B.  The data clearly show that both 1.0 W and 0.5 W PTT delay 
secondary tumor formation and result in smaller tumor sizes than in secondary mice in the Non-
Treated group, as also demonstrated by the representative images in Figures 2.4C-D.  At the 50 
cell dilution secondary tumors only formed in Non-Treated mice.  As shown in Figure 2.4E, 
extreme limiting dilution analysis [51] of secondary tumor formation for all three dilutions 
reveals a significant difference among treatment groups at Day 30 (p < 0.01) and Day 40 (p < 
0.001).  However, optimization of PTT conditions (e.g., increasing irradiation time) may be 
required to enhance the effect on ultimate tumor formation and tumor initiating cell frequency. 
PTT reduces metastasis formation in axillary lymph nodes: Based on our observations 
that SUM159 cells can metastasize to axillary lymph nodes, for our final study we sought to 
demonstrate that PTT can be used to perform the previously described first essential role of 
cancer therapy – to act locally against all populations of cancer cells to prevent future metastasis.  
Wanting to incorporate PTT into a clinically relevant model, we hypothesized that inhibition of 
BCSCs by PTT would prevent metastasis from spreading from the primary tumor when applied 
before surgery.  Accordingly, NOD/SCID mice were inoculated with Luciferase-transfected 
SUM159 cells and monitored via an in vivo imaging system (IVIS) to track primary tumor and 
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metastatic development after treatment.  Mice received either PTT (0.5 W, 10 min) ten days prior 
to surgical tumor resection (PTT + SR), or surgery without PTT (SR Only).  As denoted in the 
bioluminescence imaging scheme in Figure 2.5A, mice in both treatment groups (n=8) were 
imaged immediately following PTT (Figure 2.5B) and weekly following removal of surgical 
wound clips.  Despite our best efforts to remove all tumor tissue during surgery, initial imaging 
following surgery revealed virtually all tumors growing back in both groups (Figure 2.S3).  
Metastasis formation was tracked by IVIS for six weeks following PTT and confirmed via 
necropsy and staining for AE-1/AE-3 to detect the presence of human SUM159 cells (Figure 
2.S4) [52].  As shown in Figures 2.5B – 2.5D, PTT before surgery significantly reduces the 
proportion of mice that ultimately develop metastases (p < 0.05), presumably by reducing the 
proportion of EMT BCSCs within the residual primary tumor.  The incidence of lymph node 
metastasis was 25% in mice that received PTT versus 62.5%, with the majority of these mice 
containing additional metastatic growths (1/2 in PTT+SR, 4/5 in SR Only). 
 
2.4 Discussion 
Here we conduct translational studies to rigorously analyze the ability of PTT via highly 
crystallized iron oxide nanoparticles to inhibit two breast cancer stem cell populations (ALDH+, 
CD44+/CD24-/EpCAM+) in TNBC in vitro and in vivo, to prevent metastasis spread from 
primary tumors when used in combination with surgery.  The use of HCIONPs for PTT via NIR 
laser light is beneficial for clinical translation for multiple reasons.  Compared to the AuroLase 
gold nanoshells that are 150 nm in diameter, the smaller size of our stealthy HCIONPs facilitates 
efficient tumor accumulation after intravenous injection due to the enhanced retention and 
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permeability (EPR) effect [53, 54].  However, all nanoparticles will undergo significant uptake in 
off-target organs due to the reticuloendothelial system (RES) or mononuclear phagocyte system 
(MPS) [54-56], suggesting another advantage of the biodegradable HCIONPs [45] over 
biocompatible gold-based nanoparticles [18, 57, 58].  While iron oxide nanoparticles (IONPs) 
have been more often investigated for cancer hyperthermia by employing an alternating magnetic 
field, the translation of this approach to humans is limited.  The inability to localize this therapy 
to the tumor tissue generally requires the particles be intratumorally injected [36, 37] to avoid 
off-target heating in other organs where IONPs accumulate after intravenous injection. 
 Here we show that HCIONPs enable selective heating of cell culture medium in response 
to near infrared (885 nm) laser irradiation, which can be tuned to precisely control PTT 
temperatures to kill cancer cells.  A dose-dependent inhibition of SUM159 cell viability is 
observed with increasing PTT laser power (P1 – P3) 72 h after treatment.  PTT at P3 reduces the 
viability to 4.7% of the Non-Treated control, suggesting that HCIONP-mediated hyperthermia 
for only 10 minutes can eliminate proliferation of triple negative breast cancer cells in vitro.  
This is not surprising considering the findings by Burke et al, who compared carbon nanotube-
mediated PTT and conventional hyperthermia by water bath.  Investigating two settings for rate 
of temperature increase (ROTI) by water bath on a suspension of breast cancer stem-like cells 
(HMLERshEcaderin), they showed that hyperthermia induced by NIR-responsive nanoparticles 
enhances cytotoxicity compared to water bath-mediated hyperthermia at equivalent exposure 
times and temperatures [43].  While rapid heat transfer from PTT causes the overall solution 
temperature to become mildly hyperthermic [59], the cytotoxic effect will be amplified by the 
presence of HCIONPs in close proximity to the cells as the heat transfer is significantly greater at 
the nanoparticle surface [60]. 
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Next we sought to evaluate the effect of HCIONP-mediated PTT on the distinct 
epithelial-like and mesenchymal-like BCSCs [12].  Decreases in the percentages of SUM159 
ALDH+ MET BCSCs after 10 and 20 min PTT at increasing laser powers (P1-P3) reveals an 
increased sensitivity of this highly proliferative BCSC population to HCIONP-mediated 
hyperthermia compared to the bulk cell line.  While Atkinson et al demonstrated that gold 
nanoshell-mediated PTT and ionizing radiation together reduce the percentage of ALDH+ 
BCSCs in patient-derived xenografts [18], this is the first report that PTT alone can reduce 
ALDH+ CSCs in human breast cancer cells.  When we examined the CD44+/CD24-/EpCAM+ 
EMT BCSCs, we found their number decreases in proportion to bulk cancer cells after 10 min 
PTT.  A significant decrease in EMT BCSC percentage is observed at the P2 laser power after 20 
min PTT; this suggests preferential elimination of both BCSC populations is possible within 
breast tumors with optimization of PTT conditions, especially considering recent findings that 
EMT BCSCs are more localized at the invasive edge [12] where the nanoparticles will easily 
accumulate within the tumor tissue.  Hyperthermia has been known to trigger several cellular and 
molecular changes, including impairment of protein and DNA/RNA synthesis, protein 
denaturation and aggregation, inhibition of repair enzymes, and induction of heat shock protein 
synthesis [30, 61].  Due to their highly proliferative nature, as determined by elevated ki-67 
expression [7, 12], it is conceivable that the enhanced sensitivity of the ALDH+ BCSCs to 
hyperthermia is due to damaged proteins necessary to meet high metabolic demands and to 
coordinate DNA replication and repair.  Further investigations into the response of heat shock 
proteins within each breast cancer cell subtype may also provide insight into differences in 
sensitivity to nanoparticle-mediated hyperthermia [18].  
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Previous studies of nanoparticle-mediated hyperthermia have yet to examine the 
treatment’s effect on CSC self-renewal by evaluating mammosphere formation beyond the 
primary generation.  In the assay adapted by Dontu and colleagues [62, 63], single cells are 
plated at clonal densities in non-adherent conditions in medium containing growth factors but 
lacking serum.  The result is massive anoikis.  The surviving cells grow in three-dimensional 
colonies, termed mammospheres, that are enriched in stem cells.  First studied using human 
mammary epithelial cells, the cells from these colonies are able to differentiate into all three 
types of mammary epithelial lineages and able to self-renew to form mammospheres after serial 
passaging.  To suggest inhibition of BCSC self-renewal, treatment applied to the primary 
generation of sphere-forming cells must result in a decrease in mammosphere formation in 
subsequent generations. 
By conducting PTT at increasing laser powers, we show that PTT reduces both the 
number and size of primary MCF7 mammospheres formed in a dose-dependent manner.  This 
observation is most apparent after heating at P3, which after seven days resulted in few primary 
mammospheres large enough to collect and passage for the second generation.  For the first time 
we demonstrate the ability of PTT to inhibit secondary mammosphere formation, showing that 
the effect is again dose-dependent.  Most secondary spheres in the P2 PTT treatment group are 
just larger than our 45 µm threshold.  Consistent with the proliferation study, P3 PTT treatment 
is the most drastic; it completely abrogates self-renewal to form secondary spheres. 
 Removal of treated primary tumor cells for secondary implantation at limiting dilutions 
into immune-compromised mice has become the gold standard for in vivo efficacy of treatment 
on CSCs [64, 65].  Here we conduct the first study of secondary implantation from mice solely 
treated with nanoparticle-mediated hyperthermia, using NOD/SCID mice bearing SUM159 
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tumors subjected to 10 min PTT.  While significant decreases are observed in secondary tumor 
volumes and tumor formation rates at 30 and 40 days post-implantation of PTT-treated primary 
tumor cells, ultimate secondary tumor formation rates may have been affected by a very small 
population of residual progenitor or cancer stem cells.  While PTT conditions may need to be 
fine-tuned (e.g., increase laser irradiation time) to obtain optimal results, it is clear the ability of 
BCSCs to drive tumor formation is hindered following PTT.  Interestingly, in contrast to our 
previous study in nude mice [45], with all other variables the same except tumor size at the time 
of treatment (100 vs 40 mm3), 1.0 W PTT was unable to reduce tumor growth in primary 
NOD/SCID mice (data not shown).  Despite repeating treatment in NOD/SCID mice with 
smaller tumors, 1.0 W PTT was unable to prevent tumor growth.  These contrasting effects in 
secondary versus primary mice are consistent with observations made for primary tumor 
treatments that specifically target CSCs [66].  Taken together, this in vivo data suggests two 
important features of PTT treatment: 1) consistent with our in vitro data, BCSCs are more 
sensitive to PTT in vivo than differentiated cancer cells comprising the bulk of the primary 
tumor, and 2) PTT alone is not sufficient to eliminate the bulk of differentiated cancer cells in 
mice with highly compromised immune systems. 
Several factors beyond application time and temperature may play a role in the degree of 
response observed after PTT treatment of primary tumors.  For instance, the ability of the photo-
responsive nanoparticles to extravasate deep into tumor tissue will affect the heating distribution 
by the laser light.  Likewise, in terms of clinical translation, the depth of laser light penetration 
will dictate the efficiency to heat various types of tumors depending on their location within the 
human body.  In our current study, the variable that differed from our previous study, in which 
significant tumor reduction was observed following PTT in nude mice, was the immune 
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functionality of the mice.  Our data combined suggest that the immune function of the mice plays 
a role in the ability to shrink primary tumors following PTT.  Others have recently reported that 
in immune-competent mice proinflammatory cytokines and chemokines released by dying cells 
after nanoparticle-mediated hyperthermia trigger a tumor-specific immune response [36, 39], 
suggesting the importance of mouse model selection given the purpose of the intended study.  
While future studies of photothermal cancer therapy alone may be more efficacious in immune-
competent mice, and in fact may be enhanced if coupled with immunotherapy [32, 39], immune-
compromised NOD/SCID mice make it possible to discern the effect strictly from hyperthermia 
on both stem-like and differentiated cancer cells. 
The advancement to a metastatic disease, which eventually occurs for many women 
diagnosed with early stage breast cancer, is the primary cause of death in women with breast 
cancer [15, 67].  While patients diagnosed with metastatic breast cancer are currently considered 
incurable, palliative treatment options exist [15, 67, 68].  For breast cancer patients with less 
advanced disease, first-line therapy generally includes surgery and depends on factors such as the 
type of breast cancer, stage, and grade; preceding or following surgery, patients may also receive 
radiation, chemotherapy, hormone/endocrine therapy, or biologics (Herceptin).  Given the 
evidence suggesting that CSCs are the culprit responsible for metastasis and are resistant to and 
possibly enriched by chemotherapy and radiation [17-19, 69], there is a critical need to develop 
first-line breast cancer therapy that is effective in two roles: eliminating all types of cancer cells, 
including CSCs, at the primary tumor site to prevent future metastases, and eliminating all types 
of cancer cells at existing metastatic sites.  While extensive research is still required, initial 
reports that nanoparticle-mediated PTT can inhibit CSCs and induce a systemic cancer-specific 
immune response [32, 36, 39] suggest it may be a prime candidate to meet both components of 
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this critical unmet need.  In light of our results demonstrating PTT inhibition of MET and EMT 
BCSCs, we sought to demonstrate that PTT could prevent metastasis after treatment of the 
primary tumor. 
In our final study, we examined metastasis development in NOD/SCID mice containing 
Luciferase-transfected SUM159 tumor xenografts treated with PTT ten days before surgical 
resection.  IVIS imaging revealed PTT before surgery significantly reduces the percentage of 
mice with macrometastases, presumably by reducing the proportion of BCSCs within the 
residual primary tumor.  Considering these and the findings by Atkinson and colleagues, 
incorporating nanoparticle-mediated PTT into routine breast cancer therapy such as surgery may 
improve long-term patient outcomes by avoiding sparing or enriching the CSC population.  
However, it will be critical to conduct future studies in immune-competent mice to demonstrate 
the potential to combine PTT with clinically-used therapies to inhibit not only BCSCs located at 
the primary tumor site but those at distal sites by evoking a cancer/CSC-specific immune 
response. 
 
2.5 Conclusions 
In this study we evaluate the ability of photothermal therapy via highly crystallized iron 
oxide nanoparticles to inhibit breast cancer stem cells to prevent metastasis following treatment 
of the primary tumor.  Here we conduct rigorous, translational studies to evaluate the effect of 
PTT via HCIONPs on BCSCs, including both MET and EMT BCSC populations, in triple 
negative breast cancer in vitro and in vivo, and combine PTT with surgical resection to prevent 
lymph node and other metastasis.  We reveal in vitro that PTT eliminates MET BCSCs with the 
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greatest sensitivity and identify conditions in which EMT BCSCs are also eliminated 
preferentially to differentiated cancer cells.  For the first time, we show that PTT inhibits breast 
cancer stem cell self-renewal in vitro.  Through secondary implantation we demonstrate that PTT 
impedes BCSC-driven tumor formation.  Finally, we show that PTT before surgery significantly 
reduces metastasis development in TNBC.  Taken together, these results suggest the potential to 
combine nanoparticle-mediated photothermal therapy with current clinical treatments such as 
surgery to enhance CSC destruction and improve long-term survival in breast cancer patients. 
 
2.6 Materials and Methods 
Preparation of HCIONPs: Polymer-coated HCIONPs were prepared as previously 
described by our lab.  Briefly, HCIONPs (15 nm diameter) were synthesized in organic solvent 
by thermal decomposition [45].  Single core nanocrystals were rendered soluble in aqueous 
solution after coating with diblock copolymer poly(ethylene oxide)-b-poly(γ-
methacryloxypropyl trimethoxysilane)(PEO-b- PγMPS), which is synthesized by reversible 
addition fragmentation chain transfer (RAFT) polymerization, and purifying by a magnetic 
separator (Frantz laboratory) [45, 70].  The iron concentration of the resultant solution was 
determined using o-phenanthroline as previously described [45].  HCIONPs were diluted in 
phosphate buffered saline (PBS) for in vitro and in vivo studies. 
Photothermal effect of HCIONPs in vitro: For all in vitro studies, HCIONPs were 
suspended in cell culture medium (0.1 mg Fe/mL, 200 µL/well) on a 96-well plate resting on a 
hot plate set to 37 °C.  The solution was heated by a NIR laser (885 nm, spot size 5x8 mm2, 
MDL-III-885, OPTO Engine LLC, Midvale, UT) at increasing powers for 10 minutes and the 
     49 
 
temperature recorded each minute using an infrared camera (FLIR Systems, i7, Boston,MA).  
Laser powers were identified to produce heating curves achieving final temperatures of 42, 45, 
and 48 °C (0.34, 0.42, and 0.49 W, respectively). 
Cell Culture: SUM159 and MCF7 breast cancer cells were grown as adherent 
monolayers incubated at 37 °C with 5% CO2.  Ham’s F12 medium was supplemented with 5% 
fetal bovine serum, 1% antibiotic-antimycotic, 5 µg/mL insulin, 1 µg/mL hydrocortisone, and 4 
µg/mL gentamicin for SUM159 cell culture.  Eagle’s Minimum Essential Medium (EMEM) was 
supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic, and 10 µg/mL insulin for 
MCF7 culture. 
Alamar Blue Cell Viability Studies: SUM159 cells were seeded at 1,000 cells/well in 200 
μL on a 96-well plate and were treated the following day.  After returning to the incubator for 72 
h, 20 µL of alamarBlue reagent (AbD Serotec, Raleigh, NC) were added to each well and the 
fluorescence was measured 4 h later (540/25 nm excitation, 590/20 nm emission, 570 nm mirror) 
using a BioTek micro-plate reader (Synergy 2). 
Flow Cytometry: Suspensions of SUM159 cells (500,000/well) were treated (0.34, 0.42, 
0.49 W) in a 96-well plate.  After PTT the cells were collected, added to 25 cm2 flasks, and 
allowed to recover overnight.  The following day cells were collected and counted using Trypan 
Blue before dividing into separate tubes to stain for ALDH+ CSCs and CD44+/CD24-/EpCAM+ 
CSCs.  The Aldefluor Assay (StemCell Technologies, Durham, NC) was conducted according to 
the manufacturer’s instructions.  Antibodies used were CD44-APC, CD24-FITC, EpCAM-PE-
Cy7 (BD), which incubated for 30 min on ice with cells in HBSS + 2% FBS.  DAPI was used for 
cell viability.  Samples were run on a FACSCanto II (BD) to collect 10,000 live cells, and 
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analyzed using Flowing Software 2.5.1 (Perttu Terho, Turko Centre for Biotechnology, 
University of Turko, Finland). 
Mammosphere Assay: Mammosphere culture was conducted in Mammary Epithelial 
Basal Medium (MEBM) supplemented with 1% antibiotic-antimycotic, 5 µg/mL insulin, 1 
µg/mL hydrocortisone, and 4 µg/mL gentamicin, 0.02 µg/mL epidermal growth factor (EGF), 
0.02 µg/mL basic fibroblast growth factor (bFGF), B27 (Invitrogen), 1:25,000,000 β-
mercaptoethanol [49].  For PTT, suspensions of MCF7 cells (100,000/well) were heated in an 
ultralow adhesion 96-well plate.  To achieve final temperatures of 42, 45, and 48 °C on the 
ultralow plate required laser powers, designated P1-P3, of 0.37, 0.52, and 0.66 W, respectively.  
After PTT the cells were collected and added to an ultralow adhesion 6-well plate at a density of 
6,000 cells in 2 mL mammosphere medium per well.  Primary spheres were allowed to form for 
seven days and then were counted and imaged using an inverted microscope (Nikon TE 2000S).  
The medium from each well was then passed through a 40 µM strainer to collect the 
mammospheres, which were dissociated into single cells.  The single cells were counted and re-
plated on a fresh ultralow adhesion 6-well plate (non-treated, 42 °C PTT, and 45 °C PTT 
treatment groups) or 96-well plate (48 °C PTT treatment group).  Secondary mammospheres 
were allowed to form for seven days before counting and imaging. 
Mouse Models for PTT: All mouse studies were conducted in accordance with a standard 
animal protocol approved by the University of Michigan University Committee on the Use and 
Care of Animals. Five week old NOD/SCID (non-obese diabetic/severe combined 
immunodeficient) mice were obtained from Harlan laboratories.  Primary xenograft tumors were 
formed in the no 4 inguinal mammary pad by orthotopic injection of 0.5x106 SUM159 cells 
suspended in matrigel.  Upon the detection of palpable tumors, tumor volumes were calculated 
     51 
 
according to the following equation: volume = 0.5 x length x (width)2.  Mice were divided into 
treatment groups (n = 5) once tumor volumes reached ~100 mm3.  PTT for all in vivo studies was 
conducted as previously described [45].  Briefly, mice were intravenously injected with 
HCIONPs by tail vein (20 mg Fe per kg mouse body weight).  Following anesthesia 48 h later, 
the NIR laser was applied for 10 min.  Tumor surface temperatures were continuously monitored 
using an infrared camera (FLIR Systems, i7, Boston, MA). 
Secondary Implantation Studies: Primary mice were subjected to ten minute PTT using 
laser powers of 1.0 W or 0.5 W (2.5 W/cm2 or1.25 W/cm2 irradiance, respectively).  Mice were 
humanely euthanized 72 h after PTT, and tumors were harvested and digested using a 
gentleMACS Octo Dissociator (MACS Miltenyi Biotec, San Diego, CA) according to the 
manufacturer’s protocol.  Single tumor cells were counted, stained with DAPI to isolate viable 
cells and H2K[d]-APC to discriminate mouse cells, and sorted on a FACSAria III (BD).  DAPI-
/H2K[d]- cells were pooled from each tumor per treatment group and injected double-sided into 
the no 4 mammary fat pads of secondary NOD/SCID mice (five weeks) in limiting dilutions 
(5,000, 500, 50 cells). 
Metastasis Studies: Luciferase-expressing SUM159 cells [9] were used for xenograft 
tumor formation.  Mice were randomly divided into treatment groups (n = 8) once tumor 
volumes reached ~75 mm3.  Mice were imaged using an IVIS 200 and Living Image software 
(PerkinElmer, Waltham, MA) one day following PTT (0.5 W).  Ten days following PTT (tumors 
< 1 cm diameter), tumor resections were performed using a high temperature cauterizer (Bovie 
Change-A-Tip, Clearwater, FL).  Mice were monitored weekly by IVIS for metastasis formation 
following removal of surgical wound clips, and sacrificed at six weeks post-PTT due to tumor 
burden.  Results of IVIS bioluminescence images were confirmed via necropsy and Pan-
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cytokeratin (AE1/AE3) staining of metastatic tissues following fixation in formalin and 
embedding in paraffin. 
Statistical Analysis: All data are represented as mean ± standard deviation.  The 
significance values of data sets with more than two groups were calculated using Minitab 
software via one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc 
comparisons to the non-treated control, and proportions were compared via the Chi-square test 
[71].  Statistical analysis of limiting dilution transplantation data was conducted using Extreme 
Limiting Dilution Analysis (ELDA) software as described by Hu and Smith [18, 51].  A p < 0.05 
was considered statistically significant. 
 
2.7 Figures 
 
Figure 2.1. (A) Ten minute heating curves of SUM159 medium subjected to PTT (Laser + 
HCIONPs), compared to Laser Only controls.  Laser powers tested were 0.34, 0.42, 0.49 W, 
designated P1, P2, P3, respectively.  Solutions were spiked with HCIONPs (0.1 mg Fe/mL) for 
PTT or PBS for Laser Only control treatment.  (B)  SUM159 cell viability determined by 
alamarBlue 72 h after PTT (10 min) at P1, P2, and P3 laser powers, compared to IONP Only, 
Laser Only (P1-P3), and Non-Treated controls.  Addition of alamarBlue Reagent results in a 
colorimetric change that is proportional to the number of metabolically active cells.  * p< 0.05, 
** p < 0.01, *** p < 0.001 via Dunnett’s post-hoc comparison to Non-Treated control. 
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Figure 2.2. SUM159 cell viability 24 h after 10 min (A) and 20 min (D) PTT.  MET-like 
ALDH+ BCSC percentage and absolute number 24 h after 10 min (B) and 20 min (E) PTT.  
EMT-like CD44+/CD24-/EpCAM+ BCSC percentage and absolute number 24 h after 10 min 
(C) and 20 min (F) PTT.  It should be noted that after 20 min PTT at P3, the number of viable 
cells was insufficient for analysis by flow cytometry.  For cell viabilities and percentages of 
BCSCs, * p < 0.05, ** p < 0.01, *** p < 0.001 via Dunnett’s post-hoc comparison to Non-
Treated control. For absolute numbers of BCSCs, # p < 0.05, ## p < 0.01, ### p < 0.001 via 
Dunnett’s post-hoc comparison to Non-Treated control. 
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Figure 2.3. (A) MCF7 primary mammosphere formation seven days after PTT (10 min) at P1, 
P2, P3 laser powers, grown at a density of 6,000 cells/well.  (B) Representative images of 
primary mammosphere size seven days after PTT.  (C)  Secondary mammosphere formation 14 
days after primary PTT, normalized by number of cells plated per well.  (D) Representative 
images of secondary mammosphere size 14 days after primary PTT.  Primary spheres were 
collected on Day 7, digested to single cells and plated for secondary mammosphere formation.  * 
p< 0.05, ** p < 0.01, *** p < 0.001 via Dunnett’s post-hoc comparison to Non-Treated control. 
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Figure 2.4. Tumor growth curves for secondary mice receiving dual injections of 5,000 (A) and 
500 (C) treated SUM159 tumor cells from primary mice.  Representative images of secondary 
mice at Day 40 after receiving 5,000 treated cells (B) and at Day 49 after receiving 500 treated 
cells (D).  (E) Tumor formation in secondary mice after receiving injections of 5,000, 500, or 50 
treated SUM159 tumor cells from primary mice.  Primary mice were administered HCIONPs (20 
mg Fe/kg body weight) intravenously 48 h prior to laser application.  * p< 0.05, ** p < 0.01, *** 
p < 0.001 via Extreme Limiting Dilution Analysis software as described by Hu and Smith [18, 
51]. 
 
 
     56 
 
 
Figure 2.5. (A) Schematic of bioluminescence imaging of SUM159 tumor-bearing mice, relative 
to treatment.  † denotes bioluminescence imaging.  ‡ denotes removal of surgical wound clips.  
(B) IVIS bioluminescence images of mice one day and six weeks following PTT on Day 0.  To 
image metastases with higher sensitivity, the lower portions of all mice were covered to mask the 
tumor signal.  (C) Percentage of mice with metastasis detectable via bioluminescence imaging 
over time after treatment.  (D)  Summary of axillary lymph node (ALN) and other metastases 
detected in treated mice during necropsy. * p< 0.05 by Chi-square test of proportions. 
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2.8 Supplemental Figures 
 
Figure 2.S1. (A) SUM159 cell viability after overnight recovery from IONP Only and Laser 
Only (P3 power, 10 min) control treatments.  (B) MET-like ALDH+ BCSC percentage and 
absolute number after control treatments.  (C) EMT-like CD44+/CD24-/EpCAM+ BCSC 
percentage and absolute number after control treatments. 
 
     58 
 
 
Figure 2.S2. (A) MCF7 primary mammosphere formation seven days after IONP Only and Laser 
Only (P3 power, 10 min) control treatment.  (B) Representative images of primary 
mammosphere size seven days after control treatment.   
 
Figure 2.S3. (A) Representative images of tumors excised by surgery from treated mice on Day 
10.  (B) Bioluminescence images of treated SUM159 tumor-bearing mice taken at Week 3, 
eleven days after surgery.   
 
Figure 2.S4. (A) Representative images of treated tumors with normal or metastatic lymph nodes 
from Week 6 necropsy.  (B) Representative images of pan-cytokeratin (AE-1/AE-3) staining of 
human metastatic cancer cells (in brown) located within tumors and lymph nodes from Week 6 
necropsy of treated mice (corresponding to Figure 2.S4A) bearing SUM159 tumors. 
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CHAPTER 3: INVESTIGATIONS OF PHOTOTHERMAL AND IMMUNE 
CHECKPOINT BLOCKADE TO INHIBIT METASTATIC BREAST CANCER BY 
ELIMINATION OF CANCER STEM CELLS AND INDUCTION OF A SYSTEMIC T-
CELL RESPONSE 
 
3.1 Abstract 
As increasing evidence implicates breast cancer stem cells (BCSCs) as drivers of 
metastasis that evade traditional therapies, it has become imperative to explore the untapped 
potential of nanomedicine to develop translational therapies that can be incorporated into current 
clinical practices to achieve significant improvements in patient survival.  One of only few 
nanoparticle-based treatments to enter human clinical trials is photothermal therapy (PTT) to 
induce localized tumor hyperthermia.  Here we employ highly crystallized iron oxide 
nanoparticle (HCIONP)-mediated PTT in a model of metastatic breast cancer to investigate the 
ability to inhibit BCSCs and induce an enhanced, and potentially synergistic, effect with cancer 
immunotherapy to trigger a systemic, cancer (stem) cell-specific immune response.  In 4T1 
metastatic breast cancer cells, twenty minute HCIONP-mediated PTT significantly reduces 
ALDH+ BCSCs in vitro.  In BALB/c mice bearing 4T1 tumors ALDH+ BCSCs are significantly 
inhibited by PTT when given as monotherapy and in combination with PD-L1 antibody.  
Combination treatment with PTT and PD-L1 antibody reveals promising reductions in tumor 
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growth and formation of lung macrometastases.  Increases of key inflammatory cytokines (IL-6) 
and immune cell-attracting chemokines (CXCL-1, CXCL-9, CXCL-10) in serum of dual-treated 
mice suggest the potential to enhance the population of tumor-infiltrating effector T-cells, which 
will be confirmed with quantitative immunophenotyping of saved tumor tissues.  With additional 
studies we expect to conclusively demonstrate PTT conditions which, when combined with 
immune checkpoint blockade, effectively prevent metastasis through inhibition of BCSCs and 
eliminate existing metastases by triggering a systemic, cancer (stem) cell-specific immune 
response.  Successful development of such nanomedicine to enhance efficacy of both BCSC 
elimination and a T-cell-driven immune response could potentially extend immunotherapy as a 
viable treatment option for metastatic breast cancer and drastically improve patient survival. 
 
3.2 Introduction 
Advancement to a metastatic disease is the primary cause of death in breast cancer 
patients, at which point treatment becomes palliative [1-3].  Up to 10% of patients have Stage IV 
or metastatic breast cancer at the time of diagnosis, and it is estimated that metastatic recurrence 
accounts for 20-30% of breast cancer cases [4].  The ability to detect, prevent, and successfully 
treat metastasis remains one of the greatest challenges in breast cancer therapy.  Accumulating 
evidence points to breast cancer stem cells (BCSCs), identified as aldehyde dehydrogenase 
positive (ALDH+) or by the surface receptor phenotype CD44+/CD24-, as the culprit driving the 
spread of cancer cells from the breast [5-8].  Also shown to be responsible for tumor growth and 
recurrence, this subset of cells exhibits resistance to and may even be enriched by conventional 
breast cancer therapies such as radiation and chemotherapy [9-14].  This underscores a critical 
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need to develop innovative therapies that at the cellular level kill BCSCs and are effective 
against metastatic disease. 
Therapeutic regimens exploiting advances in nanoparticle development offer a 
tremendous potential to enhance treatment efficacy against cancer stem cells (CSCs) and 
consequently inhibit metastasis-initiating cells.  However, the most effective future therapies 
must not only act locally against all populations of cancer cells (differentiated and stem) to 
prevent future metastasis but also systemically against all populations of cancer cells in existing 
metastases.  Recent findings by ourselves and reported in the literature together suggest that 
nanoparticle-mediated photothermal therapy (PTT) may be a prime candidate for development of 
cancer therapy that is effective against BCSCs and differentiated cancer cells, both locally and 
systemically. 
In photothermal cancer therapy, near infrared (NIR) laser light is absorbed by 
nanoparticles that in response produce heat that is effective at killing cells.  It is one of few 
nanoparticle-based treatments to enter clinical trials in human cancer patients [15, 16].  
Hyperthermic cell death is localized to cancer tissue based on application of the laser light.  In 
some pre-clinical models the PTT-mediating nanoparticles are injected into the tumor directly 
[17, 18].  The gold nanoshell formulation, AuroLase, currently in clinical trials is injected into 
the blood stream and accumulates in the tumor tissue through passive targeting by the enhanced 
permeability and retention (EPR) effect [19-21].  Although treatment is localized by requiring 
external activation by laser light, use of biocompatible nanoparticles composed of gold and 
carbon minimizes potential off-target side effects of PTT.  Iron oxide-based nanoparticles have 
been used to induce hyperthermia triggered by an alternating magnetic field (AMF), and our lab 
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has recently shown that those with a highly crystallized structure produced by thermal 
decomposition are also capable of PTT [22]. 
Atkinson et al. were the first to study a translational approach to include nanoshell-based 
PTT with radiation therapy to enhance the efficacy against ALDH+ BCSCs [9].  In our recent 
studies described in Chapter 2, we examined iron oxide nanoparticle (IONP)-mediated PTT in 
human SUM159 triple negative (estrogen, progesterone, and Her2 receptor negative) breast 
cancer models.  We showed PTT inhibits both epithelial-like ALDH+ and mesenchymal-like 
CD44+/CD24- BCSCs, and that in immune-compromised mice PTT prevents the spread of 
SUM159 cells to axillary lymph nodes.  Other works examining the mechanism by which PTT 
effects tumor growth and metastasis have not focused on the role of CSCs but the immune 
system.  In the last year multiple groups have reported initial findings that nanoparticle-mediated 
hyperthermia induces a systemic cancer-specific immune response in which cytotoxic T-cells are 
trained to recognize and inhibit distal cancer cells [17], a response that may be strengthened by 
coupling with immunotherapy [23, 24].  Various cancer immunotherapy approaches have already 
advanced to the clinic.  The simplest for pre-clinical research is checkpoint inhibition using 
monoclonal antibodies, to suppress inhibitory signaling of cytotoxic T-cells by cancer cells [25-
27].  Other clinically investigated cancer immunotherapy approaches, which may be considered 
for combination with PTT, are genetic engineering of T-cells to enhance specificity for tumor-
associated antigens and adoptive T-cell transfer.  In the latter, a patient’s T-cells are first 
removed to culture and expand ex vivo and then reintroduced into the patient (with the T-cell 
growth factor IL-2 potentially included in either step) [28-30].   
Recent findings from photothermal therapy in immune-competent mice [17, 23, 24] 
collectively suggest a mechanism in which PTT at the primary tumor site triggers a release of 
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inflammatory cytokines and chemokines, such as those seen in burn patients, that attract antigen 
presenting cells (APCs) such as dendritic cells (DCs) to the tumor site.  This results in activated 
DCs in tumor draining lymph nodes that present to CD8+ cytotoxic T-cells, which are drawn to 
the tumor site by the released chemokines such as CXCL1.  The effector T-cell response is 
evident by an increase of IFN-γ at the tumor site released by dying cancer cells.  Furthermore, it 
was shown that the systemic immune effect of PTT is enhanced by combination with 
immunotherapy intended to boost T-cell populations.  Decreased lung metastasis and increased 
CD8+ populations and decreased growth in contralateral tumors that did not receive PTT were 
improved when PTT was supplemented with either adoptive T-cell therapy or immune 
checkpoint inhibition via a CTLA-4 antibody [23, 24].  Wang et al also reported the unique 
ability of carbon nanotubes photothermal mediators to act as an adjuvant to boost maturation of 
DCs and production of antitumor cytokines [24]. 
 Here we sought to expand upon our previous study to inhibit breast cancer stem cells and 
prevent metastasis by iron oxide nanoparticle-mediated PTT, discussed in Chapter 2, by 
investigating treatment conditions which in immune-competent mice would induce local 
hyperthermia and a systemic immune response, both effective against BCSCs.  Our first 
objective was to examine PTT efficacy against BCSCs in immune-competent mice with 4T1 
metastatic breast cancer.  Furthermore, we sought to determine whether in this setting PTT 
combination with immunotherapy will be additive or even synergistic.  Our next objectives were 
to investigate the ability of such treatment to trigger cytokine and chemokine release by dying 
cancer cells and consequently increase cytotoxic T-cells in the tumor tissue.  HCIONP-mediated 
PTT was first studied in vitro in 4T1 cells, revealing successful inhibition of ALDH+ BCSCs 
after 20 minutes heating to 46 °C.  Furthermore, ALDH+ BCSCs in BALB/c mice bearing 4T1 
     70 
 
tumors were significantly inhibited 48 h after PTT when given as monotherapy and in 
combination with PD-L1 antibody.  Our initial results reveal that dual treatment combining PTT 
and PD-L1 blockade reduces tumor growth and formation of lung macrometastases, which may 
be further improved with adjustments to the treatment regimen.  Analysis of serum in tumor-
bearing mice post-treatment reveals induction of key inflammatory cytokines (IL-6) and immune 
cell-attracting chemokines (CXCL-1, CXCL-9, CXCL-10).  To overcome challenges with 
quantification of T-cells by flow cytometry of homogenized tumor tissue, sections of saved 
tumor tissue will be analyzed by quantitative immunophenotyping. 
The preliminary data presented here lays the groundwork to establish conditions in which 
localized PTT mediated by biodegradable iron oxide nanoparticles can prevent metastasis 
through inhibition of BCSCs in the primary tumor and, in combination with cancer 
immunotherapy, induce an immune response effective at eliminating existing metastatic cancer 
cells including BCSCs.  Successful development of such translational nanomedicine to extend 
immunotherapy to metastatic breast cancer patients, enhancing recruitment of cytotoxic T-cells 
which become trained to recognize and kill distal cancer (stem) cells, would have potential to 
significantly improve survival of a widespread and currently incurable disease. 
 
3.3 Results and Discussion 
Our lab has developed highly crystallized iron oxide nanoparticles (HCIONPs) that are 
efficient mediators of photothermal therapy in vivo [22].  In contrast to more commonly used 
gold-based nanoparticles for PTT, the HCIONPs are biodegradable, capable of magnetic 
resonance imaging (MRI) of tumors, and their small size (~15 nm) is ideal for passive tumor 
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accumulation by the enhanced permeation and retention (EPR) effect [22, 31-33].  As discussed 
in Chapter 2, we have shown that HCIONP-mediated PTT eliminates BCSCs in SUM159 triple 
negative breast cancer cells in vitro and in immune-compromised NOD/SCID mice bearing 
SUM159 tumors.  In order to study the ability of HCIONP-mediated PTT to induce a systemic 
antitumor effect in our follow up work, mouse breast cancer cells would be needed to establish 
tumors in immune-competent mice.  For this work we selected the 4T1 cell line for in vitro and 
in vivo studies, as it has been used as a model for stage IV metastatic triple negative breast 
cancer and has a quantifiable ALDH+ BCSC population [34-36]. 
Like with our previous study, we first sought to demonstrate the ability of PTT to 
eliminate ALDH+ BCSCs in vitro by flow cytometry.  4T1 cells were subjected to 20 min PTT 
(HCIONPs + Laser) in a 96-well plate.  Control treatments included Laser Only and HCIONP 
Only.  As shown in Figure 3.1A, medium containing cells exposed to HCIONPs (0.1 mg Fe/mL) 
prior to laser treatment (0.24 W) reached a temperature ~46.5 °C within 10 minutes, at which 
point the temperature had essentially plateaued (~47 °C at 20 min).  In contrast, a minimal 
temperature increase from ~31 to ~35 °C was observed in the medium containing cells in the 
Laser Only treatment group.  Cells were counted and bulk viability determined 24 hours 
following PTT, prior to quantification of each BCSC population by flow cytometry.  While Laser 
Only and HCIONP Only control treatments did not significantly affect 4T1 cell viability, the 
relative viability of PTT-treated cells dropped to 26% (p < 0.001) of the Non-Treated control 
(Figure 3.1B).  Live BCSCs with elevated expression of the aldehyde dehydrogenase enzyme 
(ALDH+) were quantified after PTT by staining with DAPI and the Aldefluor kit followed by 
flow cytometry.  As shown in Figure 3.1C only in the PTT-treated group does the ALDH+ cell 
population significantly decrease (p < 0.001), 3-fold from ~2% in the Non-Treated control.  The 
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treatment effect is more apparent considering the absolute BCSC number (Figure 3.1C), 
accounting for the dramatic decrease in overall cell survival. 
Next we intended to confirm our in vitro results with analysis of HCIONP-mediated PTT 
inhibition of ALDH+ BCSCs in immune-competent BALB/c mice with orthotopic 4T1 tumors 
grown in the inguinal mammary fat pad.  For each of our in vivo experiments, we sought to 
investigate the potential to enhance response to treatment by combining PTT with cancer 
immunotherapy intended to boost the efficacy of effector cytotoxic T-cells in the tumor tissue.  
Our rational for this was three-fold.  First, as described above, recent studies have revealed that 
PTT-mediated cell death triggers cytokine release and a signaling cascade that attracts cytotoxic 
CD8+ T-cells to tumor site [17, 23, 24].  Second, PTT via HCIONPs that have greatest tumor 
accumulation at the periphery [37] may induce damage to vasculature at the tumor boundary to 
enhance T-cell tumor infiltration.  Third, immunotherapy aimed to boost efficacy of cytotoxic T-
cells drawn to the primary tumor by PTT may promote development of an adaptive immune 
response against metastatic cancer cells [23, 24].  For our studies of PTT combined with cancer 
immunotherapy in mice, we chose an antibody to block the interaction between the programmed 
death 1 (PD-1) receptor on T-cells and the programmed death ligand 1 (PD-L1) receptor on 
cancer cells.  Ligand activation of the PD-1 immune checkpoint pathway is normally used in 
regulating autoimmunity.  However, many cancers have adapted to express the PD-L1 ligand to 
inhibit T-cell function and escape attack by these cells [38].  As the 4T1 cell line has been shown 
to have induced expression of PD-L1 in vivo [39, 40], we chose an anti-PD-L1 antibody for our 
studies.  The PTT/PD-L1 antibody treatment regimen in immune-competent BALB/c mice with 
orthotopic 4T1 tumors grown in the inguinal mammary fat pad is shown in Scheme 3.1.  
Following tumor measurement on Day 0, mice were administered PD-L1 antibody every other 
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day beginning on Day 1.  HCIONPs were injected by tail vein on Day 1 and PTT conducted on 
Day 2. 
For our first in vivo study, we sought to confirm our in vitro results with analysis of 
HCIONP-mediated PTT inhibition of ALDH+ BCSCs.  Mice with 4T1 tumors (~55 mm3) were 
divided into Non-Treated, PD-L1 Antibody, PTT, and PTT + PD-L1 Antibody treatment groups 
(n=5-6).  Mice in both groups given PD-L1 antibody received intraperitoneal (IP) injections (200 
μg) 24 h before and 24 h after PTT.  Mice receiving PTT were administered HCIONPs by tail 
vein (20 mg Fe/kg body weight) 24 h before 20 min laser application at a power of 0.52 W.  As 
shown in Figure 3.2A, this resulted in a rapid increase in tumor surface temperature to ~55 °C 
within five minutes.  Mice were sacrificed 48 h after PTT and tumors were digested for 
Aldefluor staining of single cells.  Analysis by flow cytometry in Figure 3.2B reveals an average 
population of ALDH+ cells in the Non-Treated group of ~1.6%, consistent with our in vitro 
results.  As expected, PTT significantly decreased the ALDH+ cells 3-fold to ~0.5% (p < 0.001).  
Similar results were obtained with the dual PTT + PD-L1 Antibody group (p < 0.001), while the 
ALDH+ population in the PD-L1 Antibody group was comparable to the Non-Treated control.  
While this suggests that PTT is the main inhibitor of ALDH+ BCSCs, recent efforts to develop 
CSC vaccines specifically targeting ALDH+ BCSCs [41-43] indicate that the death of these cells 
at the tumor site may result in BCSC inhibition by T-cells at distal sites; we expect this effect 
would be bolstered by PD-L1 antibody immunotherapy to boost the activity of cytotoxic T-cells 
at the primary tumor site following PTT. 
The primary factors to determine efficacy of HCIONP-mediated PTT and anti-PD-L1 
antibody treatments alone and in combination were tumor growth and development of lung 
macrometastases.  4T1 cells are syngeneic in BALB/c mice and spontaneously metastasize to the 
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lungs, which is the major cause of death, and other organs [44, 45].  Mice with tumors ≤ 80 mm3 
were randomized into treatment groups (n=5-6) on Day 0 and treated as shown in Scheme 3.1.  
Tumors were measured every five days following PTT on Day 2, and twenty days later mice 
were sacrificed.  As shown in Figure 3.3A, PTT and PTT + PD-L1 Ab groups have modest but 
not significant reductions in tumor size compared to the Non-Treated control mice; tumor sizes 
in mice treated only with the anti-PD-L1 antibody were similar to control.  While not quite 
significant compared to the Non-Treated control, mice in the dual-treatment group had the least 
development of lung metastases as shown in Figure 3.3B.  Mice receiving the anti-PD-L1 
antibody alone had the next greatest reduction in observable lung metastases.  Photos of the 
excised lungs (Figure 3.3C) and representative hematoxylin and eosin (H&E) slides of lung 
sections confirm these observable differences (Figure 3.3D).  On average the mice in PTT + PD-
L1 Ab treatment group also had slightly smaller lung masses (data not shown), potentially an 
effect of having fewer metastatic growths.  While the combination of HCIONP-mediated 
hyperthermia and anti-PD-L1 antibody immunotherapy appear to have the greatest ability to 
reduce 4T1 tumor growth and lung metastases, it is clear the therapeutic regimen must be altered 
to achieve statistically significant results.  For example, like the anti-PD-L1 antibody 
administered multiple times over several days, multiple laser applications following HCIONP 
administration could help eliminate residual cancer cells after one PTT session.   
To study whether PTT and PD-L1 inhibition can induce a substantial immune response 
driven by activation of CD8+ cytotoxic T-cells as described above [17, 23, 24], mice were 
treated according to Scheme 3.1 and were sacrificed on Days 4 and 10 to analyze serum cytokine 
and chemokine concentrations as well as tumor T-cell populations.  While the majority of the 22 
cytokines and chemokines tested were not significantly affected by the conditions of treatment, 
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our data revealed significant increases in four promising molecules: IL-6, CXCL-1, CXCL-9 and 
CXCL-10.  A proinflammatory cytokine and typical marker of cellular immunity mediated 
through CD8+ T-cells, IL-6 was reported to be elevated in mouse serum following PTT induced 
by carbon nanotubes (subcutaneously injected) and hollow gold nanoshells (intratumorally 
injected) [23, 24].  The chemoattractant CXCL-1, known to draw neutrophils to burned tissues, 
was also higher in serum following PTT, as previously reported [23].  The chemoattractants 
CXCL-9 and CXCL-10 are recruiters of CD8+ T-cells and are directly correlated with the 
number of effector CD8+ T-cells that infiltrate tumors [46, 47].  As shown in Figure 3.4 (A-D), 
on Day 10 IL-6 and the three CXCL chemokines are elevated in serum following PTT + PD-L1 
Antibody treatment compared to serum in Non-Treated mice.  Surprisingly, the initial results in 
the mice receiving monotherapy suggest that PD-L1 Antibody treatment may have had a greater 
effect than PTT.  These results may too have been influenced by the much longer duration of 
PD-L1 Antibody treatment compared to PTT, but follow up studies will need to be conducted to 
confirm these initial findings and make definitive conclusions. 
In addition to serum collection for cytokine/chemokine analysis on Days 4 and 10, 
tumors were harvested and digested for flow cytometry analysis of CD8+ cytotoxic T-cells, 
CD4+ helper T-cells, and CD4+/FoxP3+ regulatory T-cells.  CD4+ T-helper cells release IL-2 to 
promote CD8+ T-cell function and viability [48].  Regulatory T-cells, which are also 
characterized by high CD25 expression, normally function to help to maintain self-tolerance by 
inhibition of effector T-cell responses; one way this is accomplished is competition with CD8+ 
T-cells for IL-2 [30, 49, 50].  Immunotherapy efficacy is correlated with the ratio of CD8+ 
effector T-cells to regulatory T-cells [23, 30, 51].  Unfortunately, it was difficult to make 
conclusions from our flow data due to issues likely caused by high non-specific antibody 
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staining.  It is possible that our observations may have been affected by staining the samples for 
concurrent ALDH analysis.  Incubating the samples with Aldefluor reagent and the T-cell-
binding antibodies at 37 °C in Aldefluor buffer, which contains efflux pump inhibitors, may have 
altered T-cell receptor expression and increased non-specific antibody binding [52].  While this 
approach has been previously used by our lab and others for concurrent ALDH and CD44/CD24 
receptor expression analysis, for T-cell analysis in future studies it would be better incubate 
samples on ice in standard buffer (e.g., Hanks’ balanced salt solution (HBSS) + 2% FBS) [53].  
For our current analysis, we saved sections of each tumor sample before digestion and preserved 
them by formalin fixation and embedding in paraffin (FFPE).  Thus as an alternate to T-cell 
analysis of homogenized samples by flow cytometry, we can perform quantitative 
immunophenotyping with multispectral imaging of the FFPE samples following multicolor 
immunofluorescence staining [54-56].  Besides eliminating the time-sensitivity and viability 
challenges presented by flow cytometry, this quantitative immunophenotyping approach allows 
for spatial analysis of cell type within preserved tissues that is not possible with flow cytometry 
analysis of homogenized samples.  Repeating the analysis of our tumor tissue with this approach 
will give us a better picture of the cellular immune response triggered by our current conditions 
for PTT and PD-L1 immunotherapy, and will serve as a reference point to enhance future 
treatment regimens (e.g., further increase the population of CD8+ tumor-infiltrating effector T-
cells). 
There are many observations from our current data to consider to enhance the efficacy of 
PTT and immune checkpoint inhibition in metastatic cancer.  Our most conclusive results were 
significant inhibition of the ALDH+ BCSCs in orthotopic 4T1 mammary tumors.  Our initial 
data revealing inhibition of tumor growth and formation of lung metastasis in dual-treated mice 
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receiving PTT and immunotherapy are promising, but demonstrate that the therapeutic regimen 
and possibly other factors will need to be adjusted to achieve significant results.  Two 
observations highlight the significant potential to improve treatment efficacy by performing 
multiple applications of PTT (e.g., 24 h and 48 h after the HCIONP injection, and possibly 
following additional injections).  Our initial findings suggest that metastasis development may be 
better correlated with PD-L1 Ab treatment than PTT, which may be a consequence of multiple 
antibody treatments given through Day 9 whereas PTT was performed only once on Day 2.  
Furthermore, ALDH BCSC analysis on Day 10 revealed that the initial drop in the ALDH+ 
population observed at Day 4 begins to recover (data not shown), which may explain why tumor 
growth was reduced following PTT compared to Non-Treated mice but not significantly.  
Alternately, hyperthermic cell death by PTT of the primary tumor may be improved by 
intratumoral injection of HCIONPs, as reported in the literature [17, 18], to increase the 
nanoparticle concentration and distribution throughout the tumor tissue.  This may also prevent 
any added burden to the immune system following intravenous HCIONP injection, as the 
immune system begins to recognize the foreign material and attempt to eliminate it through 
organs of the reticuloendothelial system (RES) or mononuclear phagocyte system (MPS) [57-
59]. 
Several factors play a role in the efficacy of T-cell focused immunotherapies.  Inherent 
tumor immunogenicity, particularly the population of cytotoxic T-cells present in the tumor, is 
correlated with patient outcome following therapy [60, 61].  Mouse 4T1 breast cancer cells have 
been shown to have low PD-L1 expression in vitro, but it is induced when grown in vivo due to 
IFN-γ signaling [39, 40].  While several papers have used a 4T1 mouse model to study immune 
checkpoint inhibition, others have reported it to be a poorly immunogenic model and have 
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encountered issues dealing with myeloid-derived suppressor cells (MDSCs) [62, 63].  Stemming 
from a variety of cells of myloid origin, MDSCs exist predominantly in bone marrow in a non-
inflammatory state; in cancer or other inflammatory states, secretion of cytokines and other 
soluble factors trigger immune-suppressive activity of MDSCs at the tumor.  The role of these 
“natural suppressor cells” in immune suppression is multi-faceted.  Literature investigating how 
MDSCs suppress T-cells has primarily focused on their effects on T-cell priming [64].  It has 
also been shown that they may indirectly inhibit activity of effector CD8+ and CD4+ T-cells by 
inducing regulatory T-cells [64, 65].  In BALB/c mice bearing 4T1 tumors, Kim et al. showed 
that treatment with both anti-CTLA-4 and anti-PD-1 antibodies was insufficient to eradicate 
tumor growth and sustain survival.  However, addition of MDSC inhibitors resulted in complete 
regression of primary tumors and increased overall survival from 30% to 80% at 100 days post-
tumor implantation [62].  When Bear et al. first investigated nanoparticle-mediated PTT in mice 
bearing poorly immunogenic B16-F10 tumors they found that PTT needed to be coupled with 
ACT to overcome MDSC activity.  Especially considering that CXCL-1 production has been 
reported to attract MDSCs to breast cancer tumors [66], our therapeutic efficacy may benefit 
from studies conducted to better understand how MDSCs respond to PTT and immunotherapy 
and whether they play a significant role in the immune response to treatment.  Aside from 
potential changes in the therapeutic regimen, such as multiple applications of PTT, we may 
consider use of an alternative antibody to the anti-PD-L1 for continued work with 4T1 cells.  For 
instance, an anti-CTLA-4 antibody to boost T-cells in the priming phase may be more 
efficacious. 
The 4T1 breast cancer model has several advantages for our studies: it spontaneously 
metastasizes and is a great model for human stage IV breast cancer, it is syngeneic with BALB/c 
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mice and thus enables the study of the immune response to treatment, and has a quantifiable 
ALDH+ BCSC population [34-36].  However, little research has been performed to evaluate 
CD44+/CD24- as a marker for 4T1 (mesenchymal-like) BCSCs [67-70].  One group reported 
isolating CD24+/CD44+/ALDH+ tumor-initiating 4T1 cells [67], and another group found 
enhanced tumorigenic capabilities of CD24-/CD44+ 4T1 cells versus CD24+/CD44+ cells or a 
mixture of these two populations when injected into BALB/c mammary fat pads [68].  The 
ability to build off of our previous work by analyzing the effect of PTT on both ALDH+ 
epithelial-like BCSCs and CD44+/CD24- mesenchymal-like BCSCs would be ideal for future 
studies.  While the two BCSC populations may plastically transition from one to the other, recent 
findings suggest that ALDH+ BCSCs may be the dominate driver of tumor growth and 
CD44+/CD24- BCSCs may more directly mediate metastasis [5]. 
The preliminary data presented here will serve to guide future studies of combination 
PTT and immunotherapy aimed to enhance inhibition of tumor growth and metastasis formation, 
and to initiate a CD8+ T-cell driven immune response that involves development of memory T-
cells that will recognize breast cancer cell and BCSC antigens for sustained protection against 
recurrence and metastasis.  Our immediate objectives will be to repeat studies of tumor growth, 
development of lung macrometastases, serum cytokine and chemokine induction, and changes in 
tumor T-cell populations.  We also plan to conduct in vitro and in vivo experiments to investigate 
the ability of PTT to trigger activation of CD8+ T-cells that, upon exposure to dying cells in the 
primary tumor, become trained to recognize and kill BCSCs.  Ideally we expect to unveil 
conditions for which PTT, as shown recently with ionizing irradiation [71], has an additive or 
synergistic effect when coupled with cancer immunotherapy, and to demonstrate the potential for 
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clinical translation of such combination therapy to significantly improve responses in patients 
with metastatic disease.   
 
3.4 Conclusions 
Here we sought to inhibit breast cancer stem cells and prevent metastasis in immune-
competent mice by photothermal therapy using highly crystallized iron oxide nanoparticles, and 
conduct initial studies of the ability to induce a (BCSC-specific) systemic immune response 
when used in conjunction with immunotherapy.  HCIONP-mediated PTT of BCSCs was first 
studied in vitro in 4T1 metastatic breast cancer cells, revealing successful inhibition of ALDH+ 
BCSCs after 20 minutes heating to 46 °C.  Furthermore, ALDH+ BCSCs in BALB/c mice 
bearing 4T1 tumors were significantly inhibited 48 h after PTT when given as monotherapy and 
in combination with PD-L1 antibody.  Combination treatment with PTT and PD-L1 antibody 
reduces tumor growth and formation of lung macrometastases but may be improved through 
adjustments to the treatment regimen.  Analysis of serum in tumor-bearing mice post-treatment 
reveals induction of key inflammatory cytokines (IL-6) and immune cell-attracting chemokines 
(CXCL-1, CXCL-9, CXCL-10).  Challenges encountered with quantification of T-cells by flow 
cytometry of homogenized tumor tissue necessitate follow up analysis of sections of tumor tissue 
saved for quantitative immunophenotyping.  The preliminary data summarized here lays a 
foundation for continued experiments to demonstrate conditions in which localized PTT 
mediated by biodegradable iron oxide nanoparticles can: prevent metastasis through inhibition of 
BCSCs in the primary tumor, and induce a T-cell driven immune response effective at 
eliminating existing metastatic cancer cells, including BCSCs, when stimulated by immune 
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checkpoint blockade.  Clinical translation of this nanomedicine approach to enhance cancer 
immunotherapy could lead to a viable treatment option for cancers in which patients don’t 
currently respond to immunotherapy alone, potentially improving survival of patients with 
currently incurable metastatic breast cancer. 
 
3.5 Materials and Methods 
Preparation of HCIONPs: Polymer-coated HCIONPs were prepared as discussed in 
Chapter 2.  Briefly, HCIONPs (15 nm diameter) were synthesized in organic solvent by thermal 
decomposition [22] and coated with diblock copolymer poly(ethylene oxide)-b-poly(γ-
methacryloxypropyl trimethoxysilane) (PEO-b- PγMPS) synthesized by reversible addition 
fragmentation chain transfer (RAFT) polymerization [72].  Following purification by a magnetic 
separator (Frantz laboratory), the iron concentration was determined using o-phenanthroline as 
previously described [22].  HCIONPs were diluted in phosphate buffered saline (PBS) for in 
vitro and in vivo studies. 
HCIONP-mediated PTT in vitro: 4T1 murine breast cancer cells were grown at 37 °C 
with 5% CO2 as adherent monolayers in RPMI-1640 medium supplemented with 10% fetal 
bovine serum and 1% antibiotic-antimycotic.  For PTT, a 96-well plate containing 4T1 cells 
(500,000/well) suspended in cell culture medium was rested on a hot plate set to 37 °C.  
HCIONPs were added at a final concentration of 0.1 mg Fe/mL in 200 µL per well.  The solution 
was heated by a NIR laser (885 nm, spot size 5x8 mm2, MDL-III-885, OPTO Engine LLC, 
Midvale, UT) at a power of 0.24 W for 20 minutes.  The temperature was recorded each minute 
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using an infrared camera (FLIR Systems, i7, Boston, MA).  After PTT the cells were collected, 
added to 25 cm2 flasks, and allowed to recover overnight. 
Mouse Models for PTT: All mouse studies were conducted in accordance with a standard 
animal protocol approved by the University of Michigan University Committee on the Use and 
Care of Animals.  Five week old BALB/c immune-competent mice were obtained from Harlan 
laboratories.  Primary xenograft tumors were formed in the no 4 inguinal mammary pad by 
orthotopic injection of 0.5x104 4T1 cells suspended in matrigel.  Upon the detection of palpable 
tumors, tumor volumes were calculated according to the following equation: volume = 0.5 x 
length x (width)2.  For all in vivo studies mice were intravenously injected with HCIONPs by tail 
vein (20 mg Fe per kg mouse body weight) and, following anesthesia, 24 h later the NIR laser 
(0.52 W) was applied for 20 min.  Tumor surface temperatures were continuously monitored 
using an infrared camera (FLIR Systems, i7, Boston, MA). 
Flow Cytometry: For analysis 24 h after in vitro PTT, 4T1 cells were collected and 
counted using Trypan Blue before staining.  The Aldefluor Assay (StemCell Technologies, 
Durham, NC) was conducted according to the manufacturer’s instructions.  DAPI was used for 
cell viability.  Samples were run on a FACSCanto II (BD) to collect 10,000 live cells.  For 
analysis of in vivo PTT, mice were humanely euthanized two or eight days after PTT (Day 4, 
Day 10).  4T1 tumors were harvested and digested using a gentleMACS Octo Dissociator 
(MACS Miltenyi Biotec, San Diego, CA) according to the manufacturer’s protocol.  Cells were 
stained with Aldefluor reagent, CD3-BV711, CD8-PE-Cy7, CD4-APC, FoxP3-PE antibodies 
(BioLegend) and DAPI for 30 min at 37 °C in Aldefluor reagent.  Samples were run on a 
FACSAria III (BD) to collect 10,000 live cells.  Analysis was conducted using Flowing Software 
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2.5.1 (Perttu Terho, Turko Centre for Biotechnology, University of Turko, Finland) and 
FACSDiva Software (BD). 
Metastasis Studies: Following PTT, tumors were measured every five days.  Twenty days 
post-PTT, mice in each treatment group were sacrificed based on tumor burden.  Lungs were 
removed and their mass recorded, and macrometastases were counted.  Lungs and tumors were 
formalin fixed and paraffin embedded (FFPE).  Sections of lung tissue were imaged using an 
inverted microscope (Nikon Eclipse Ti-E) following hematoxylin and eosin (H&E) staining to 
detect micro- and macrometastases. 
Cytokine Analysis: Two or eight days following PTT, mice were sacrificed and blood 
collected via cardiac puncture.  Serum was obtained through centrifugation using Microtainer 
tubes (BD) at 1500 g for 10 minutes.  Cytokine and chemokine concentrations were measured in 
duplicate using a Milliplex Mouse Premixed 22-plex assay (Millipore) and a Luminex200 System. 
Statistical Analysis: All data are represented as mean ± standard deviation.  The 
significance values of data sets with more than two groups were calculated using Minitab 
software via one-way analysis of variance (ANOVA) followed by either Dunnett’s post-hoc 
comparisons to the non-treated control or Tukey’s post-hoc testing as indicated..  A p < 0.05 was 
considered statistically significant. 
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3.6 Figures 
 
Figure 3.1. (A) Heating curves of 4T1 cells receiving Laser Only or PTT (HCIONPs 0.1 mg 
Fe/mL) treatments on a 96-well plate.  (B) 4T1 cell viability 24 h after 20 min PTT.  (C) ALDH+ 
BCSC percentage and absolute number 24 h after 20 min PTT.  For cell viabilities and 
percentages of BCSCs, * p < 0.05, ** p < 0.01, *** p < 0.001 via Dunnett’s post-hoc comparison 
to Non-Treated control.  For absolute numbers of BCSCs, # p < 0.05, ## p < 0.01, ### p < 0.001 
via Dunnett’s post-hoc comparison to Non-Treated control. 
 
Scheme 3.1. For in vivo studies, BALB/c mice bearing orthotopic 4T1 mammary tumors were 
divided into treatment groups based on tumor size on Day 0.  Mice were injected with HCIONPs 
(intravenously) and PD-L1 antibody (intraperitoneally) on Day 1.  PTT occurred on Day 2, 
allowing 24 hours for HCIONP intratumoral accumulation.  PD-L1 antibody was administered 
every other day a total of five times, ceasing on Day 9. 
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Figure 3.2. (A) Heating curves of 4T1 mammary fat pad tumors in BALB/c mice receiving PTT 
or PTT + PD-L1 Antibody treatments.  (B) ALDH+ BCSC percentage 2 d after 20 min PTT.  * 
p< 0.05, ** p < 0.01, *** p < 0.001 via Tukey’s post-hoc comparison to Non-Treated control.  # 
p< 0.05, ## p < 0.01, ### p < 0.001 via Tukey’s post-hoc comparison to PD-L1 Ab treatment. 
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Figure 3.3. (A) 4T1 tumor growth in BALB/c mice following photothermal and immunotherapy 
treatments.  (B) Number of lung metastases in individual mice, counted in tissue harvested on 
Day 22.  Averages per treatment group are shown in red.  (C) Photos of excised lungs after 
sacrificing mice on Day 22.  (D) Representative H&E staining of sectioned lung tissue. 
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Figure 3.4. Serum concentrations of IL-6 (A), CXCL-1 (B), CXCL-9 (C), and CXCL-10 (D) on 
Day 4 and Day 10. 
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CHAPTER 4. OPTIMIZING CANCER CELL UPTAKE OF GOLD NANOPARTICLES 
BY ‘LIVING’ PEGYLATION TO CONTROL TARGETING LIGAND AND CHARGE 
DENSITIES 
 
4.1 Abstract 
After decades of cancer treatment dominated by non-specific therapies with detrimental 
side effects and often resulting in development of resistance and recurrence, nanotechnology 
offers tremendous untapped potential in the movement toward more specific, personalized cancer 
therapies. One of few nanoparticle-based treatments to enter clinical trials in human cancer 
patients is localized photothermal therapy (PTT) activated by near infrared (NIR) light-absorbing 
gold nanoshells, which currently accumulate in tumor tissue through passive targeting. Patient 
tolerance and response to such therapy may benefit from formulation to develop stealthy, 
actively targeted nanoparticles. Here we report and demonstrate biomedical applications of a 
new technique – ‘living’ PEGylation – that allows control of the density and composition of 
heterobifunctional PEG (HS-PEG-R) on gold nanoparticles (AuNPs). We first establish ‘living’ 
PEGylation by incubating HS-PEG5000-COOH with AuNPs (~20 nm) at increasing molar ratios 
from zero to 2000. This causes the hydrodynamic layer thickness to differentially increase up to 
26 nm. The controlled, gradual increase in PEG-COOH density is revealed after centrifugation, 
based on the ability to re-suspend the pellet and increase the AuNP absorption. Using a 
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fluorescamine-based assay we quantify differential HS-PEG5000-NH2 binding to AuNPs, 
revealing it is highly efficient until AuNP saturation. Furthermore, the zeta potential 
incrementally changes from −44.9 to +52.2 mV and becomes constant upon saturation.  Using 
‘living’ PEGylation we prepare AuNPs with different ratios of HS-PEG-RGD and incubate them 
with U-87 MG and non-target cells, demonstrating that targeting ligand density is critical to 
maximizing the targeting efficiency of AuNPs to cancer cells. The ability to minimize non-
specific binding/uptake by healthy cells could further improve targeted nanoparticle efficacy. 
Consequently, we sequentially control the HS-PEG-R density to develop multifunctional 
nanoparticles, conjugating positively-charged HS-PEG-NH2 at increasing ratios to AuNPs 
containing negatively-charged HS-PEG-COOH to reduce uptake by macrophage cells. 
Application of this facile PEGylation technique to PTT-mediating nanoparticles to enhance the 
ratio of uptake by target versus non-target cells could significantly improve patient response and 
decrease both the dose and cost of treatment.  Furthermore, future work to enhance formulation 
of such stealthy, targeted nanoparticles to confer imaging capabilities could potentially enable 
PTT to be applied to metastatic cancers. 
 
4.2 Introduction 
The ability to target delivery of nanoparticles to solid tumors and minimize their 
distribution to non-target sites are critical tasks in the development of cancer nanomedicine for in 
vivo molecular imaging and targeted therapy [1]. It is generally accepted that the presentation of 
multiple targeting ligands on nanoparticle surfaces can improve cell targeting. A variety of 
tumor-targeting ligands, such as the RGD peptide [2], epidermal growth factor (EGF) [3], folate 
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[4], transferrin (Tf) [5], or antibodies and antibody fragments, such as a single-chain variable 
fragment (scFv) [6], have been used to facilitate the binding/uptake of carriers to target cells. 
However, little work has been done to determine whether an optimal ligand density exists [7].In 
order to achieve an effective level of nanoparticles in the targeted tissue or tumor site, targeted 
nanoparticles should transition from circulating blood to the tissue of interest and bind to their 
molecular target as a first step in nanoparticle retention or cellular internalization. The reality is 
that even with targeting ligands, many types of systemically delivered nanoparticles are rapidly 
cleared from the blood stream through non-specific uptake by the reticuloendothelial system 
(RES) and the mononuclear phagocytic system (MPS) in the liver, spleen, and bone marrow [8]. 
This results in reduced bioavailability of the targeting agents, a low therapeutic index, and 
potential toxicity to normal organs. Therefore, enhancing target-ligand interactions and reducing 
both non-specific binding by biomolecules and uptake of nanoparticles by the RES are major 
challenges for improving the sensitivity and specificity of biomarker targeted nanoparticles. 
Gold nanoparticles (AuNPs) have been attracting increasingly widespread interest as a 
multifunctional platform for various applications in biology and medicine [9-12]. AuNPs are 
particularly useful for these applications, as they can function as contrast agents in optical 
imaging [13-15], sensitizers for Raman scattering-based diagnostic probes [16-18], and as 
vectors for photothermal therapy [19-21]. A key feature of nanoparticle agents is their 
multifunctionality; the ability to append ligands, antibodies, imaging labels, drugs, or other 
molecules to nanoparticles enables targeted molecular imaging and therapy [22-24]. AuNPs 
serve as an excellent platform to attach functional moieties facilely due to a strong Au-S linkage 
formed using thiol-terminated poly(ethylene glycol) (HS-PEG-R) molecules [25]. 
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For biomedical applications of AuNPs using PEG molecules with functional R-groups, 
the ability to control the PEG-R chain density can have profound implications. An optimal 
targeting ligand density on nanoparticles might enhance their targeting efficiency to tumors with 
minimized non-specific uptake by healthy tissues and organs. While advances have been made in 
the development of functionalized AuNPs, current AuNP synthesis approaches lack the ability to 
subsequently control PEG chain density and therefore the density and stability of the functional 
groups coating the AuNPs [26-30]. Traditional PEGylation on chemically made AuNPs is 
typically achieved through a ligand exchange process by using thiol-terminated PEG molecules 
to replace the original capping ligands (e.g., citrate). Therefore, stabilization of AuNPs during 
PEGylation requires excessive PEG molecules [16, 26, 27], making it impossible to control the 
PEG-R chain density on AuNPs. 
Here we report a ‘living’ PEGylation technique with the ability to control the density of 
functional PEG chains, and thus the targeting ligand or charge density, on AuNPs. The principle 
behind this technique is similar to that of living polymerization, which is widely used by polymer 
chemists to control chain length by changing the ratio of monomer/initiator to build di-block or 
tri-block copolymers [31]. For our studies we used AuNPs made by femtosecond laser ablation 
[32, 33]. Different from traditional AuNPs made by chemical synthesis, AuNPs made by 
femtosecond laser ablation have ‘naked’ surfaces without any capping ligands. Consequently, it 
is possible to develop stable AuNP formulations while controlling the molar ratio of HS-PEG-
R/AuNP, when it is below the saturation ratio. PEGylation is so efficient that essentially all of 
the added HS-PEG-R molecules become bound to the AuNPs. Using ‘living’ PEGylation, we 
investigate the potential to improve key requirements for targeted nanomedicine. First we control 
the targeting ligand density on AuNPs to optimize the specific targeting ability to cancer cells. 
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Furthermore, via ‘living’ PEGylation we can add PEG-R chains in sequential steps to AuNPs, 
controlling the density of different functional PEG-R chains on the nanoparticles. Using this 
controlled, sequential PEGylation we develop double-charged AuNPs, conjugating positively-
charged HS-PEG-NH2 at increasing ratios to AuNPs containing negatively-charged HS-PEG-
COOH, to reduce uptake by macrophage cells.  Therefore, this unique PEGylation process using 
laser-produced AuNPs facilitates unprecedented control over the development of multifunctional 
nanoparticles, with implications for both therapeutic and diagnostic nanoparticle applications.  
Of particular interest is its potential application in clinical trials for nanoparticles capable of 
photothermal therapy. 
 
4.3 Results and Discussion 
In our first step to establish ‘living’ PEGylation, we mixed gold nanoparticles (~20 nm in 
diameter based on TEM imaging) with HS-PEG-COOH at different HS-PEG-COOH/AuNP 
molar ratios from zero to 2000. This molar ratio range was chosen based on the surface area of 
20 nm AuNP and the footprint of PEG molecules. For PEGylation we selected thiolated PEG5000, 
which is most widely used to modify gold nanoparticles [30, 34]. The thiol concentration (>95%) 
was confirmed by an Ellman’s test. During PEGylation the AuNP concentration was fixed at 1.0 
nM, determined by correlating our measured extinction spectra to the experimentally determined 
extinction cross-section data (8.8 × 108 M-1cm-1 for AuNPs with a diameter of 20 nm) [35]. 
Control over the AuNP PEGylation process was monitored by the change in particle size. 
As shown in Figure 4.1, the change in hydrodynamic layer thickness differentially increased with 
increasing molar ratios of HS-PEG-COOH/AuNP and reached a constant at 26 nm after the 
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AuNP surface was saturated at molar ratio of 500.  This revealed an increase in PEG chain 
density on AuNP surfaces upon increasing the HS-PEG-COOH/AuNP molar ratio. For free PEG 
molecules in a good solvent, the radius of gyration Rg can be empirically calculated as shown in 
equation (1): 
 ܴ௚ሾ݊݉ሿ ൌ 0.181 ൈ ܰ଴.ହ଼ (1) 
where N is the number of ethylene glycol (EG) monomer units per PEG chain [36]. For 
the PEG5000 used here, Rg is 2.8 nm and the size increase should be around 11.2 nm (2.8 × 4) if 
the PEG chains form isolated hemispheres (mushroom) on the surface with a critical PEG 
density σ* (1/πRg2) around 0.04 PEG/nm2. At a molar ratio of 500 the PEG density σ is around 
0.4 PEG/nm2, which is 10 times higher than the critical grafting density [29]. The grafting PEG 
chains are most likely reconfigured, stretching out in a brush conformation as shown in the insert 
of Figure 4.1. This explains why the hydrodynamic layer thickness (ΔD) is more than four times 
the radius of gyration.  
Figure 4.S1(a) shows the optical spectra of AuNPs at all HS-PEG-COOH/AuNP ratios. 
The overlapping curves and the constant OD reveal that there is no loss of AuNPs after 
PEGylation for each of the HS-PEG-COOH/AuNP molar ratios. This is in contrast to traditional 
PEGylation to citrate-capped AuNPs made by chemical synthesis, which requires a large excess 
of thiolated PEG molecules [27]. Otherwise, the citrate-capped gold colloids will not be stable 
[26]. The high colloidal stability of laser-made AuNPs after PEGylation with different molar 
ratios is attributed to the highly negatively-charged ‘naked’ surface in Figure 4.S1(b), which 
shows that the zeta potential is independent of the HS-PEG-COOH/AuNP molar ratio. Although 
there are not any capping ligands on the AuNP surfaces before PEGylation, the AuNPs made by 
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femtosecond pulse laser ablation have a natural negative surface with a zeta potential of about 
−33.3 mV. The negatively-charged surface is caused by partial oxidation from the oxygen 
present in solution, followed by proton transfer to adjacent hydroxide ions [37]. This natural 
negative surface free of capping ligands makes these laser-generated gold colloids unique from 
traditional ones in that PEGylation can be controlled. 
The differential PEG-COOH chain densities on AuNPs after PEGylation at varying molar 
ratios of HS-PEG-COOH/AuNP were confirmed by centrifuging the solutions and re-suspending 
the pellet of AuNPs. Figure 4.2 compares the optical densities (OD) of the absorption peaks after 
centrifugation for each HS-PEG-COOH/AuNP molar ratio, and Figure 4.S2 shows typical 
absorption spectra. The data in Figure 4.2 clearly demonstrate the controlled increase in HS-
PEG-COOH density with each AuNP formulation, as the HS-PEG-COOH/AuNP molar ratio 
dictates the stability of the formulations after centrifugation. For ratios less than 100 the AuNP 
pellet could not be re-dispersed after centrifugation, revealing the PEG-COOH chain density is 
too low to maintain a stable formulation. As the molar ratio increased from 100 to 300 the OD 
number increased by 25 times, with a relative change from 4% to 100% when compared to the 
OD before centrifugation, respectively. The data also indicate that even though the AuNP surface 
is not fully covered with PEG at a molar ratio of 300, the AuNPs are stable against 
centrifugation. This differential stability based on the changing HS-PEG-COOH density on 
AuNPs is also apparent in Figure 4.S2. As the molar ratio increased from 100 to 200 more 
AuNPs were recovered after centrifugation, determined by the increase of the absorption peak at 
524 nm. However, detection of a second, smaller peak (or ‘bump’) at ~650 nm suggests these 
partially PEGylated AuNPs tend to form aggregates after centrifugation, indicating a higher 
PEG-COOH chain density is required to maintain stability. 
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To further analyze the PEGylation efficiency of our laser-made AuNPs we incubated HS-
PEG-NH2 with AuNPs at increasing molar ratios, which allowed us to use a fluorescamine-based 
assay to quantify HS-PEG-NH2 binding to AuNPs [27]. We varied the HS-PEG-NH2 
concentration during incubation from 50 to 2000 nM while keeping the AuNP concentration 
constant at 1.0 nM. First we monitored the zeta potential values of the PEGylated AuNPs as 
shown in Figure 4.3(a). They gradually transformed from highly negative (−44.9 mV) at low 
molar ratios to highly positive (reaching +52.2 mV) and remained constant for molar ratios 
higher than 500, revealing the increasing PEG-NH2 chain density on the AuNPs until the 
surfaces become saturated. Successful differential PEGylation was further demonstrated by 
monitoring the size increase after PEGylation with increasing HS-PEG-NH2/AuNP molar ratios, 
as shown in Figure 4.S3. The data show that the hydrodynamic layer thickness incrementally 
increased up to 26 nm at the saturated HS-PEG-NH2/AuNP molar ratio of 500, which is 
consistent with the PEGylation using HS-PEG-COOH. The data combined clearly reveal a 
controlled increase in the PEG-NH2 chain density as we increased the HS-PEG-NH2/AuNP 
molar ratio. 
Using the fluorescamine-based assay we established a linear calibration curve for free 
HS-PEG-NH2 (Figure 4.S4(b)) based on the peak intensity at 480 nm observed in the 
fluorescence spectra at PEG concentrations from 50 to 2000 nM (Figure 4.S4(a)). In this assay a 
non-fluorescent fluorescamine reacts with a primary amine to generate a compound that emits 
fluorescence at 480 nm when excited at 390 nm, as shown in Scheme 4.S1. Originally developed 
for quantification of primary amines in biomolecules, this assay has sensitivity on the pM scale 
[38]. After incubation with AuNPs followed by centrifugation, we quantified the concentration 
of free HS-PEG-NH2 in the supernatants as shown in Figure 4.3(b) (corresponding fluorescence 
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spectra shown in Figure 4.S4(c)). Although the HS-PEG-NH2 concentration increased 10 times 
up to 500 nM there was no obvious fluorescence increase after measuring the supernatants, 
whereas for ratios higher than 500 the supernatant fluorescence began to increase. This revealed 
that the gradual increase in HS-PEG-NH2 binding to AuNPs is highly efficient below saturation 
at 500 nM, and this point of saturation is consistent with our zeta potential and size change 
measurements. Measuring the PEG concentration in supernatants to estimate the PEG chain 
density on AuNPs is a widely used method [27, 30]. However, in previous reports using 
chemically prepared AuNPs, more than 90% of the added HS-PEG-R molecules remained in the 
supernatants because of the excessive HS-PEG-R required to stabilize AuNPs during PEGylation 
[26]. In our case as most of the added HS-PEG-NH2 molecules were bound to AuNPs, our assay 
measurements are more sensitive than those in the previous reports. The combined experiments 
using HS-PEG-COOH and HS-PEG-NH2 demonstrate a highly efficient PEGylation process that 
allows control of the PEG density on AuNPs by manipulating the molar ratio of HS-PEG-
R/AuNP, while the ratio is less than the saturated one. This technique is similar to living 
polymerization, through which a polymer chain length can be controlled by the ratio of 
monomer/initiator. Thus we termed this technique ‘living’ PEGylation. 
One important application of ‘living’ PEGylation is to control the targeting ligand density 
on AuNPs to improve specific targeting efficiency. Consequently, we synthesized HS-PEG-RGD 
to investigate specific targeting efficacy of AuNPs to αvβ3 integrin receptors. The targeting 
peptide conjugation to PEG was performed based on traditional coupling reactions between NHS 
ester and amine groups using thiol-protected OPSS-PEG-NHS and cyclo(RGDfk)-NH2 followed 
by deprotection of the thiol groups using DTT (Scheme 4.S2) [39, 40]. The expected HS-PEG-
RGD was purified by a size exclusion column and confirmed by HPLC, with the retention time 
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shifting from 16.87 to 19.64 min compared to unconjugated RGD (Figure 4.S5) [41]. The 
characteristic peak of the optical spectrum of purified HS-PEG-RGD is identical to RGD alone, 
revealing the successful peptide conjugation (Figure 4.S6). An Ellman’s test also confirmed 
effective deprotection to reveal a terminal free thiol. PEGylation using HS-PEG-RGD on AuNPs 
with serial HS-PEG-RGD/AuNP molar ratios was done as described for HS-PEG-COOH. 
Hydrodynamic size and zeta potential measurements were used to monitor the PEGylation 
process (Figure 4.S7). As expected, the hydrodynamic size of PEGylated AuNPs incrementally 
increased as we increased the molar ratio of HS-PEG-RGD/AuNP below the saturation ratio 
(Figure 4.S7(a)). The zeta potential data revealed that all PEG-RGD-modified AuNPs have 
highly negatively charged surfaces (~ −40 mV) (Figure 4.S7(b)). Taken together, the data clearly 
show that AuNPs with different PEG-RGD densities on the surface were successfully obtained in 
a controlled way. 
Specific cellular targeting efficiency to cancer cells was tested using two cancer cell 
lines: U-87 MG, positive for αvβ3 integrin receptors, and MCF-7, classified negative for the 
receptor and serving as an example of non-target cells. The gold content inside the cells after 
digestion with aqua regia was measured by ICP-OES. Using the same conditions as for live cell 
incubations the stability of these PEGylated AuNPs in media was first confirmed by the optical 
spectra in Figure 4.S8, as there is no change of peak OD over four hours in DMEM plus 10% 
FBS. 
The effect of the PEG-RGD/AuNP ratio on cellular uptake after incubation with AuNPs 
is shown in Figure 4.4(a) for U-87 MG cells and in Figure 4.4(b) for MCF-7 cells. These data 
clearly show that U-87 MG cells uptake more AuNPs modified with RGD than MCF-7 cells, 
which demonstrates the specific targeting ability of the RGD peptide [2, 41]. Furthermore, for 
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incubations with AuNPs with PEG-RGD/AuNP molar ratios of 50 or lower U-87 MG cells 
demonstrate consistently increased uptake as the PEG-RGD/AuNP molar ratio is increased, with 
uptake reaching up to 3.7 pg/cell as the ratio increased to 50. On the contrary, MCF-7 cells 
uptake is independent of PEG-RGD density change in this range, which is around 0.2 pg/cell and 
18-fold lower than in U-87 MG cells. For AuNPs with PEG-RGD/AuNP molar ratios higher than 
50, uptake in both U-87 MG cells and MCF-7 cells began to increase with increasing RGD 
density. Comparing Figures 4.4(a) and 4.4(b), the relative uptake of U-87 MG (compared to 
MCF-7) versus PEG-RGD chain density revealed a clear optimal targeting ligand density around 
50 PEG-RGD on each AuNP that maximizes specific uptake by target cells while minimizing 
uptake in non-target cells. 
We next incubated MCF-7 cells with AuNPs containing a control RAD peptide that does 
not specifically target αvβ3 integrin receptors in order to determine whether the increased gold 
content in MCF-7 cells for PEG-RGD/AuNP molar ratios higher than 50 was caused by non-
specific uptake [42]. We found that the gold content in MCF-7 cells does not increase for even 
the highest PEG-RAD/AuNP molar ratios (Figure 4.S9). This suggests that the rise in uptake 
observed for higher molar ratios of PEG-RGD/AuNP in Figure 4.4(b) is from specific uptake due 
to very low expression of αvβ3 integrin receptors on MCF-7 cells, triggered by a threshold RGD 
density.  Consequently, we decided to next investigate the potential for targeting ligand density 
to affect non-specific uptake by macrophage cells. 
Figure 4.5 shows the uptake of AuNPs with different PEG-RGD surface densities after 
incubation with macrophage cells. Similar to the trend observed in MCF-7 cells in Figure 4.4(b), 
for molar ratios below 50 the uptake is independent of the targeting ligand density while above 
50 the uptake consistently increases with increasing ligand density. This suggests αvβ3 integrin 
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receptors are present on macrophage cells [43], and this can trigger increased nanoparticle uptake 
at higher PEG-RGD densities on AuNPs. Taken with the results of Figure 4.4, this confirms it is 
possible to control the targeting ligand density on AuNPs and that it plays a critical role in 
optimizing specific targeting efficacy. 
Another application of ‘living’ PEGylation is to control PEG-R chain densities on AuNPs 
in a sequential way for multifunctional purposes, like building di-block or tri-block copolymers 
using living polymerization. Here we investigated a two-step PEGylation process, first partially 
PEGylating with HS-PEG-R1 and then PEGylating with HS-PEG-R2 as shown in Scheme 4.1. As 
long as the AuNPs are not saturated (i.e. the molar ratio of HS-PEG-R/AuNP is lower than 500), 
one can control the density of functional moieties (R groups) covalently attached to AuNPs. In 
this sequential way, double-charged AuNPs with varying PEG-NH2/PEG-COOH molar ratios 
were prepared by partially PEGylating with HS-PEG-COOH first, then adding different amounts 
of HS-PEG-NH2, and finally adding more HS-PEG-COOH to saturate the surface. 
The different double-charged AuNP formulations containing both HS-PEG-NH2 and HS-
PEG-COOH were incubated with RAW 264.7 macrophage cells and the uptake results are shown 
in Figure 4.6. The data show that by increasing the ratio of PEG-NH2 on AuNPs from 50 to 300 
through living PEGylation, the non-specific uptake of Au/cell (pg) gradually halved from 0.63 ± 
0.01 to 0.33 ± 0.01. The reduced cell uptake can be explained by the overall surface charge 
becoming more neutral with controlled addition of more PEG-NH2, as shown in Figure 4.S10. 
These results are consistent with those obtained by Liu et al for AuNPs modified via zwitterionic 
self-assembled monolayers (SAMs) composed of both negatively- and positively-charged, thiol-
containing carbon chains [44].Compared to AuNPs modified with only negatively-charged 
carbon chains, as they increased the ratio of positive to negative carbon chains on the AuNP 
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surfaces the negative zeta potential gradually increased and reduced the AuNP uptake by 
macrophage cells. 
In Figure 4.6 we also observe that our double-charged AuNP formulations have less non-
specific uptake than all of the control AuNPs decorated with a single type of PEG-R (i.e. -OCH3, 
-COOH, -NH2). For instance, the double-charged AuNP formulations show a relative uptake 
ranging from 40% to 76% when compared to AuNP-PEG-OCH3, the control with the least 
uptake. As expected, the AuNP control containing only HS-PEG-NH2 exhibits the greatest non-
specific uptake due to the electrostatic attraction between the positively-charged AuNPs and the 
negatively-charged cell membrane [45-48]. The uptake of the negatively-charged AuNP-PEG-
COOH control is greater than those for each double-charged AuNPs for two reasons. First, 
phagocytic cells preferentially uptake anionic particles versus those that are more neutral in 
charge [44, 46, 49]. Second, the zwitterionic property of double-charged AuNPs confers stealth 
due to a layer of tightly bound water molecules on the AuNP surface. This has been shown to 
reduce binding of plasma proteins, and recognition and non-specific uptake by cells [44, 45, 50-
53]. This also explains why the uptake of the double-charged AuNPs is reduced even when 
compared to the neutral AuNP-PEG-OCH3 control. Our uptake results for the double-charged 
AuNPs relative to the positively-charged and negatively-charged controls are consistent with 
those of Liu et al in RAW 264.7 macrophage cells [44]. Furthermore, they observed the same 
uptake trend based on AuNP charge/zeta potential in normal human umbilical vein endothelial 
cells (HUVEC) and human hepatocellular liver carcinoma cells (HepG2), with one slight 
difference. They found that in the macrophage cells the reduction in uptake of double-charged 
AuNPs relative to the negatively-charged AuNPs is greater than those observed in the two non-
phagocytic cell lines, and they attribute this to the preferential uptake of anionic particles by 
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phagocytic cells. Overall, our cellular uptake data with sequentially modified double-charged 
AuNPs exemplifies a second approach to reduce nanoparticle clearance by the immune system. 
Even greater potential to maximize specific uptake in target cells while minimizing non-specific 
uptake lies in an AuNP formulation containing both an optimal targeting ligand density and 
double-charged surface obtained by ‘living’ PEGylation, and merits further exploration. Our data 
suggests a facile and feasible approach would be to sequentially PEGylate using negatively-
charged HS-PEG-COOH and an optimal density of HS-PEG-R1, where R1 represents a 
positively-charged targeting ligand.  
Enhanced stability to partial PEGylation in a sequential way makes laser-made, ‘naked’ 
AuNPs unique from chemically-made ones capped with citrate, as demonstrated in the 
photograph in Figure 4.S11. While all commercial and laser-made AuNP formulations are stable 
if excessively PEGylated with HS-PEG-R (irrespective of charge), only laser-made AuNPs are 
stable after sequential PEGylation involving HS-PEG-NH2. In AuNPs capped with citrate, this 
causes aggregation of the AuNPs and the solutions become black. Our work collectively 
demonstrates that this new PEGylation process with laser-made AuNPs facilitates creation of 
multifunctional AuNPs with a range of biomedical applications, including photothermal therapy 
if expanded to laser-produced, near infrared light-absorbing gold nanoparticles. 
 
4.4 Conclusions 
Using gold nanoparticles generated by femtosecond pulse laser ablation we revealed the 
unique ability to control the density of HS-PEG-R (-COOH, -NH2, and -RGD) conjugated to 
AuNP surfaces for one or sequential rounds of conjugation, terming this process ‘living’ 
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PEGylation. After PEGylation with HS-PEG-COOH at different molar ratios of HS-PEG-
COOH/AuNP up to 2000, the hydrodynamic layer thickness incrementally increased with 
increasing molar ratio and became constant upon AuNP saturation. We then centrifuged and re-
suspended the PEGylated AuNP to demonstrate the differential PEG chain density on the AuNP 
surface. As the PEG-COOH/AuNP molar ratio increased to the point of saturation, the OD for 
the absorption spectrum peak gradually increased up to 25 times and the AuNP recovery 
consistently increased. Next, PEGylation using HS-PEG-NH2 was quantified by a fluorescamine-
based assay. For differential HS-PEG-NH2 ratios below the saturation ratio, essentially all the 
added HS-PEG-NH2 bound to the AuNPs. Furthermore, as the molar ratio of HS-PEG-
NH2/AuNP increased the zeta potential incrementally changed from −44.9 to +52.2 mV and 
became constant upon AuNP saturation. Taken together, our results confirm that the PEG-R 
chain density on AuNP surfaces can be precisely controlled by changing the molar ratio of HS-
PEG-R/AuNP. Next we used ‘living’ PEGylation to investigate the dependence of specific 
targeting efficacy on targeting ligand density on nanoparticle surfaces, controlling the density of 
the model peptide RGD to AuNPs via HS-PEG-RGD. An optimal targeting ligand density 
around 50 PEG-RGD on each AuNP maximizes the specific targeting efficiency to U-87 MG 
cancer cells. Additionally, we sequentially conjugated HS-PEG-COOH and HS-PEG-NH2 to 
AuNPs to create double-charged AuNPs with precise control over the PEG-NH2/PEG-COOH 
ratio to reduce non-specific uptake by macrophage cells. This unique PEGylation process 
facilitates unprecedented control in the synthesis of multifunctional nanoparticles, with 
implications for both therapeutic and diagnostic nanoparticle development. Of particular interest 
is its potential application for photothermal therapy, given its advancement to clinical trials in 
human cancer patients. 
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4.5 Materials and Methods 
Materials and Instrumentation: HS-PEG5000-NH2, HS-PEG5000-COOH, and ortho-
pyridyl-disulfide-PEG-succinimidyl ester (OPSS-PEG-NHS, 5 kD) were purchased from 
Creative PEGWorks (Winston-Salem, NC). HS-PEG5000-OCH3 was purchased from NanoCS. 
Cyclo (Arg-Gly-Asp-D-Phe-Lys) (RGD-NH2, Peptides International, Inc) were used as received. 
Fluorescamine, Ellman’s reagents, and all other solvents were obtained from Sigma-Aldrich. 
Milli-Q water (18.2 MΩ cm) was prepared using Milli-Q Academic water purification system 
(Billerica, MA). UV visible spectra were recorded in a BioTek micro plate reader (Synergy 2). A 
luminescence spectrometer LS-50B (Perkin Elmer, UK) was used to characterize the emission 
spectra of the fluorescamine assay. The nanoparticle hydrodynamic size and zeta potential were 
measured using a dynamic light scattering (DLS) instrument (Malvern Zeta Sizer Nano S-90) 
equipped with a 22 mW He-Ne laser operating at λ = 632.8 nm. The AuNPs were viewed by 
transmission electron microscopy (TEM) (Philips CM-100 60 kV). 
Preparation of AuNPs: AuNPs were generated by laser ablation with the following laser 
parameters. Femtosecond pulses delivered from the above-stated laser system (repetition rate of 
100 kHz, 10 μJ pulse energy, 700 fs pulse width centered at a wavelength of 1.045 μm) were 
focused onto a spot size of about 50 μm on a gold metal plate (99.99% purity) placed on the 
bottom of a glass vessel filled with 20 mL of deionized water. After a couple of days of aging, 
the top clear red solution was collected. 
PEGylation of AuNPs with HS-PEG-R: In a typical process, 1.0 mL of AuNP solution 
(1.0 nM) was added with 10 μL of HS-PEG-R solution at different concentrations to obtain the 
following final molar ratios: 0, 50, 80,100, 150, 200, 300, 400, 500, 600, 800, 1000, 2000. The 
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reaction mixture was vortexed immediately and then incubated at room temperature for two 
days. After PEGylation, half of each solution was used for measuring absorption spectra, 
hydrodynamic size and zeta potential. The other half of each solution was centrifuged at 14000 
rpm for 20 min and re-dispersed with Milli-Q water by gentle shaking. This process was repeated 
three times. For PEGylation using HS-PEG-NH2, the supernatant after the first centrifugation 
was carefully collected and also centrifuged two more times to remove any remaining AuNPs. 
The resultant supernatant solution was analyzed via the fluorescamine assay. For the sequential 
PEGylation with a combination of both HS-PEG-COOH and HS-PEG-NH2, AuNPs were first 
partially PEGylated with HS-PEG-COOH, then different amounts of HS-PEG-NH2 was added. 
Quantification of Unbound HS-PEG-NH2 in Supernatant: For a typical fluorescamine 
assay, 400 μL of each supernatant solution or calibration solution (without mixing with AuNPs) 
was mixed with 20 μL of Na2HPO4 (0.2 M, pH 10.0) and then 4.0 μL of fluorescamine solution 
in DMSO (2 mM). After 15 min, fluorescence spectra (λex: 390 nm, λem: 480 nm) were recorded. 
The fluorescence intensities at 480 nm for each solution were plotted as a function of the HS-
PEG-NH2/AuNP molar ratio. 
Preparation of HS-PEG-RGD and PEGylation to AuNPs: To a 25-mL round bottom 
flask, 50.1 mg of OPSS-PEG-NHS were dissolved in 1.0 mL of benzene. The solution was 
frozen before evaporating the solvent under reduced pressure to remove trace amounts of water. 
Anhydrous DMF (10 mL) was added to dissolve the powder, then 6.1 mg of c(RGDfK) was 
added and mixed together, and finally N, N-Diisopropylethylamine was added. The solution was 
stirred at room temperature for 48 h. Dithiothreitol (DTT) was then added to the reaction mixture 
and stirred for additional 2 h to reduce the disulfide and obtain a free thiol at the end of the PEG-
RGD polymer. The resultant powder was harvested through precipitation in dry diethyl ether. 
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Unconjugated RGD was removed by a size exclusion NAP-5 Column (GE Healthcare, UK) and 
the purified HS-PEG-RGD was confirmed by HPLC. PEGylation using HS-PEG-RGD to AuNPs 
at different molar ratios is carried out the same as for HS-PEG-COOH. After centrifugation 
twice, the final AuNP pellets were re-suspended in 0.5 mL Milli-Q H2O to concentration the 
solution 20 times. 
Cell Culture and Preparation: The U-87 MG brain cancer (glioblastoma), MCF-7 breast 
cancer, and RAW 264.7 macrophage cell lines were maintained as adherent cultures and grown 
as monolayers in a humidified incubator (95% air; 5% CO2) at 37 °C in a Petri dish containing 
medium supplemented with antibiotic-antimycotic and 10% heat-inactivated fetal bovine serum 
(FBS). To test targeting efficiency of AuNPs with different PEG-RGD density, cells were seeded 
into 6-well plates and left overnight. Cell numbers (3.0×105 U-87 MG/well, 7.3×105 MCF-
7/well, 2.7x105 RAW 264.7/well) were counted using a Countess automated cell counter 
(Invitrogen, USA). After exposure to AuNPs (5 nM) formulated with different ratios of PEG-
RGD in complete media supplied with 10% FBS at 37 °C for 4 h (U-87 MG, MCF-7) or 8 h 
(RAW 264.7), cells were washed with PBS twice and digested in aqua regia for 2 h. The aqua 
regia solutions were transferred to 15 mL centrifuge tubes and the final volumes were adjusted 
using Milli-Q water. The final gold content was measured using inductively coupled plasma 
optical emission spectrometry (ICP-OES). To test non-specific uptake of double-charged AuNPs 
with HS-PEG-COOH and HS-PEG-NH2, macrophage cells (2.7×105/well) were seeded into 6-
well plates overnight and then incubated with 1.0 nM double-charged AuNPs in complete media 
at 37 °C for 4 h. AuNPs coated with a single type of thiolated PEG (HS-PEG-OCH3, HS-PEG-
COOH, or HS-PEG-NH2) were used as controls. 
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4.6. Figures 
 
Figure 4.1. Hydrodynamic size change of AuNPs PEGylated with HS-PEG-COOH at all molar 
ratios before centrifugation, where the insert shows a schematic illustration of the conformation 
change of PEGylated chains on gold nanoparticles from mushroom at lower PEG chain densities 
to brush at higher PEG chain densities. 
 
Figure 4.2. Optical density at absorption peak of AuNPs PEGylated with HS-PEG-COOH at all 
molar ratios after centrifugation. 
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Figure 4.3. (a) Zeta potential before centrifugation of AuNPs PEGylated with HS-PEG-NH2 at 
all molar ratios and (b) fluorescence intensity at 480 nm, via fluorescamine-based assay, of the 
corresponding supernatants after centrifugation. 
 
 
Figure 4.4. Cellular uptake of AuNPs PEGylated with different PEG-RGD densities on the 
AuNP surface in U-87 MG (a) and MCF-7 (b) cells. 
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Figure 4.5. Macrophage cell uptake of AuNPs PEGylated with different PEG-RGD densities on 
the AuNP surfaces. 
 
 
Scheme 4.1. Schematic illustration of ‘living’ PEGylation with different functional PEG chains 
and controllable PEG chain density. 
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Figure 4.6. Macrophage cell non-specific uptake of AuNPs decorated with PEG-R in single 
(control) or successive (double-charged) conjugations. 
 
4.7 Supplemental Figures 
 
Figure 4.S1. Absorption spectra (a) and zeta potential (b) versus HS-PEG-COOH/AuNP molar 
ratios, before centrifugation. 
 
     115 
 
 
Figure 4.S2. Absorption spectra at typical molar ratios of AuNPs PEGylated with HS-PEG-
COOH, after centrifugation. 
 
 
Scheme 4.S1. Scheme of the reaction between fluorescamine and a primary amine that generates 
a fluorescent product. 
 
Figure 4.S3. Hydrodynamic size change of AuNPs PEGylated with HS-PEG-NH2 at all molar 
ratios, before centrifugation. 
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Figure 4.S4. Fluorescence spectra of the HS-PEG-NH2 calibrating solutions (a) and the plot of 
corresponding fluorescence intensity at 480 nm (b). Fluorescence spectra of the supernatants 
containing free HS-PEG-NH2 after mixing with AuNP at different molar ratios followed by 
centrifugation (c). 
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Scheme 4.S2. Synthesis of HS-PEG-RGD. 
 
 
Figure 4.S5. HPLC profile of synthesized HS-PEG-RGD before and after purification. 
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Figure 4.S6. Optical spectra of HS-PEG-RGD and RGD. 
 
 
Figure 4.S7. (a) Hydrodynamic size change and (b) zeta potential of AuNPs PEGylated with HS-
PEG-RGD at different molar ratios, before centrifugation. 
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Figure 4.S8. Stability of AuNPs PEGylated with HS-PEG-RGD at typical molar ratios in 
DMEM media plus 10% FBS. 
 
Figure 4.S9. MCF-7 cell non-specific uptake of AuNPs decorated with PEG-RAD (control) at 
different surface densities. 
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Figure 4.S10. Zeta potential of double-charged AuNPs sequentially PEGylated three times 
(COOH/NH2/COOH), with increasing HS-PEG-NH2/AuNP molar ratios. 
 
Figure 4.S11. Photograph of laser-generated (top panel) and chemically-made AuNPs (bottom 
panel) after PEGylation with 1 μM (large excess) of HS-PEG-OCH3 (a, a’), HS-PEG-COOH (b, 
b’), and HS-PEG-NH2 (c, c’) (both laser- and chemically-made AuNPs are stable); 150 nM of 
HS-PEG-OCH3 then 100 nM of HS-PEG-NH2 (d, d’); 150 nM of HS-PEG-COOH then 100 nM 
of HS-PEG-NH2 (e, e’); 150 nM of HS-PEG-COOH then 300 nM of HS-PEG-NH2 (f, f’) (laser-
made AuNPs are stable but chemically-made AuNPs are not).  
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CHAPTER 5. CORE-SATELLITE NANOPARTICLES WITH CLICKABLE PEPTIDES 
FOR ACTIVELY TARGETED PHOTOTHERMAL CANCER THERAPY AND 
MAGNETIC RESONANCE IMAGING 
 
5.1 Abstract 
The advent of nanomedicine has brought tremendous potential to push the boundaries of 
traditional cancer therapies and design specific treatments with enhanced control over delivery 
and targeting.  Photothermal therapy (PTT) to induce localized hyperthermia is one of few 
nanoparticle-based treatments to enter clinical trials in human cancer patients, but currently relies 
on passive tumor targeting clinically.  Employing actively targeted, theranostic nanoparticles for 
PTT combines multiple approaches at controlled delivery of localized therapy and may be 
adapted in the future for metastatic cancer settings, particularly in light of recent reports in 
animal models that PTT can trigger a cancer-specific immune response.  Here we describe a 
facile, optimal design for actively targeted, theranostic nanocomposites with a core-satellite 
structure for photothermal therapy and magnetic resonance imaging (MRI).  A small, “clickable” 
targeting peptide facilely synthesized with an N-terminal alkyne separated by two 6-
aminohexanoic acid spacers acids enables precise control over attachment to the nanoparticles to 
prevent steric hindrance and optimize binding with the target receptor.  Poly(ethylene glycol)-
azide (PEG-N3)-coated PTT nanocomposites with a highly crystallized iron oxide nanoparticle 
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(HCIONP) core (17 nm) and ultra-small AuNP satellites (4 nm) results in enhanced stability with 
highly efficient conjugation of the targeting peptide by azide-alkyne click chemistry, as 
determined by changes in hydrodynamic size (33.1 to 39.7 nm) and peptide quantification via the 
Bradford assay.  The high stability of the HCIONP-AuNP-PEG-N3 nanocomposite makes it ideal 
for controlled conjugation of cysteine-containing peptides which would otherwise attach directly 
to the AuNP surface.  Furthermore, compared to AuNPs often used for PTT, the HCIONP core 
of the nanocomposite enables purification by magnet if desired and in vivo MRI to visualize the 
tumor tissue before and after treatment.  The HCIONP-AuNP nanocomposites with tumor-
targeting, clickable peptides for PTT and MRI presented here exemplify controlled delivery of 
localized therapy to reduce off-target toxicity and consequently increase both patient tolerance 
and response to cancer treatment. 
 
5.2 Introduction 
The wealth of knowledge in the cancer field gained through bioinformatics and rapid 
technological advances since the advent of the computer sparked a movement toward 
personalized cancer therapy that will significantly improve patient response and tolerance.  
Critical to individualized cancer treatment are the ability to identify which mutations and 
aberrant signaling are driving each patient’s cancer and consequently target and deliver specific 
therapies.  For decades non-surgical cancer treatment has been dominated by radiation and 
chemotherapy, which are generally aimed at rapidly dividing cells and don’t offer much 
specificity.  Consequently, it can be difficult to strike a balance between minimizing off-target 
side effects and maintaining treatment efficacy.  A decrease in the dose or frequency may be 
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achieved by development of targeted therapies either employing an active homing mechanism or 
passive carrier [1-3].  Resultant improvements in biodistribution and pharmacokinetic (PK) 
properties (e.g., half life) enhance the amount and proportion of the therapeutic at the target site.  
The majority of research on targeted therapies that has advanced to use in patients has focused on 
increasing delivery to cancer cells in general [3-10], yet there remains great potential to develop 
therapies that hit more specific targets such as organelles within the cells (e.g., nucleus) [11, 12] 
or a particular subset of cancer cells such as cancer stem cells [13, 14]. 
Both passively and actively targeted therapeutics have advanced beyond pre-clinical 
research.  Passive targeting relies on physical properties, such as size or surface charge, of the 
therapeutic formulation that enhance physiological characteristics such as half-life in the 
bloodstream (i.e., rate of elimination), plasma protein binding, recognition by immune cells, and 
ability to exploit the enhanced permeability and retention (EPR) effect resulting from the 
relatively leaky vasculature and poor drainage of the tumor environment [15, 16].  Abraxane 
(albumin-bound Paclitaxel, Celgene) and Doxil (Doxorubicin encapsulated into polymer-coated 
liposomes, Johnson & Johnson’s Janssen) are commercially available, passively targeted 
nanoparticle formulations that have improved the therapeutic index of standard chemotherapy 
drugs [16, 17].  Various approaches have been taken to develop actively targeted therapeutics, in 
which (part of) the molecule avidly binds to a specific receptor in a homing fashion [16].  
Monoclonal antibodies (mAbs) developed through genetic engineering pioneered by Herb Boyer 
at the University of California, San Francisco led to a medical breakthrough to produce actively 
targeted biologics such as Herceptin [18, 19], which became part of frontline treatment for 
women with Her2+ breast cancer.  More recently monoclonal antibodies targeting PD-L1 
receptors on cancer cells have been developed for cancer immunotherapy to block cancer cell 
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suppression of the immune cells attempting to destroy them [20-22].  Examples include 
BMS936559 (Brystol-Myers Squibb) and MPDL3280A (Genentech) tested in clinical trials for 
multiple cancers including melanoma and non-small cell lung cancer [23].Antibody-drug 
conjugates (ADCs) are another approach to develop commercially producible, actively targeted 
cancer therapy [24].  Examples include Kadcyla (Genentech), in which Herceptin is conjugated 
to a taxane, approved for metastatic Her2+ breast cancer [25]and Adcetris (Seattle Genetics), 
composed of a CD30-targeting mAb linked to a microtubule-disrupting compound, approved for 
Hodgkin lymphoma and systemic anaplastic large cell lymphoma [26].Peptide-based therapies 
have also been investigated in clinical trials, such as Merck KGaA’s Cilengitide [27, 28].  An 
integrin inhibitor containing the RGD-targeting peptide motif, it is believed to affect both tumor 
cell growth and formation of new blood vessels that supply the tumor (angiogenesis).  Another 
example in clinical trials is AN-152, a peptide analog of luteinizing hormone-releasing hormone 
(LHRH) that is bound to Doxorubicin, for targeted prostate cancer therapy [29].  Similarly, the 
peptide Cetrorelix became the first clinically approved LHRH antagonist, and has been indicated 
for both prostate and breast cancer treatment [28]. 
While nanoparticles offer tremendous untapped potential for controlled delivery of 
targeted cancer therapies, few nanoparticle therapies beyond Abraxane and Doxil have advanced 
to clinical settings.  One that has is Aurimune (CytImmune), which entered Phase I clinical trials 
in 2006 for advanced or metastatic solid organ cancers [30]. It relies on passive targeting from 
precisely sized, polymer-coated gold nanoparticles (AuNPs) to deliver tumor necrosis factor 
(TNF) to help normalize tumor blood flow for enhanced penetration of chemotherapy [31].  
Another is AuroLase (Nanospectra Biosciences), polymer-coated gold nanoshells that kill cancer 
cells through thermal ablation [32].  The nanoshells accumulate in the tumor tissue through 
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passive targeting, which results in localized destruction as laser light is applied and efficiently 
converted into heat by the nanoshells (i.e., photothermal therapy).  More sophisticated 
nanoparticle formulations have been designed and tested in the laboratory setting to enhance 
control over targeted delivery of therapeutic agents, such as those designed for pH-sensitive 
intracellular drug release in acidic lysosomes or enzyme-mediated release [33-39].  
Nanoparticles may not only serve as a platform for targeted drug delivery but also diagnostic 
tumor imaging, for which a few iron oxide-based nanoparticles, such as Feridex (Berlex 
Laboratories), have already been approved for use in humans [17]. 
Nanoparticle-mediated photothermal therapy such as AuroLase provides additional 
control beyond tumor targeting of agents injected into the patient, since the inert gold nanoshells 
will only be activated under locally applied laser light.  Active targeting of such heat-mediating 
nanoparticles may reduce the intravenous dose required to achieve a similar intratumoral 
nanoparticle concentration and potentially the cost of treatment.  However, many factors must be 
taken into account when considering an optimized actively targeted nanoparticle formulation.  In 
terms of the targeting ligand, antibodies are possible to commercially produce and have high 
binding affinities for their target receptor; however, production and purification is expensive and 
their relatively large size limits the potential loading capacity of a therapeutic drug onto the 
nanoparticle surface [40].  A design to maximize both targeting efficiency and potency of drug-
loaded nanoparticles would be ideal.  High affinity peptides derived from the binding region of 
an antibody are cheaper and simpler to produce and purify, would allow more room on the 
nanoparticle surface for attachment of a drug, and may be better suited to benefit from the 
multivalent effect [40, 41].  Regarding attachment to the nanoparticle surface, peptides and 
antibodies are generally conjugated using chemically-reactive groups (NH2, COOH, SH) on the 
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side chains of their amino acid building blocks [42]; however, this approach may affect the 
binding of the ligand to target receptors.  A simple modification of the ligand in a region outside 
of the primary binding site to allow a specific conjugation reaction would be ideal for 
maximizing binding affinity.  Similarly, a balance must be struck in selecting chemistry 
approaches to control the addition of the targeting ligand while maintaining stability of a 
colloidal nanoparticle. 
Here we propose an optimized design for actively targeted, theranostic nanoparticles for 
localized, externally controlled photothermal therapy (PTT) and tumor imaging capabilities.  
Nanocomposites composed of a highly crystallized iron oxide nanoparticle (HCIONP) core and 
gold nanoparticle (AuNP) satellites facilely synthesized in our lab have been shown to be 
efficient PTT mediators capable of magnetic resonance imaging (MRI) in an in vivo breast 
cancer model, and can be simply modified through thiol-gold linkage [43].  These core-satellite 
nanocomposites will be modified with heterobifunctional polyethylene glycol, thiol-PEG-azide 
(HS-PEG-N3), to precisely control conjugation of a targeting peptide through click chemistry 
using a peptide bearing an N-terminal alkyne separated by two spacers.  This design avoids using 
amino acid side chains for conjugation of the peptide, preventing possible interference of its 
interaction with the target receptor.  The high stability of the HCIONP-AuNP nanocomposite 
makes it ideal for controlled conjugation of cysteine-containing peptides with thiol groups, 
which requires the PEG-azide to be attached to the nanoparticle prior to click chemistry with the 
peptide to prevent the peptide from attaching to the gold nanoparticle surface directly through its 
cysteine side chains.  Furthermore, while purification by centrifugation after modification of the 
nanoparticle surface can affect nanoparticle stability, the HCIONP core of the nanocomposite 
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enables more gentle purification by magnet.  Compared to AuNPs often used for PTT, the 
HCIONP core also allows in vivo MRI to visualize the tumor tissue before and after treatment. 
 
5.3 Results and Discussion 
 Decades of cancer treatment dominated by surgery, radiation, and chemotherapy has 
resulted in many patients not only struggling to cope with the knowledge of carrying a 
potentially fatal disease but the detrimental side effects they face with non-specific treatments.  
The ability to develop and effectively deliver personalized, targeted medicine may increase 
patient tolerance and response to treatment as well as avoid future complications from stresses 
put on the body (e.g., heart) directly caused by treatment (e.g., Doxorubicin).  Employing 
actively targeted nanoparticles for photothermal therapy combines multiple approaches at 
delivering localized cancer therapy with reduced off-target toxicity.  The nanoparticle size 
facilitates passive targeting of therapy to the tumor site, where the ligand on the nanoparticle 
surface will direct it to the cells of interest.  Using nanoparticles composed of inert materials, 
such as gold, that are externally activated to produce heat localizes damage to cancer cells 
despite not all of the nanoparticles reaching the tumor site. 
Due to simple, cost effective production and small size relative to a monoclonal antibody, 
a peptide was considered the ideal targeting ligand to attach to the surface of the nanoparticle for 
photothermal therapy and selected for our study.  The 9-mer model peptide selected has an 
amino acid sequence of Asp-Arg-Phe-Cys-Asp-Arg-Phe-Pro-Phe (DRFCDRFPF), giving it side 
chains with functional groups that are commonly used for chemical attachment to the surface of 
nanoparticles: the carboxylic acid (COOH) groups in the aspartic acid (D) residues, and the thiol 
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(SH) group in the cysteine (C) residue [42, 44].  This sequence was derived from the nine amino 
acids deemed critical for the interaction of the Jagged1 ligand with its Notch receptor over-
expressed on several types of cancer cells including breast cancer [45, 46].  However, using 
functional groups within the side chains of any critical amino acid to conjugate a peptide to 
therapeutic nanoparticles may interfere with binding affinity for the target receptor. 
 Here we propose to use click chemistry for a specific chemical conjugation of the 
targeting peptide to the surface of the nanoparticle for photothermal therapy (Scheme 5.1).  
“Click” chemistry was first described by Sharpless and coworkers seeking simple, high yield, 
stereo-specific reactions that create only “inoffensive” by-products [47].  Being bio-orthogonal 
reactions, the functional groups of both the reactants and products will not interact with naturally 
occurring biomolecules [48, 49].  Azide-alkyne cycloaddition (Scheme 5.2) has become one of 
the most used click chemistry reactions.  Like many click chemistry reactions, it can be 
performed at room temperature in water.  A linear alkyne functional group will react highly 
efficiently with an azide group in the presence of a copper catalyst to form a triazole product.  If 
desired, copper-less azide-alkyne cycloaddition may be performed using a ring-strained alkyne 
[48].  As a modification to previously described “clickable” peptides [50, 51], we propose the N-
terminal addition of two 6-aminohexanoic acid (Ahx) spacers between the targeting peptide’s 
amino acids to minimize steric hindrance when attached to the nanocomposite and optimize the 
ligand-target interaction.  Furthermore, both the spacers and the 4-pentynoic acid contain the 
necessary functional groups to continue FMOC chemistry used during peptide synthesis to add 
each amino acid to the chain.  Following manual synthesis of the 9-mer-alkyne shown in Scheme 
5.3, the peptide was purified by reverse phase high performance liquid chromatography (RP-
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HPLC).  The analytical run of the purified product is shown in Figure 5.1A and confirmation of 
the correct mass by electrospray ionization mass spectroscopy in Figure 5.1B.  
 The gold standard for nanoparticle mediators of photothermal cancer therapy are gold-
based nanoparticles, following the works of Mostafa El-Sayed and Jennifer West applying gold 
nanorods (AuNRs) and developing the silica-core gold nanoshells (AuNSs) that were 
commercialized to AuroLase therapy [11, 32, 52-55].  These particular gold structures have a 
peak absorbance of near infrared (NIR) light, which allows for maximal tissue penetration and 
selective heating of nanoparticles due to the low light absorbance by tissue chromophores at this 
wavelength [56].  Gold efficiently converts light irradiation into heat by causing oscillations of 
electrons at the nanoparticle surface, a phenomenon known as surface plasmon resonance [57].  
In addition to being biocompatible, an advantage of gold nanoparticles is the ability to facilely 
modify their surface using thiol functional groups.  However, this poses a challenge when the 
required targeting ligand contains one or more thiol-bearing cysteines if a unique reaction is 
desired for the chemical conjugation.  Normally, AuNPs are coated with the hydrophilic polymer 
poly(ethylene glycol) (HS-PEG-R) to render them stable in physiological conditions [58, 59], 
and small targeting molecules like peptides would be attached to the PEG rather than directly to 
the nanoparticle surface to prevent it being masked by the polymer [58].  If the peptide contains a 
cysteine, it must be added to the AuNPs after they are coated with PEG rather than simply 
attaching the thiol-PEG-peptide conjugate.  For our study the azide-PEG-coated nanoparticles 
must remain stable during the attachment of the cysteine-containing targeting peptide by click 
chemistry and subsequent purification, making the HCIONP-AuNP core-satellite nanocomposite 
previously reported by our lab ideal. 
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 Commercial gold nanoparticles (15 nm) were originally selected for proof-of-concept 
studies for peptide attachment by click chemistry.  The stability of colloidal gold can be tracked 
through absorbance measurements related to their concentration by the Beer-Lambert Law [60].  
The concentration of AuNPs coated with HS-PEG-N3 was determined before and after click 
chemistry using their peak absorption at 520 nm (Figure 5.2A).  As shown in Figure 5.2B, the 
AuNP instability is apparent from the dramatic drop in concentration after allowing the copper-
catalyzed click chemistry reaction to proceed overnight.  Next we sought to test whether PTT-
mediating AuNPs stabilized onto HCIONPs, as previously described in our lab [43], would 
remain stable during peptide addition via click chemistry.  Furthermore, the HCIONP core grants 
the nanocomposites MRI capabilities not possible with commonly used AuNRs and AuNSs for 
photothermal therapy and enables purification of the nanoparticles by magnet, a gentler process 
than centrifugation.  
For the initial stability study, HCIONP-AuNP nanocomposites with and without the 
PEG-N3 coating were used.  HCIONPs (17 nm) for the nanocomposite core were synthesized by 
thermal decomposition and rendered water soluble by coating with an antifouling polymer, as 
previously described by our lab [43, 61, 62].  AuNP satellites (~7 nm) were synthesized from 
chloroauric acid [43].  After overnight mixing of the polymer-coated HCIONPs and the AuNPs 
to form the nanocomposites, a portion was coated with thiol-PEG-azide before purification by 
magnet.  The stability of the nanocomposites to the click chemistry reagents (copper sulfate, 
sodium ascorbate) was tested using alkyne-5-FAM as a model for the 9-mer-alkyne peptide.  As 
shown in Figure 5.2C, the nanocomposites are most stable when the alkyne and azide groups are 
reacted in the presence of the click chemistry reagents.  Both solutions tested using 
nanocomposites lacking the PEG-N3 coating are unstable to click chemistry conditions. 
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 For subsequent studies, the nanocomposites were formulated with ultra-small AuNP 
satellites (~4 nm) similarly synthesized from chloroauric acid.  Previously tested by our lab, 
these ultra-small PTT-mediating AuNPs no longer express the absorbance peak at 520 nm.  The 
structure and size of the HCIONP-AuNP-PEG-N3 nanocomposites were viewed by transmission 
electron microscopy (TEM), as shown in Figure 5.3A.  Initial measurements of the 
hydrodynamic size and zeta potential before addition of the 9-mer-alkyne were taken by dynamic 
light scattering (Figure 5.3B).  The 33.1 nm hydrodynamic size following PEGylation meets our 
expectations based on the HCIONP and AuNP sizes determined by TEM.  The nanocomposite 
iron and gold concentrations were determined by inductively coupled plasma optical emission 
spectrometry (ICP-OES) (Figure 5.3C); from this the molar ratio of AuNPs per HCIONP was 
determined to be 8.0:1, which is consistent with the number of AuNP satellites per HCIONP core 
according to TEM.  The PEG-N3 concentration for click chemistry was estimated according to 
the footprint of PEG5000 on gold nanoshells [63].  Calculating the surface area of AuNP satellites 
and assuming roughly half will be freely available for conjugation by HS-PEG-N3, accounting 
for the surface area required for attachment to the HCIONP core, the molar ratio of PEG 
molecules per AuNP satellite was estimated to be 3:1. 
 Upon initiating the click chemistry reaction of the HCIONP-AuNP-PEG-N3 
nanocomposites and 9-mer-alkyne, initial and final absorption curves were obtained to 
demonstrate the nanocomposite stability as shown in Figure 5.4A.  Successful attachment of the 
9-mer-alkyne was confirmed in two ways.  Following the click chemistry reaction, the solution 
was centrifuged to collect the unbound peptide in the supernatant and the nanocomposites were 
resuspended.  First, the nanocomposite hydrodynamic size and zeta potential were determined, as 
shown in Figure 5.4B.  The modest yet significant (p = 0.05) size increase from 33.1 to 39.7 nm 
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following click chemistry suggests the alkyne-peptide was conjugated to the end of the PEG-
azide.  Given the two positive arginine (R) and two negative aspartic acid (D) residues, a 
relatively consistent zeta potential before (-30.8 mV) and after (-30.5 mV) click chemistry is to 
be expected.  Second, the Bradford Quick Start assay was chosen to quantify 9-mer-alkyne 
binding to the nanocomposites.  The Coomassie Brilliant Blue dye converts from a cationic form 
to an anionic form upon binding to proteins through amino acids that are basic (e.g., arginine) 
and aromatic (e.g., phenylalanine), resulting in a shift from a red to a blue color that is detectable 
at 595 nm [64].  The unbound peptide collected was quantified using a standard curve of the 9-
mer-alkyne generated at limiting peptide dilutions but maintaining a constant concentration of 
click chemistry reagents equal to that used in the reaction, as shown in Figure 5.4C.  The 
absorbance value of the peptide supernatant after click chemistry was 0.005 above the 
background (click chemistry reagents without peptide), suggesting a highly efficient reaction in 
which virtually all of the peptide was conjugated to the nanocomposites. 
 For follow up studies, it would be optimal to purify the peptide-modified nanocomposites 
by magnet as a portion could not be resuspended following centrifugation.  To test the targeting 
efficiency of the peptide-modified nanocomposites with cancer cells in vitro, ideally a well-
characterized targeting peptide should be used in place of our model peptide.  One example 
would be the RGD peptide that targets αvβ3 integrin receptors such as those found on U-87 MG 
glioblastoma cells [7, 58].  Furthermore, while our lab has previously shown the non-targeted 
HCIONP-AuNP nanocomposites are stable in vivo, demonstrating the proportions of Fe and Au 
are consistent in each tissue to which the nanocomposites distribute, the stability of the peptide-
modified nanocomposites should be confirmed in blood. 
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Collectively our results presented here suggest that development of actively targeted, 
photothermal-mediating nanocomposites modified with clickable peptides offer many 
formulation benefits: stable nanoparticles that can be specifically and facilely appended with 
targeting peptides to promote optimal interactions with the target receptor.  Employing 
nanocomposites that are stable to click chemistry allows controlled addition of cysteine (thiol)-
containing peptides to gold-based photothermal mediators.  The iron oxide core of the HCIONP-
AuNP core-satellite nanocomposite enables purification by magnet if desired as well as MRI 
diagnostic therapy, for which a few iron oxide-based nanoparticles, such as Feridex and 
Combidex, have already been used in humans for tumor imaging [17].  Production of targeting 
peptides is much simpler and cheaper than monoclonal antibodies, which must be produced in 
bacteria and undergo multiple purification steps.  Furthermore, the smaller size of peptides better 
facilitates drug loading if dual PTT and targeted drug delivery are desired.  Nanoparticle-
mediated photothermal therapy poses an attractive strategy for targeted cancer therapy in that it 
is inherently localized by requiring external activation.  While its use in clinical trials is currently 
limited to head and neck cancer and primary and metastatic lung cancer [65, 66], PTT offers 
tremendous untapped potential for site-specific cancer therapy that has a relatively wide 
therapeutic index.  As heat-mediated cell death isn’t pathway specific, PTT could be applied to a 
variety of cancers including the difficult-to-treat triple negative breast cancer.  Targeted 
nanoparticles capable of in vivo imaging, such as those described here, may even be adapted to 
apply PTT to metastatic sites in the future.  Similarly, recent reports that PTT at primary tumor 
sites triggers an immune response to attack cancer cells at metastatic sites [67-69] has opened 
doors to developing potentially synergystic therapies combining PTT with the exploding field of 
cancer immunotherapy. 
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5.4 Conclusions 
Here we demonstrate successful formulation of actively targeted, theranostic 
nanoparticles for localized, externally controlled photothermal therapy (PTT) and tumor imaging 
capabilities.  First, we facilely synthesize a model clickable peptide with an N-terminal alkyne 
separated by two 6-aminohexanoic acid spacers acids, designed for precise control over 
attachment to the nanoparticles to prevent steric hindrance and optimize binding with the target 
receptor.  Next we synthesize and characterize azide-coated PTT nanocomposites with a 
HCIONP core (17 nm) and ultra-small AuNP satellites (4 nm), and demonstrate their enhanced 
stability to azide-alkyne click chemistry through absorption measurements.  Highly efficient 
peptide conjugation is confirmed by measuring changes in hydrodynamic size (33.1 to 39.7 nm) 
and quantifying unbound peptide via the Bradford assay.  The high stability of the IONP-AuNP-
PEG-N3 nanocomposite makes it ideal for controlled conjugation of cysteine-containing peptides 
with thiol groups, which would otherwise attach directly to the AuNP surface if not previously 
PEGylated.  Furthermore, compared to AuNPs often used for PTT, the HCIONP core of the 
nanocomposite enables purification by magnet if desired and in vivo MRI to visualize the tumor 
tissue before and after treatment.  Employing actively targeted, facilely synthesized composite 
nanoparticles for photothermal therapy, as described here, combines multiple approaches for 
delivering localized therapy with reduced off-target toxicity to increase both patient tolerance 
and response to cancer treatment. 
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5.5 Materials and Methods 
Synthesis of alkyne-peptide: The model targeting peptide was produced manually via 
FMOC solid phase synthesis using chlorotrityl resin.  Following addition of the nine amino acids 
(DRFCDRFPF) to the resin, two 6-aminohexanoic acid spacers and 4-pentynoic acid were added 
at the N-terminus before cleavage from the resin.  Purification of the peptide, designated 9-mer-
alkyne, was performed via reverse phase high performance liquid chromatography (RP-HPLC) 
with a C-18 column (Sunfire, 19 mm × 150 mm, 5 μm), and electrospray ionization mass 
spectroscopy confirmed the correct mass. 
Synthesis of iron oxide-gold core-satellite nanocomposite: Polymer-coated HCIONPs 
were prepared as previously described by our lab.  Briefly, HCIONPs (17 nm diameter) were 
synthesized in organic solvent by thermal decomposition.  They were rendered soluble in 
aqueous solution after coating with diblock copolymer poly(ethylene oxide)-b-poly(γ-
methacryloxypropyl trimethoxysilane)(PEO-b- PγMPS), which is synthesized by reversible 
addition fragmentation chain transfer (RAFT) polymerization, and purifying by a magnetic 
separator (Frantz laboratory) at 4 °C.  The iron concentration of the resultant solution was 
determined using o-phenanthroline as previously described. 
 Ultra-small AuNPs were synthesized from chloroauric acid (HAuCl4, 2.0 mM stock) 
using sodium sulfide (Na2S, 1.0 mM stock) as the reducing reagent, which was first prepared and 
aged in the dark for 48 h before use. Na2S and HAuCl4 were mixed in the dark at a volume ratio 
of 3.0/1.75 for 3 h.  The HCIONP-AuNP core-satellite nanocomposites were formed in the dark 
by mixing polymer-coated HCIONPs (1.0 mL of 4.3 mg Fe/mL stock) with AuNPs (50 mL) 
overnight at 4 °C and subsequently coated with HS-PEG5000-N3 (NanoCS) overnight in the dark 
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at 4 °C.  Azide-modified nanocomposites were purified by magnet at 4 °C and viewed by 
transmission electron microscopy (TEM) (JEOL JEM-1400Plus 120 kV).  Hydrodynamic size 
and zeta potential were determined by dynamic light scattering (DLS) on a Zetasizer Nano S90 
(Malvern).  The iron and gold concentrations were measured by inductively coupled 
plasmaoptical emission spectrometry (ICP-OES) using yttrium as the internal standard, 
following dissolution of the nanocomposite in aqua regia (3:1 hydrochloric acid to nitric acid).  
The PEG-N3 concentration on the HCIONP-AuNP nanocomposites was calculated using a 
footprint of 9.6 nm2 for PEG-5000 [63] and the assumption that half of each AuNP surface could 
be coated with PEG after binding to a HCIONP core. 
 Peptide conjugation to nanocomposites by click chemistry: HCIONP-AuNP-PEG-N3 (25 
μM PEG-N3) were mixed in the dark overnight with the 9-mer-alkyne (50 μM)  in the presence 
of copper sulfate (CuSO4) catalyst (200 μM) and sodium ascorbate (1 mM) reducing agent.  
Unbound peptide was removed by centrifugation with nanocomposites at 10,000 RPM for 10 
min followed by additional centrifugation at 15,000 RPM for 5 min after separating from the 
nanocomposite pellet.  Following both centrifugations, the supernatant was collected and used 
for quantification of unbound peptide.  The resuspended HCIONP-AuNP-PEG-N3 pellet was 
analyzed by DLS. 
 Peptide quantification with Bradford assay: Peptide quantification was performed 
according to the manufacturer’s microassay protocol for the Quick Start Bradford Protein Assay 
(Bio-Rad), using absorbance measurements from a BioTek microplate reader (Synergy 2).  The 
concentration of unbound peptide concentration in the click chemistry supernatant was 
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calculated from a standard curve of the 9-mer-alkyne at limiting dilutions but with a constant 
concentration of click chemistry reagents equal to that used in the click chemistry reaction. 
 Statistical Analysis: Data are represented as mean ± standard deviation.  The significance 
values of data sets with two groups were calculated by a student’s t-test.  A p ≤ 0.05 was 
considered statistically significant. 
 
5.6 Figures 
 
 
 
Scheme 5.1. Schematic of HCIONP-AuNP core-satellite nanocomposites with clickable peptides 
for targeted photothermal therapy 
 
 
Scheme 5.2. Schematic (MarvinSketch) of copper-catalyzed alkyne-azide cycloaddition 
(CuAAC) to form a triazole product. 
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Scheme 5.3. Schematic (MarvinSketch) of 9-mer (DRFCDRFPF) with N-terminal alkyne (4-
pentynoic acid) spaced by two 6-aminohexanoic acid linkers. 
 
 
Figure 5.1. (A) Single peak from the analytical run of the purified 9-mer-Ahx-Ahx-Alkyne (MW 
~1509 g/mol).  (B) Confirmation of the correct mass by electrospray ionization (ESI) mass 
spectroscopy, revealing the +2 peak at 755.5 m/z. 
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Figure 5.2. (A) Absorbance curves of azide-PEG-coated AuNPs before and after overnight click 
chemistry reaction with alkyne-peptide.  (B) Relative concentration of azide-PEG-coated AuNPs 
before and after overnight click chemistry reaction with alkyne-peptide.  After determining the 
AuNP concentration from the absorbance using the Beer-Lambert Law, the post-click 
concentration was adjusted to account for the dilution that occurred when mixing with peptide 
and click chemistry reagents.  (C) Stability of HCIONP-AuNPs, with and without PEG-N3 
coating, to click chemistry reagents (CCR) as determined by relative absorbance shown before 
and after overnight mixing with alkyne-5-FAM. 
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Figure 5.3. (A) TEM of core-satellite structure of azide-PEG-coated HCIONP-AuNPs before 
overnight click chemistry reaction with alkyne-peptide (scale bar = 20 nm).  (B) Hydrodynamic 
size and zeta potential (average ± standard deviation) of HCIONP-AuNP-PEG-N3 before click 
chemistry reaction, obtained using dynamic light scattering.  (C) ICP-OES elemental standard 
curves of iron (Fe) and gold (Au) used to calculate the HCIONP and AuNP concentrations of the 
azide-PEG-coated HCIONP-AuNPs digested overnight in aqua regia. 
 
 
Figure 5.4. (A) Absorbance curves of azide-PEG-coated HCIONP-AuNP nanocomposites before 
and after overnight click chemistry reaction with alkyne-peptide.  Note as the PTT-mediating 
AuNP satellites become ultra-small, they no longer express the 520 nm peak.  (B) Hydrodynamic 
size and zeta potential (average ± standard deviation) of HCIONP-AuNP-PEG-N3 after click 
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chemistry addition of alkyne-peptide, obtained using dynamic light scattering.  (C) Bradford 
standard curves of 9-mer-alkyne in presence of 200 μM copper sulfate and 1 mM sodium 
ascorbate, used to calculate the concentration of unbound alkyne-peptide in the supernatant after 
click chemistry addition to the of HCIONP-AuNP-PEG-N3 nanocomposite. 
 
5.7 Acknowledgements 
Others who contributed to this work include Nicholas O. Stevers, Hongwei Chen, and Duxin Sun 
in the Pharmaceutical Sciences department at the University of Michigan.  I would also like to 
thank Mitchell Smith and Anne McNeil in the University of Michigan Chemistry Department for 
their gel permeation chromatography support.  This work was supported in part by the NIH 
Pharmacological Sciences Training Program (H. Paholak), the American Foundation for 
Pharmaceutical Education Pre-Doctoral Fellowship (H. Paholak), and the University of Michigan 
Rackham Pre-Doctoral Fellowship (H. Paholak). 
 
5.8 References 
1.  Chandasana, H., et al., Corneal targeted nanoparticles for sustained natamycin delivery and their 
PK/PD indices: an approach to reduce dose and dosing frequency. Int J Pharm, 2014. 477(1‐2): p. 
317‐25. 
2.  Shegokar, R., Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. 
Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases, 2015: p. 233‐
249. 
3.  Milane, L., Z.F. Duan, and M. Amiji, Pharmacokinetics and biodistribution of 
lonidamine/paclitaxel loaded, EGFR‐targeted nanoparticles in an orthotopic animal model of 
multi‐drug resistant breast cancer. Nanomedicine, 2011. 7(4): p. 435‐44. 
4.  Chen, H., et al., Anti‐HER2 antibody and ScFvEGFR‐conjugated antifouling magnetic iron oxide 
nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int J 
Nanomedicine, 2013. 8: p. 3781‐94. 
     147 
 
5.  Adolphi, N.L., et al., Imaging of Her2‐targeted magnetic nanoparticles for breast cancer 
detection: comparison of SQUID‐detected magnetic relaxometry and MRI. Contrast Media Mol 
Imaging, 2012. 7(3): p. 308‐19. 
6.  Gormley, A.J., et al., Biological evaluation of RGDfK‐gold nanorod conjugates for prostate cancer 
treatment. J Drug Target, 2011. 19(10): p. 915‐24. 
7.  Polyak, D., et al., Development of PEGylated doxorubicin‐E‐[c(RGDfK)(2)] conjugate for integrin‐
targeted cancer therapy. Polymers for Advanced Technologies, 2011. 22(1): p. 103‐113. 
8.  Choi, H., et al., Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging 
via folate receptor‐targeted delivery. Acad Radiol, 2004. 11(9): p. 996‐1004. 
9.  Madan, J., et al., Enhanced noscapine delivery using estrogen‐receptor‐targeted nanoparticles 
for breast cancer therapy. Anticancer Drugs, 2014. 25(6): p. 704‐16. 
10.  Yue, J., et al., Transferrin‐conjugated micelles: enhanced accumulation and antitumor effect for 
transferrin‐receptor‐overexpressing cancer models. Mol Pharm, 2012. 9(7): p. 1919‐31. 
11.  Oyelere, A.K., et al., Peptide‐conjugated gold nanorods for nuclear targeting. Bioconjugate 
Chemistry, 2007. 18(5): p. 1490‐1497. 
12.  Porta, F., et al., Folic acid‐modified mesoporous silica nanoparticles for cellular and nuclear 
targeted drug delivery. Adv Healthc Mater, 2013. 2(2): p. 281‐6. 
13.  Wang, L., et al., CD44 antibody‐targeted liposomal nanoparticles for molecular imaging and 
therapy of hepatocellular carcinoma. Biomaterials, 2012. 33(20): p. 5107‐14. 
14.  Wang, C.H., et al., Photothermolysis of glioblastoma stem‐like cells targeted by carbon 
nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine, 2011. 7(1): p. 69‐79. 
15.  Torchilin, V.P., Passive and active drug targeting: drug delivery to tumors as an example. Handb 
Exp Pharmacol, 2010(197): p. 3‐53. 
16.  Bertrand, N., et al., Cancer nanotechnology: the impact of passive and active targeting in the era 
of modern cancer biology. Adv Drug Deliv Rev, 2014. 66: p. 2‐25. 
17.  Wang, R.B., P.S. Billone, and W.M. Mullett, Nanomedicine in Action: An Overview of Cancer 
Nanomedicine on the Market and in Clinical Trials. Journal of Nanomaterials, 2013. 
18.  Molina, M.A., et al., Trastuzumab (herceptin), a humanized anti‐Her2 receptor monoclonal 
antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer 
Res, 2001. 61(12): p. 4744‐9. 
19.  Russo, E., The birth of biotechnology. Nature, 2003. 421(6921): p. 456‐7. 
20.  The Role of Anti‐PD‐L1 Immunotherapy in Cancer. OncLive, 2014. 
     148 
 
21.  Deng, L., et al., Irradiation and anti‐PD‐L1 treatment synergistically promote antitumor immunity 
in mice. J Clin Invest, 2014. 124(2): p. 687‐95. 
22.  Kim, J.W. and J.P. Eder, Prospects for targeting PD‐1 and PD‐L1 in various tumor types. Oncology 
(Williston Park), 2014. 28 Suppl 3: p. 15‐28. 
23.  Postow, M.A., M.K. Callahan, and J.D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy. 
J Clin Oncol, 2015. 33(17): p. 1974‐82. 
24.  Alley, S.C., N.M. Okeley, and P.D. Senter, Antibody‐drug conjugates: targeted drug delivery for 
cancer. Curr Opin Chem Biol, 2010. 14(4): p. 529‐37. 
25.  Yao, S., FDA approves new treatment for late‐stage breast cancer. FDA.gov, 2013. 
26.  Jefferson, E., FDA approves Adcetris to treat two types of lymphoma. FDA.gov, 2011. 
27.  Mas‐Moruno, C., F. Rechenmacher, and H. Kessler, Cilengitide: the first anti‐angiogenic small 
molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem, 
2010. 10(10): p. 753‐68. 
28.  Thundimadathil, J., Cancer treatment using peptides: current therapies and future prospects. J 
Amino Acids, 2012. 2012: p. 967347. 
29.  Schally, A.V., et al., Use of analogs of peptide hormones conjugated to cytotoxic radicals for 
chemotherapy targeted to receptors on tumors. Curr Drug Deliv, 2011. 8(1): p. 11‐25. 
30.  Libutti, S.K., et al., Phase I and pharmacokinetic studies of CYT‐6091, a novel PEGylated colloidal 
gold‐rhTNF nanomedicine. Clin Cancer Res, 2010. 16(24): p. 6139‐49. 
31.  Powell, A.C., G.F. Paciotti, and S.K. Libutti, Colloidal gold: a novel nanoparticle for targeted 
cancer therapeutics. Methods Mol Biol, 2010. 624: p. 375‐84. 
32.  Aurolase Therapy. Nanospectra. 
33.  Zou, P., et al., Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging 
and pH‐dependent intracellular drug release. Mol Pharm, 2010. 7(6): p. 1974‐84. 
34.  Murthy, N., et al., Bioinspired pH‐responsive polymers for the intracellular delivery of 
biomolecular drugs. Bioconjug Chem, 2003. 14(2): p. 412‐9. 
35.  Murthy, N., et al., Design and synthesis of pH‐responsive polymeric carriers that target uptake 
and enhance the intracellular delivery of oligonucleotides. J Control Release, 2003. 89(3): p. 365‐
74. 
36.  Muhammad, F., et al., pH‐Triggered controlled drug release from mesoporous silica 
nanoparticles via intracelluar dissolution of ZnO nanolids. J Am Chem Soc, 2011. 133(23): p. 
8778‐81. 
     149 
 
37.  Hua, D., et al., Potent tumor targeting drug release system comprising MMP‐2 specific peptide 
fragment with self‐assembling characteristics. Drug Des Devel Ther, 2014. 8: p. 1839‐49. 
38.  Roomi, M.W., et al., Patterns of MMP‐2 and MMP‐9 expression in human cancer cell lines. Oncol 
Rep, 2009. 21(5): p. 1323‐33. 
39.  Foda, H.D. and S. Zucker, Matrix metalloproteinases in cancer invasion, metastasis and 
angiogenesis. Drug Discov Today, 2001. 6(9): p. 478‐482. 
40.  Cai, W., et al., Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci 
Appl, 2008. 2008(1). 
41.  Montet, X., et al., Multivalent effects of RGD peptides obtained by nanoparticle display. J Med 
Chem, 2006. 49(20): p. 6087‐93. 
42.  Hamley, I.W., PEG‐peptide conjugates. Biomacromolecules, 2014. 15(5): p. 1543‐59. 
43.  Chen, H., et al., Facile Fabrication of Near‐Infrared‐Resonant and Magnetic Resonance Imaging‐
Capable Nanomediators for Photothermal Therapy. ACS Appl Mater Interfaces, 2015. 7(23): p. 
12814‐23. 
44.  Chemistry of Crosslinking. ThermoFisher Scientific, 2015. 
45.  Chen, J., et al., Hypoxia potentiates Notch signaling in breast cancer leading to decreased E‐
cadherin expression and increased cell migration and invasion. Br J Cancer, 2010. 102(2): p. 351‐
60. 
46.  D'Angelo, R.C., et al., Notch reporter activity in breast cancer cell lines identifies a subset of cells 
with stem cell activity. Mol Cancer Ther, 2015. 14(3): p. 779‐87. 
47.  Le Droumaguet, B. and K. Velonia, Click chemistry: A powerful tool to create polymer‐based 
macromolecular chimeras. Macromolecular Rapid Communications, 2008. 29(12‐13): p. 1073‐
1089. 
48.  Sletten, E.M. and C.R. Bertozzi, From Mechanism to Mouse: A Tale of Two Bioorthogonal 
Reactions. Accounts of Chemical Research, 2011. 44(9): p. 666‐676. 
49.  Nwe, K. and M.W. Brechbiel, Growing Applications of "Click Chemistry" for Bioconjugation in 
Contemporary Biomedical Research. Cancer Biotherapy and Radiopharmaceuticals, 2009. 24(3): 
p. 289‐302. 
50.  von Maltzahn, G., et al., In vivo tumor cell targeting with "Click" nanoparticles. Bioconjugate 
Chemistry, 2008. 19(8): p. 1570‐1578. 
51.  Lu, J., M. Shi, and M.S. Shoichet, Click Chemistry Functionalized Polymeric Nanoparticles Target 
Corneal Epithelial Cells through RGD‐Cell Surface Receptors. Bioconjugate Chemistry, 2009. 
20(1): p. 87‐94. 
     150 
 
52.  Huang, X.H., et al., Cancer cell imaging and photothermal therapy in the near‐infrared region by 
using gold nanorods. Journal of the American Chemical Society, 2006. 128(6): p. 2115‐2120. 
53.  Huang, X.H., et al., Determination of the minimum temperature required for selective 
photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. 
Photochemistry and Photobiology, 2006. 82(2): p. 412‐417. 
54.  Hirsch, L.R., et al., Nanoshell‐mediated near infrared photothermal tumor therapy. Proceedings 
of the 25th Annual International Conference of the Ieee Engineering in Medicine and Biology 
Society, Vols 1‐4, 2003. 25: p. 1230‐1231. 
55.  Loo, C., et al., Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano 
Letters, 2005. 5(4): p. 709‐711. 
56.  Mahmood, U. and R. Weissleder, Near‐infrared optical imaging of proteases in cancer. 
Molecular Cancer Therapeutics, 2003. 2(5): p. 489‐496. 
57.  Eustis, S. and M.A. El‐Sayed, Why gold nanoparticles are more precious than pretty gold: Noble 
metal surface plasmon resonance and its enhancement of the radiative and nonradiative 
properties of nanocrystals of different shapes. Chemical Society Reviews, 2006. 35(3): p. 209‐
217. 
58.  Chen, H.W., et al., Living' PEGylation on gold nanoparticles to optimize cancer cell uptake by 
controlling targeting ligand and charge densities. Nanotechnology, 2013. 24(35). 
59.  Dreaden, E.C., et al., Beating cancer in multiple ways using nanogold. Chem Soc Rev, 2011. 
40(7): p. 3391‐404. 
60.  Liu, X., et al., Extinction coefficient of gold nanoparticles with different sizes and different 
capping ligands. Colloids Surf B Biointerfaces, 2007. 58(1): p. 3‐7. 
61.  Chen, H.W., et al., Highly crystallized iron oxide nanoparticles as effective and biodegradable 
mediators for photothermal cancer therapy. Journal of Materials Chemistry B, 2014. 2(7): p. 757‐
765. 
62.  Chen, H.W., et al., Reducing non‐specific binding and uptake of nanoparticles and improving cell 
targeting with an antifouling PEO‐b‐P gamma MPS copolymer coating. Biomaterials, 2010. 
31(20): p. 5397‐5407. 
63.  Levin, C.S., et al., Determining the conformation of thiolated poly(ethylene glycol) on Au 
nanoshells by surface‐enhanced Raman scattering spectroscopic assay. Analytical Chemistry, 
2006. 78(10): p. 3277‐3281. 
64.  Lü, X.L., Dejun; Huang, Yan; Zhang, Yiyun, Application of a modified Coomassie brilliant blue 
protein assay in the study of protein adsorption on carbon thin films. Surface & Coatings 
Technology, 2007. 201: p. 6843‐6846. 
65.  Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and 
Neck. ClinicalTrials.gov. 
     151 
 
66.  Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors. 
ClinicalTrials.gov. 
67.  Toraya‐Brown, S., et al., Local hyperthermia treatment of tumors induces CD8(+) T cell‐mediated 
resistance against distal and secondary tumors. Nanomedicine, 2014. 10(6): p. 1273‐85. 
68.  Wang, C., et al., Immunological Responses Triggered by Photothermal Therapy with Carbon 
Nanotubes in Combination with Anti‐CTLA‐4 Therapy to Inhibit Cancer Metastasis. Advanced 
Materials, 2014. 26(48): p. 8154‐8162. 
69.  Bear, A.S., et al., Elimination of metastatic melanoma using gold nanoshell‐enabled 
photothermal therapy and adoptive T cell transfer. PLoS One, 2013. 8(7): p. e69073. 
 
 
 152 
 
CHAPTER 6. SUMMARY 
 
 Rapid advances in bioinformatics and nanotechnology have led to an exciting time in the 
history of medicine; pre-clinical cancer research is booming with development of innovative 
therapies with promise to transform clinical approaches to cancer therapy, which for decades has 
been dominated by surgery, chemotherapy, and radiation.  Cancer nanomedicine is a broad field 
of research that offers tremendous potential to be combined with current cancer therapies to 
overcome key challenges that stem from the inherent properties of cancer cells.  Here we 
highlight a few of these challenging features of cancer, and present nanoparticle-mediated 
photothermal therapy as a multifunctional platform to address the obstacles they pose for cancer 
medicine.   
 First, cancer cells are highly adaptable for survival, which often allows them to rely on 
alternate signaling in response to cancer therapy and can lead to acquired resistance [1-3].  
Second, cells comprising solid tumors can be heterogeneous in type(e.g., cancer-associated 
fibroblasts), and can differ more subtly in terms of genetic or epigenetic changes that alter 
phenotype and can lead to varying functional roles to sustain tumors [4, 5].  Consequently, these 
cellular differences may necessitate more than one therapeutic target for effective elimination 
[6].  In the last decade cancer stem cells (CSCs) have attracted increasing attention as a critical 
target, given the growing body of evidence suggesting a role in driving tumor initiation, tumor 
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growth, metastasis, and resistance to conventional therapies [7-13].  Third, for tumor growth and 
metastasis to occur, cancer cells adapt to escape recognition and destruction by immune cells 
[14, 15]. 
 These features of cancer pose significant obstacles in achieving lasting effects from 
conventional therapies alone, such as chemotherapy and radiation which generally aim to kill 
rapidly dividing cells but offer little specificity.  While many localized cancers caught early 
enough are not fatal, efficacy of treatment is severely impaired when cancer cells are no longer 
localized but have disseminated from the primary tumor site and established metastatic growths 
[16]. 
The overall goal of this work is to develop a nanoparticle approach to address two key 
challenges of cancer medicine: enhancing efficacy in metastatic settings and increasing 
specificity to reduce associated toxicity.  As such, we developed two objectives utilizing 
nanoparticle-mediated photothermal therapy as a multifunctional platform: 1) to inhibit cancer 
stem cells and tumor-mediated immunosuppressive signaling as vital drivers of tumor growth 
and metastasis, and 2) to enhance targeting specificity of therapy. 
In the first section of this dissertation (Chapters 2 and 3), we investigate the efficacy of 
employing nanoparticle-mediated photothermal therapy (PTT) to inhibit cancer stem cells and 
tumor-mediated immunosuppressive signaling – vital drivers of cancer growth and metastasis.  
Combination therapy incorporating nanoparticle-mediated PTT, as we present here, or 
modification of the nanoparticles themselves for multimodal therapy (e.g., PTT and drug 
delivery) may be utilized to enhance treatment efficacy and mitigate acquired resistance.  In 
addition to serving as a multifunctional platform to address key challenges of cancer therapy, 
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another major advantage of nanoparticle-mediated PTT is its potential to improve the specificity 
and efficiency of cancer cell destruction by being localized and targeted.  Given the lack of 
specificity and off-target toxicity of mainstream cancer therapy (e.g., chemotherapy), we 
dedicated the second section of this dissertation (Chapters 4 and 5) to the development of 
optimized formulations of targeted nanoparticles for photothermal cancer therapy. 
In Chapter 2, we evaluate the ability of photothermal therapy via highly crystallized iron 
oxide nanoparticles (HCIONPs) to inhibit breast cancer stem cells (BCSCs) to prevent metastasis 
following treatment of the primary tumor.  We conduct rigorous, translational studies to evaluate 
the effect of PTT via HCIONPs on epithelial-like (ALDH+) and mesenchymal-like 
(CD44+/CD24-) BCSCs in triple negative breast cancer in vitro and in vivo, and combine PTT 
with surgical resection to prevent lymph node and other metastasis.  We reveal in vitro that PTT 
ALDH+ BCSCs are more sensitive to PTT than CD44+/CD24- BCSCs, and identify conditions 
in which both populations are eliminated preferentially to differentiated cancer cells.  For the 
first time, we show that PTT inhibits breast cancer stem cell self-renewal in vitro.  Through 
secondary implantation we demonstrate that PTT impedes BCSC-driven tumor formation in 
immune-compromised mice.  Finally, we show that PTT before surgery significantly reduces 
metastasis development in triple negative breast cancer.  Taken together, these results suggest the 
potential to combine nanoparticle-mediated photothermal therapy with current clinical treatments 
such as surgery to enhance CSC destruction and improve long-term survival in breast cancer 
patients. 
In Chapter 3, we sought to inhibit breast cancer stem cells and prevent metastasis in 
immune-competent mice with photothermal therapy using HCIONPs, and to conduct initial 
studies of the ability to induce a systemic (BCSC-specific) immune response when used in 
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conjunction with immunotherapy.  In 4T1 metastatic breast cancer cells, twenty minute 
HCIONP-mediated PTT significantly reduces ALDH+ BCSCs in vitro.  In 4T1 tumor-bearing 
mice ALDH+ BCSCs are significantly inhibited by PTT when given as monotherapy and in 
combination with PD-L1 antibody.  Combination treatment with PTT and PD-L1 antibody 
reveals promising reductions in tumor growth and formation of lung macrometastases.  Increases 
of key inflammatory cytokines (IL-6) and immune cell-attracting chemokines (CXCL-1, CXCL-
9, CXCL-10) in serum of dual treated mice suggest the potential to enhance the population of 
tumor-infiltrating effector T-cells, which will be confirmed with quantitative 
immunophenotyping of saved tumor tissues.  The preliminary data summarized here lays a 
foundation for continued experiments to demonstrate conditions in which localized PTT, when 
combined with immune checkpoint blockade, effectively prevents metastasis through inhibition 
of BCSCs and eliminates existing metastases by triggering a systemic, cancer (stem) cell-specific 
immune response.  Successful development of such translational nanomedicine to extend 
immunotherapy to metastatic breast cancer patients would have potential to significantly 
improve survival of a widespread and currently incurable disease. 
In Chapter 4, we report a new technique – ‘living’ PEGylation – that allows control of the 
density and composition of heterobifunctional PEG (HS-PEG-R) on gold nanoparticles (AuNPs), 
and demonstrate potential applications in cancer nanomedicine including photothermal therapy.  
We first establish ‘living’ PEGylation by incubating HS-PEG-COOH with AuNPs at increasing 
molar ratios from zero to 2000. This causes the hydrodynamic layer thickness to differentially 
increase up to 26 nm. The controlled, gradual increase in PEG-COOH density is revealed after 
centrifugation, based on the ability to re-suspend the pellet and increase the AuNP absorption. 
Using a fluorescamine-based assay we quantify differential HS-PEG-NH2 binding to AuNPs, 
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revealing it is highly efficient until AuNP saturation. Furthermore, the zeta potential 
incrementally changes from −44.9 to +52.2 mV and becomes constant upon saturation.  Using 
‘living’ PEGylation we prepare AuNPs with different ratios of HS-PEG-RGD and incubate them 
with U-87 MG and non-target cells, demonstrating that targeting ligand density is critical to 
maximizing the targeting efficiency of AuNPs to cancer cells. The ability to minimize non-
specific binding/uptake by healthy cells could further improve targeted nanoparticle efficacy. 
Consequently, we sequentially control the HS-PEG-R density to develop multifunctional 
nanoparticles, conjugating positively-charged HS-PEG-NH2 at increasing ratios to AuNPs 
containing negatively-charged HS-PEG-COOH to reduce uptake by macrophage cells. 
Application of this facile PEGylation technique to PTT-mediating nanoparticles to enhance the 
ratio of uptake by target versus non-target cells could significantly improve patient response and 
decrease both the dose and cost of treatment.  Furthermore, future work to enhance formulation 
of such stealthy, targeted nanoparticles to confer imaging capabilities could potentially enable 
PTT to be applied to metastatic cancers. 
In Chapter 5, we describe a facile, optimized design for actively targeted, theranostic 
nanocomposites with a core-satellite structure for photothermal therapy and magnetic resonance 
imaging (MRI).  A small, “clickable” targeting peptide facilely synthesized with an N-terminal 
alkyne separated by two 6-aminohexanoic acid spacers enables precise control over attachment 
to the nanoparticles to prevent steric hindrance and optimize binding with the target receptor.  
The PTT nanoparticle formulation consisting of azide-coated nanocomposites with a HCIONP 
core (17 nm) and ultra-small AuNP satellites (4 nm) results in enhanced stability with highly 
efficient conjugation of the targeting peptide by azide-alkyne click chemistry.  This was 
determined by changes in hydrodynamic size (33.1 to 39.7 nm) and peptide quantification via the 
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Bradford assay.  The high stability of the HCIONP-AuNP-PEG-N3 nanocomposite makes it ideal 
for controlled conjugation of cysteine-containing peptides which would otherwise directly attach 
to the AuNP surface.  Furthermore, compared to AuNPs often used for PTT, the HCIONP core 
of the nanocomposite enables purification by magnet if desired. MRI capabilities allow in vivo 
visualization of tumor tissue by MRI before and after treatment, and may even enable PTT at 
metastatic sites.  The HCIONP-AuNP nanocomposites with tumor-targeting, clickable peptides 
for PTT and MRI presented here exemplify controlled delivery of localized therapy to reduce 
off-target toxicity and consequently increase both patient tolerance and response to cancer 
treatment. 
 Ideally, future studies inspired by this work would focus on developing targeted 
photothermal therapy to engage patients’ own immune systems to fight metastatic cancers.  The 
theranostic HCIONP-AuNP nanocomposites formulated via click chemistry for multivalent 
display of peptides, discussed in Chapter 5, could be used to demonstrate efficient PTT targeting 
to BCSCs, perhaps utilizing the Notch receptor-targeting 9-mer peptide studied in Appendix A.  
To achieve long-term efficacy, therapy utilizing PTT should be designed to inhibit local and 
distal BCSCs.  Building off of the work described in Chapter 3, PTT via the nanocomposites 
could be evaluated for its ability to kill both differentiated cancer cells and BCSCs located in 
primary tumors and consequently train T-cells to recognize and kill remaining cells at the tumor 
and metastatic sites.  As in Chapter 3, the potential to enhance this effect following PTT could be 
studied by combination with cancer immunotherapy such as antibodies for T-cell checkpoint 
inhibition.  Furthermore, the ability for MRI via the targeted HCIONP-AuNP nanocomposites 
would facilitate studies to detect the nanocomposites bound to distal cancer cells and conduct 
PTT at certain metastatic sites, such as the lungs.   
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Following such efficacy studies, additional studies to demonstrate safety would be critical 
to pushing the therapy described here into clinical trials.  The actively targeted nanoparticles for 
externally controlled photothermal therapy combines multiple approaches for delivering 
localized therapy that when applied in the clinic could reduce off-target toxicity and increase 
patient tolerance to treatment.  Clinical translation of this nanomedicine approach to stimulate 
patients’ immune systems to eliminate differentiated cancer cells and CSCs at both local and 
distal sites could lead to viable treatment options for multiple types of metastatic cancer, with 
significant potential to improve long-term survival in patients considered incurable with current 
therapies. 
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APPENDIX A. EVALUATION OF JAGGED1 PEPTIDES TO TARGET BREAST 
CANCER STEM CELLS THROUGH NOTCH RECEPTOR EXPRESSION 
 
A.1 Abstract 
Recent advances in nanoparticle development offer great potential to enhance efficacy of 
cancer therapies against treatment-resistant cancer stem cells.  Given the advancement of 
nanoparticle-mediated photothermal therapy (PTT) to clinical trials and preliminary pre-clinical 
reports of efficacy at eliminating breast cancer stem cells (BCSCs), we sought to develop 
targeted nanoparticles to specifically direct photothermal therapy to BCSCs.  Here we present 
our work to evaluate peptides to target PTT-mediating nanoparticles to Notch receptors over-
expressed on BCSCs.  Various peptides ranging in size from nine to 23 amino acids were 
selected based on sequences in the Delta/Serrate/Lag-2 (DSL) and epidermal growth factor 
(EGF) regions of the endogenous Notch ligand Jagged1.  Following synthesis and purification, 
the effect of peptide incubation on Notch activity was determined by a Luciferase assay 
following six hour incubation with Notch-expressing breast cancer cell lines (MDA-MB-231, 
ZR-75-1) transduced with a Notch reporter.  None of the Jagged1 peptides caused a significant 
difference in the luminescence signal compared to non-treated cells, mitigating concerns of 
potential stimulation of Notch activity.  Fluorescent forms of each peptide, with Fluorescein 
added to the N-terminus separated by two 6-aminohexanoic acid spacers, were also synthesized 
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to determine peptide binding affinity for Notch receptors.  First fluorescence imaging was 
conducted of MDA-MB-231 cells and negative control H520 cells incubated with fluorescent 
peptides.  Next, fluorescence imaging was conducted following a competition study in MDA-
MB-231 cells, which were incubated with fluorescent peptides following pre-treatment with 
unlabeled peptide to assess specificity of binding.  In both experiments the nine amino acid 
peptide appeared to have favorable binding properties over the other peptides, with higher 
fluorescence observed in the first imaging study and lower non-specific fluorescence following 
pre-treatment with unlabeled peptide in the competition study.  Competition studies with the 9-
mer and fluorescent 9-mer were then repeated in four Notch-expressing breast cancer cell lines 
for quantitative analysis via flow cytometry.  However, pre-treatment with unlabeled 9-mer did 
not affect the fluorescence signal compared to cells incubated only with fluorescent 9-mer.  Our 
data suggest that Jagged1 peptides, when incubated freely in solution, have low binding affinities 
for Notch receptors, requiring relatively high concentrations for in vitro studies.  Presentation of 
the Jagged1 peptides on a nanoparticle surface, enabling a multivalent effect in which 
simultaneous interactions with the cell surface occur, may improve peptide binding affinity and 
potentially enhance uptake of nanoparticles by Notch-expressing cells, meriting further study. 
 
A.2 Introduction 
Despite only comprising a small portion of solid tumors, by their resilient nature and 
critical role in driving multiple events in cancer progression, cancer stem cells (CSCs) present 
one of the greatest obstacles in developing effective therapies that lead to long-term patient 
survival.  Cancer stem cells were first discovered in 1997 in acute myeloid leukemia by Dick and 
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colleagues [1].  While evidence of the existence of CSCs has been reported for multiple types of 
solid cancers [2-6], those in breast cancer remain among the most extensively studied largely in 
part to Wicha and colleagues [2, 7-15].  An increasing body of research supports a model in 
which tumors arise from transformed stem or progenitor cells that normally exist in healthy 
tissues to support tissue maintenance and repair.  These relatively long-lived stem cells have a 
greater susceptibility to acquiring mutations, which, through alterations in regulation of self-
renewal and differentiation, results in an ability to drive tumor formation [16, 17].  Furthermore, 
the literature supports a model for metastasis in which CSCs are the only type of disseminated 
cancer cell with the ability to drive growth of macrometastases at distal sites [16, 18, 19].  As 
recently reported by the Wicha lab, breast cancer stem cells (BCSCs) can transition between 
epithelial-like and mesenchymal-like states traceable by aldehyde dehydrogenase (ALDH+) and 
CD44+/CD24- markers, respectively.  Their data suggest that mesenchymal-like BCSCs may 
play a more dominant role in dissemination and migration, while epithelial-like BCSCs are more 
proliferative and more likely to drive tumor growth at the site of origin and distal sites [13].  As 
expected given the key role of stem cells in ensuring maintenance and survival of healthy tissue, 
CSCs also exhibit resilient qualities.  For instance, features such as resistance to apoptosis and 
increased transporter activity [16] facilitate increased resistance to conventional therapies such as 
chemotherapy and radiation [9, 20-22].  While success of cancer therapies varies widely by type 
and stage of the disease, incorporating a component specifically aimed to eliminate CSCs may be 
a critical factor to prevent development of acquired resistance, recurrence, and progression of the 
disease [23, 24]. 
Various strategies have been explored to develop CSC-specific therapies.  Agents such as 
all-trans retinoic acid may be used to induce stem cell differentiation into cancer cells which are 
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more responsive to subsequent treatment with conventional therapies [24-26].  Another strategy 
to incorporate agents selective to CSCs is to inhibit key CSC signaling pathways, such as Wnt, 
Hedgehog, and Notch that modulate self-renewal [16, 17, 24, 27-29].  In 2012 Genentech’s 
Vismodegib, an inhibitor of Smoothened (SMO) in the Sonic Hedgehog (SHH) pathway, was 
approved in 2012 by the Food and Drug Administration (FDA) for basal-cell carcinoma (BCC) 
[29].  Like Vismodegib, most other SHH-targeting agents in clinical trials are cyclopamine-
competitive antagonists of SMO, including Sonidegib and Saridegib.  Notch inhibitors in 
development aim to block signaling at various points in the pathway including binding of the 
Delta-like (DLL) and Jagged ligands, and activity of the γ-secretase enzyme which plays a key 
role in trafficking that leads to transcription of Notch target genes [30-32].  Clinical trials of 
Notch-targeting agents include several γ-secretase inhibitors (GSIs) produced by various 
companies as well as monoclonal antibodies to block ligand binding, including anti-Notch 1, 2, 
and 3 antibodies and multiple anti-DLL4 antibodies [29].  Additional methods that have been 
explored include inhibitors of various cytokine pathways; both inhibitors of intracellular targets 
(e.g., Perifosine to inhibit AKT [33, 34]) and extracellular signaling from the tumor 
microenvironment (e.g., Repertaxin to inhibit IL-8 signaling through the CXCR1 receptor [12, 
33]). 
While few nanoparticle-based therapies, and none targeting CSCs, have advanced to 
clinical trials, recent advances in nanoparticle development offer great potential to combine 
strategies to enhance cancer treatment efficacy against CSCs.  In 2010, nanoparticle-mediated 
hyperthermia was reported to improve efficacy of ionizing radiation (IR) against BCSCs [20].  
The authors used light-activated gold nanoshells to induce photothermal therapy (PTT), one of 
few nanoparticle-based treatments to advance to clinical trials.  They found PTT impairs the 
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ability to repair double-stranded breaks in DNA caused by IR, which was suggested to be the 
result of changes in heat shock protein expression caused by PTT.  In a subsequent study, carbon 
nanotube-mediated PTT was found to sensitize breast cancer stem-like cells to hyperthermia over 
comparable heating via water bath [35].  While rapid heat transfer from PTT causes the overall 
solution temperature to become mildly hyperthermic [36], the cytotoxic effect is amplified by the 
presence of nanoparticles in close proximity to the cells as the heat transfer is significantly 
greater at the nanoparticle surface [37]. 
With this in mind, we sought to direct photothermal therapy to BCSCs through Notch-
targeted nanoparticles.  While Notch-targeting antibodies have been commercially developed 
[29, 38, 39], production and purification is expensive and their relatively large size limits the 
potential loading capacity of a therapeutic drug onto the nanoparticle surface.  A design to 
maximize both targeting efficiency and potency of drug-loaded nanoparticles would be ideal for 
multimodal therapy with PTT and extending applications to CSC-targeted drug delivery.  High 
affinity peptides derived from the binding region of an antibody are cheaper and simpler to 
produce and purify, and would allow more room on the nanoparticle surface for attachment of a 
drug.  A previously reported 17-amino acid peptide derived from the Jagged1 ligand [30] served 
as a basis for design and exploration of Notch-binding peptides intended to target nanoparticle-
mediated therapies, PTT in particular, to BCSCs. 
 
A.3 Results and Discussion 
Following the discovery of breast CSCs as the first solid tumor CSCs, Dontu et al. 
demonstrated the involvement of Notch signaling in mammary stem/progenitor cell self-renewal 
     165 
 
and differentiation and proposed that dysregulation of the pathway could give rise to breast CSCs 
[30].  Additional studies since have demonstrated a crucial role for Notch signaling in other types 
of CSCs [40-42].  The Notch receptor family is composed of four mammalian homologs 
(Notch1-4).  Signaling can be activated by binding of Delta-like (DLL1, DLL3, DLL4) or Jagged 
(Jagged1, Jagged2) ligands on a neighboring cell.  This induces a series of receptor cleavage 
events involving A Disintegrin and Metalloproteinase (ADAM) and γ-secretase enzymes, 
resulting in release of the Notch Intracellular Domain (NICD) which traffics to the nucleus and 
relieves repression of transcription factors for genes such as those in the HES family [30-32]. 
Of the various Notch receptors, the correlation between Notch1 and Notch4 receptor 
expression and poor clinical outcome has been most predominantly studied in breast and other 
cancers.  Notch2 expression has been associated with better clinical outcome than the other 
Notch receptors [30, 43-49].  Each human Notch receptor homolog contains a variable number of 
epidermal growth factor (EGF) domains that compose the majority of the extracellular region.  
All Jagged and Delta-like ligands contain several EGF domains as well as an N-terminal 
Delta/Serrate/Lag-2 (DSL) domain [50, 51].  A 17 amino acid peptide derived from the DSL 
region of the Jagged1 ligand (amino acids #187-203) has been previously used to study Notch 
signaling [30, 52, 53].  Upon detailed study of the Notch1-Jagged1 interaction, Cordle et al. 
reported five critical residues on the Jagged1 ligand.  These five residues are spread out over 
consecutive amino acids (#199-207) that overlap with the commercial 17-mer peptide, and are 
highly conserved among Notch ligands.  In selecting peptide sequences for our Notch-targeting 
peptide, we consequently chose 17-mer and 9-mer peptides using amino acids 187-203 and 199-
207, respectively.  As the EGF1 and 2 domains are also considered important for Jagged1 ligand 
binding [50, 54], we also tested a 23-mer peptide from the EGF1 domain of human Jagged1.  As 
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this peptide was shown to be less effective in blocking granulocyte colony-stimulating factor-
induced differentiation than the 17-mer described above [52], it was our hope that this peptide 
may be able to interact with Notch receptors without stimulating Notch activity.  Various 
peptides with reverse or scramble sequences were also evaluated in our studies, as detailed in 
Table A.1. 
 Peptides were synthesized by FMOC chemistry, by hand if composed of nine amino acids 
or on an ABI 433 peptide synthesizer if longer.  Each was purified by reverse phase high 
performance liquid chromatography (RP-HPLC).  Analytical runs of the final purified products 
were conducted for detection of a single peak, and correct molecular weights were confirmed by 
electrospray ionization mass spectroscopy.  Representative results for the 17-mer peptide are 
shown in Figure A.1. 
Not wanting to stimulate Notch signaling upon binding, we investigated the effect of 
Jagged1 peptides on Notch activity following incubation with Notch-expressing MDA-MB-231 
breast cancer cells.  To quantify Notch activity, MDA-MB-231 cells were transduced with a 
lentiviral vector containing either a pGreenFire1-Notch plasmid or a pGreenFire1-mCMV 
(negative control) plasmid.  Cells were incubated with the Jagged1 peptides and a human 
Jagged1 disulfide-linked homodimer as a positive control.  After six hours, Notch activation was 
quantified by luminescence using a Luciferase assay as shown in Figure A.2.  As expected, 
luminescence was negligible in the mCMV cells.  Evaluating luminescence signals in the MDA-
MB-231 Notch cells, none of the Jagged1 peptides produced significantly different results when 
compared to non-treated cells.  Comparable effects of peptide incubation were obtained in ZR-
75-1 Notch and mCMV cells (data not shown). 
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 After determining that Jagged1 peptides do not stimulate Notch activity in breast cancer 
cells, we sought to analyze the ability of peptides to target Notch receptors.  We first considered 
examining the ability of the peptides to increase nanoparticle uptake in Notch-expressing MDA-
MB-231 cells (non-transduced); H520 lung cancer cells with negligible Notch expression [55] 
were selected as a negative control.  We desired to follow a similar experimental design as 
described in Chapter 4 using Living PEGylation [56], in which we had stably controlled the ratio 
of RGD targeting peptide onto laser-produced gold nanoparticles (AuNPs).  However, in this 
previous design the RGD peptide was conjugated to the end of thiolated poly(ethylene glycol) 
(HS-PEG-RGD); this would not work here with our cysteine-containing peptides bearing thiol 
groups that could attach directly to the AuNP surface, as we would not be able to ensure the 
peptides would be presented at the free end of the PEG to enable receptor interaction.  With 
some reservations about the design, we conducted a quick experiment using a slightly different 
approach to Living PEGylation: to first partially PEGylate laser-produced AuNPs from IMRA 
America (20 nm) with neutral PEG molecules (HS-PEG5000-OCH3), and then conjugate Jagged1 
peptides directly to the AuNP surface before incubating with cells (2.5 nM AuNPs, 8 h).  While 
higher Au uptake was observed in MDA-MB-231 cells than H520 control cells as expected, 
AuNPs containing Jagged1 peptides did not have increased cellular uptake compared to AuNPs 
bearing only PEG (data not shown).  As we expected may happen, potential formulation issues, 
such as whether the larger PEG molecules could mask the smaller peptides and whether direct 
conjugation of the peptides to the AuNP surface via cysteine residues would affect the peptide 
conformation necessary for binding to Notch receptors [57], made it difficult to conclude 
whether our observations were true reflections of the peptide targeting abilities.  Following this 
quick experiment, we decided to alter our approaches for future studies: 1) to study peptide 
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binding affinity via competition studies of labeled and unlabeled peptides [58, 59], and 2) to 
formulate targeted nanoparticles with thiol-containing peptides using specific chemistry to 
control peptide conjugation onto nanoparticles already coated with PEG molecules (HS-PEG-R, 
R = chemically reactive group for peptide attachment).  The first study is described in the 
remainder of the work presented in this chapter.  The second study formed the basis for the work 
presented in Chapter 5, in which “clickable” peptides were synthesized for attachment to PTT-
mediating, AuNP-containing nanocomposites by azide-alkyne click chemistry. 
 For the work presented here, fluorescently-labeled versions of each peptide were 
synthesized for qualitative fluorescence imaging and quantitative flow cytometry following 
cellular incubation.  Like the design of alkyne-peptides described in Chapter 5 (Scheme 5.3), two 
6-aminohexanoic acid spacers were used to separate the peptide amino acids from the Fluoescein 
molecule at the N-terminus.  Representative images from incubation of the fluorescent Jagged1 
peptides with MDA-MB-231 and H520 cells are shown below for the 9-mer-FL peptide (Figure 
A.3A).  In the H520 cell line, none of the fluorescent peptides showed increased staining 
compared to non-treated cells.  In the MDA-MB-231 cell line the 9-mer-FL and 17-mer-FL 
showed the greatest increase in fluorescence in the FITC channel compared to non-treated cells, 
while the 23-mer-FL showed the least.  Oddly, the scramble 9-mer-FL showed higher FITC 
fluorescence comparable to the 9-mer-FL and the 17-mer-FL peptides.  Next, a competition 
study was performed with unlabeled peptides to distinguish specific versus non-specific peptide 
binding.  Similar studies have been performed with either fluorescent or radio-labeled peptides.  
If binding is specific, pre-treatment with unlabeled peptides will block binding of labeled 
peptides.  Representative images of MDA-MB-231 cells from incubation of the fluorescent 
Jagged1 peptides following pre-treatment with 100-fold concentrated unlabeled peptides are 
     169 
 
shown below for the 9-mer-FL and 9-mer peptides (Figure A.3B).  Appearing to be one of the 
best peptides, with less non-specific binding and a higher binding affinity relative to the others, 
the 9-mer-FL peptide was chosen for quantitative analysis via flow cytometry. 
Competition studies at multiple peptide concentrations were repeated to obtain 
quantitative data via flow cytometry.  Images of MDA-MB-231 cells from incubation of the 
fluorescent 9-mer following pre-treatment with 100-fold concentrated unlabeled 9-mer are 
shown below (Figure A.4).  Pre-treatment with unlabeled 9-mer at 50-fold concentrations of 
fluorescent 9-mer was also performed in ZR-75-1, MCF7, and SUM159 breast cancer cells, all 
shown to have expression of multiple Notch receptors [60, 61].  In all four cell lines, 
fluorescence values increase proportionally with concentration of fluorescent 9-mer.  Slightly 
higher values were observed in MCF-7 and ZR-75-1 cells than MDA-MB-231 and SUM159 
cells (data not shown).  However, pre-treatment with unlabeled peptide did not reduce the 
fluorescence signal in cells incubated with fluorescent peptide without pre-treatment.  By 
evaluating multiple cell lines, successful demonstration of specific-binding was not limited by a 
particular Notch receptor homolog expression of a particular cell line.  Consequently, our data 
suggest that the binding affinity of the Jagged1 peptides is low when presented as single peptides 
in cell culture medium and that the majority of binding observed is non-specific. 
Several factors may influence ligand binding to Notch receptors.  First, in canonical 
Notch signaling, the presented Notch ligand is attached to a neighboring cell rather than existing 
free in solution [32].  While the DSL domain of the Jagged1 ligand is considered the essential 
Notch-binding region, the EGF1 and EGF2 domains have been reported to be important for 
binding [50, 62].  (This may also be reflected in the fact that the Notch receptors exist in an 
autoinhibited state, and upon ligand binding a significant force is required to induce a 
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conformational change that exposes the site of the first enzymatic cleavage event in the negative 
regulatory region (NRR) [63].)  When Shimizu et al. analyzed Notch2 binding with different 
truncations of mouse Jagged1, held in dimerized form by hIgG Fc fragment, they reported 
profoundly lower binding affinity for the truncation containing only the DSL domain compared 
to the truncation that also contained the EGF1 and EGF2 domains [54].  Second, it has been 
suggested that the DSL domain from which the Jagged1 17-mer peptide is derived may be 
stabilized by disulfide bonds, and that the high cysteine content of the 17-mer peptide may 
potentially result in aggregation and loss of biological activity given the fact that relatively high 
concentrations are required in in vitro studies [64].  Many studies conducted with Notch peptides 
have used concentrations of 10 μM or higher [30, 52-54], which may reduce peptide dissociation 
from the receptors.  Third, as Jagged1-Notch binding is known to be calcium-dependent, 
elevated calcium levels may be beneficial; one group maintained cells in culture with 2 mM 
calcium for Jagged1 peptide studies [53].  Fourth, Fc fusion proteins in dimer form may benefit 
from a multivalent effect [65, 66].  Indeed, the commercially available human Jagged1 Fc fusion 
protein purchased for our Notch affinity studies exists in a disulfide-linked homodimer form 
[67].  It is possible that presenting the peptides on the surface of nanoparticles will result in a 
beneficial multivalent effect and significantly improve binding affinity due to simultaneous 
interactions with the cell surface [68, 69], at which point the potential to stimulate Notch activity 
may need to be reevaluated.   
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A.4 Conclusions 
Various peptides derived from the DSL and EGF regions of the endogenous Notch ligand 
Jagged1 were evaluated for their ability to serve as targeting ligands for BCSCs expressing 
Notch receptors.  Following synthesis and purification of peptides ranging in size from nine to 23 
amino acids, the effect of peptide incubation on Notch activity was determined by a Luciferase 
assay following six hour incubation with Notch-expressing breast cancer cell lines (MDA-MB-
231, ZR-75-1) transduced with a Notch reporter.  None of the Jagged1 peptides caused a 
significant difference in the luminescence signal compared to non-treated cells, mitigating 
concerns of potential stimulation of Notch activity.  Fluorescent forms of each peptide, with 
Fluorscein added to the N-terminus separated by two 6-aminohexanoic acid spacers, were also 
synthesized to determine peptide binding affinity for Notch receptors.  First, fluorescence 
imaging was conducted of MDA-MB-231 cells and negative control H520 cells incubated with 
fluorescent peptides.  Next, fluorescence imaging was conducted following a competition study 
in MDA-MB-231 cells, which were incubated with fluorescent peptides following pre-treatment 
with unlabeled peptide to assess specificity of binding.  In both experiments the nine amino acid 
peptide appeared to have favorable binding properties over the other peptides, with higher 
fluorescence observed in the first imaging study and lower non-specific fluorescence following 
pre-treatment with unlabeled peptide in the competition study.  Competition studies with the 9-
mer and fluorescent 9-mer were then repeated in four Notch-expressing breast cancer cell lines 
for quantitative analysis via flow cytometry.  As pre-treatment with unlabeled 9-mer did not 
affect the fluorescence signal compared to cells incubated only with fluorescent 9-mer, it was 
determined the majority of binding is non-specific.  Our data suggest that Jagged1 peptides, 
when incubated freely in solution, have low binding affinities for Notch receptors, requiring 
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relatively high concentrations for in vitro studies.  Presentation of the Jagged1 peptides on a 
nanoparticle surface, enabling a multivalent effect in which simultaneous interactions with the 
cell surface occur, may improve peptide binding affinity and potentially enhance uptake of 
nanoparticles by Notch-expressing cells, meriting further study. 
 
A.5 Materials and Methods 
Synthesis of peptides: Unlabeled and fluorescently-labeled Jagged1 peptides were 
produced via FMOC solid phase synthesis using chlorotrityl resin as the solid support.  Those 
composed of nine amino acids were synthesized manually; 17-mer and 23-mer peptides were 
produced on an ABI 433 peptide synthesizer.  Similar to synthesis of the alkyne-peptide in 
Chapter 5, fluorescent peptides were labeled at the N-terminus as follows: two 6-aminohexanoic 
acid spacers were added via FMOC chemistry, followed by NHS-Fluoescein (ThermoScientific) 
before cleavage from the resin.  Purification of the peptides was performed via reverse phase 
high performance liquid chromatography (RP-HPLC) with a C-18 column (Sunfire, 19 mm × 
150 mm, 5 μm), and electrospray ionization mass spectroscopy confirmed the correct mass.   
Cell culture: MDA-MB-231, ZR-75-1, MCF-7, and SUM159 breast cancer cells were 
grown as adherent monolayers incubated at 37 °C with 5% CO2.  For MDA-MB-231 and ZR-75-
1, RPMI medium was supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic.  
For MCF-7 cells, DMEM was medium supplemented with 10% fetal bovine serum and 1% 
antibiotic-antimycotic.  For SUM159 cells, Ham’s F12 medium was supplemented with 5% fetal 
bovine serum, 1% antibiotic-antimycotic, 5 µg/mL insulin, 1 µg/mL hydrocortisone, and 4 
µg/mL gentamicin. 
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Notch activity studies: MDA-MB-231 and ZR-75-1 cells with Notch activity reporters 
were a gift from the Wicha laboratory and were generated as previously described [70].  Briefly, 
MDA-MB-231 cells were transduced with a lentiviral vector containing either a pGreenFire1 
(pGF1)-Notch or a pGF1-mCMV (negative control) plasmid from System Biosciences.  The 
pGreenFire1 plasmid enables reporter activity through both green fluorescent protein (GFP) and 
Luciferase.  Cells were incubated with the Jagged1 peptides (0.5 μM) for six hours (n=3), after 
which Notch activation was quantified using a standard Luciferase assay (Promega) and a 
BioTek micro-plate reader (Synergy 2).  Human Jagged1 Fc chimera protein (R&D Systems) 
was used as a positive control. 
In vitro fluorescence imaging: For initial images of binding of fluorescent Jagged1 
peptides, MDA-MB-231 and H250 cells were incubated with peptides (1 µM) for 2 h.  
Incubation was performed on ice to prevent receptor internalization upon ligand binding.  Cells 
were then washed with PBS, fixed, and stained with DAPI for cell viability.  Binding of 
Fluorescein to cells was viewed through the FITC channel; nuclear DAPI staining was viewed 
through the DAPI channel.  For competition studies in MDA-MB-231 cells, unlabeled Jagged1 
(100 µM) peptides were added for 1 h pre-treatment, cells were washed with PBS, and 
fluorescent Jagged1 peptides were added for 2 h.  Cells were then washed with PBS, fixed, and 
stained with DAPI before imaging.  Samples were imaged on an Olympus BX-51 fluorescence 
microscope. 
In vitro flow cytometry: MDA-MB-231 cells were collected using trypsin, washed, and 
suspended for incubation with peptides on ice.  Cells were pre-treated with unlabeled Jagged1 
peptides (1000, 100, or 1 µM for 1 h) at concentrations 100-fold higher than fluorescent Jagged1 
peptides (10, 1, or 0.1 µM for 2 h).  This process was repeated for incubation with ZR-75-1, 
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MCF7, and SUM159 cells except pre-treatment concentrations of unlabeled 9-mer were 50-fold 
higher than fluorescent 9-mer.  Samples were run on a Beckman Coulter Quanta SC and 
analyzed with Attune software. 
 Statistical Analysis: Data are represented as mean ± standard deviation.  The significance 
values of data sets with two groups were calculated by a student’s t-test.  A p < 0.05 was 
considered statistically significant. 
 
A.6 Figures 
Table A.1. List of synthesized peptides with their molecular weight (MW), amino acid sequence, 
and the Jagged1 domain from which they originate. 
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Figure A.1. (A) Single peak from the analytical run of the purified 17-mer (MW ~2107 g/mol).  
(B) Confirmation of the correct mass by electrospray ionization (ESI) mass spectroscopy, 
revealing the +2 peak at ~1054 m/z, +3 peak at ~703 m/z, and +4 peak at ~528 m/z. 
 
 
Figure A.2. Notch reporter activity quantified via Luciferase in transduced MDA-MB-231 breast 
cancer cells following treatment with Jagged1 peptides (0.5 µM).  Notch = pGF1-Notch plasmid, 
MCMV = pGF1-mCMV plasmid.  *p< 0.05. 
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Figure A.3. (A) Fluorescence images (FITC/DAPI overlays) of 9-mer-FL peptide incubated with 
MDA-MB-231 Notch-expressing cells and H520 negative control cells.  (B) Fluorescence 
images (FITC) of competition of fluorescent and unlabeled 9-mer peptides to evaluate specific 
binding in MDA-MB-231 cells. 
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Figure A.4. Flow cytometry of MDA-MB-231 cells incubated with 9-mer-FL peptide at 10, 1, 
and 0.1 µM concentrations, with and without pre-treatment with unlabeled 9-mer (1000, 100, 10 
µM) to evaluate specific binding. 
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